Quarterlytics / Healthcare / Medical - Instruments & Supplies / Predictive Oncology

Predictive Oncology

poai · NASDAQ Healthcare
Claim this profile
Ticker poai
Exchange NASDAQ
Sector Healthcare
Industry Medical - Instruments & Supplies
Employees 11-50
← All annual reports
FY2023 Annual Report · Predictive Oncology
Sign in to download
Loading PDF…
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________________ to _________________________

Commission file number: 001-36790

Predictive Oncology Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

33-1007393
(I.R.S. Employer
Identification No.)

(Address of principal executive offices)

(Zip Code)

91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201

Registrant’s telephone number, including area code

(412) 432-1500

Securities registered pursuant to Section 12(b) of the Act:

(Former name, former address and former fiscal year, if changed since last report)

Title of each class
Common stock, $0.01 par value

Trading symbol(s)
POAI

Name of each exchange on which registered
NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐ 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒Yes ☐ No

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indicate  by  check  mark  whether  the  registrant  is  a  large  accelerated  filer,  an  accelerated  filer,  a  non-accelerated  filer,  smaller  reporting  company,  or  an
emerging  growth  company.  See  the  definitions  of  “large  accelerated  filer,”  “accelerated  filer,”  “smaller  reporting  company,”  and  “emerging  growth
company” in Rule 12b-2 of the Exchange Act.  

Large accelerated filer ☐
Non-accelerated filer ☒  

Accelerated filer ☐
Smaller reporting company ☒
Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control
over  financial  reporting  under  Section  404(b)  of  the  Sarbanes-Oxley  Act  (15  U.S.C.  7262(b))  by  the  registered  public  accounting  firm  that  prepared  or
issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the
filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received
by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒.

As of June 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of common stock
held by non-affiliates was $18,983,374, based upon 3,906,044 shares at $4.86 per share as reported on the NASDAQ Capital Market.

As of March 18, 2024, the registrant had 4,062,853 shares of common stock, par value $.01 per share outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREDICTIVE ONCOLOGY INC.

TABLE OF CONTENTS

PART I

ITEM 1. BUSINESS

ITEM 1A. RISK FACTORS

ITEM 1B. UNRESOLVED STAFF COMMENTS

ITEM 1C. CYBERSECURITY

ITEM 2. PROPERTIES

ITEM 3. LEGAL PROCEEDINGS

ITEM 4. MINE SAFETY DISCLOSURES

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9A. CONTROLS AND PROCEDURES.

ITEM 9B. OTHER INFORMATION

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 11. EXECUTIVE COMPENSATION

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

PART IV

ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

ITEM 16. FORM 10-K SUMMARY

SIGNATURES

Page

4

15

31

31

32

33

33

33

33

33

41

41

41

41

42

42

43

49

54

56

56

57

61

62

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ITEM 1. BUSINESS.

General

PART I

References  in  this  annual  report  on  Form  10-K  to  “Predictive”,  “Company”,  “we”,  “us”,  and  “our”  refer  to  the  business  of  Predictive  Oncology  Inc.
(NASDAQ: POAI) and its wholly-owned subsidiaries.

Cautionary Statement Concerning Forward-Looking Statements

This  Annual  Report  on  Form  10-K  contains  various  "forward-looking  statements"  within  the  meaning  of  Section 27A  of  the  Securities  Act  of  1933,  as
amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements
represent our expectations and beliefs concerning future results or events, based on information available to us on the date of the filing of this Form 10-K,
and  are  subject  to  various  risks  and  uncertainties.  Factors  that  could  cause  actual  results  or  events  to  differ  materially  from  those  referenced  in  the
forward-looking statements are listed in Part I, Item 1A. Risk Factors and in Part II, Item 7. Management's Discussion and Analysis of Financial Condition
and  Results  of  Operations.  We  disclaim  any  intent  or  obligation  to  update  or  revise  any  of  the  forward-looking  statements,  whether  in  response  to  new
information, unforeseen events, changed circumstances or otherwise, except as required by applicable law.

Overview

We  are  a  knowledge  and  science-driven  company  that  applies  artificial  intelligence  (“AI”)  to  support  the  discovery  and  development  of  optimal  cancer
therapies, which can ultimately lead to more effective treatments and improved patient outcomes. We use AI and a proprietary biobank of 150,000+ tumor
samples,  categorized  by  tumor  type,  to  provide  actionable  insights  about  drug  compounds  to  improve  the  drug  discovery  process  and  increase  the
probability of drug compound success. We offer a suite of solutions for oncology drug development from early discovery to clinical trials.

Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. By
harnessing the power of machine learning and scientific rigor, we believe that we can improve the probability of success of advancing pharmaceutical and
biological drug candidates with a higher degree of confidence.

We operate in three business areas. In our first area, we provide optimized, high-confidence drug-response predictions through the application of AI using
our proprietary biobank of tumor samples to enable a more informed selection of drug/tumor combinations and increase the probability of success during
development. We also create and develop tumor-specific 3D cell culture models mimicking the physiological environment of human tissue enabling better-
informed  decision-making  during  development.  In  our  second  business  area,  we  provide  services  and  research  using  a  proprietary  self-contained  and
automated  system  that  conducts  high-throughput,  self-interaction  chromatography  screens  using  additives  and  excipients  commonly  included  in  protein
formulations  resulting  in  soluble  and  physically  stable  formulations  of  biologics.  Our  third  business  area  produces  the  United  States  Food  and  Drug
Administration  (“FDA”)-cleared  STREAMWAY®  System  and  associated  products  for  automated  medical  fluid  waste  management  and  patient-to-drain
medical fluid disposal. As of January 1, 2023, we changed our reportable segments to align with these business areas.

We have three reportable segments, which have been delineated by location and business area:

● Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also

creates proprietary 3D culture models used in drug development.

● Birmingham segment: provides contract services and research focused on solubility improvements, stability studies, and protein production.

● Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and

patient-to-drain medical fluid disposal.

4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PITTSBURGH

Drug Discovery Solutions – PEDAL

Patient-centric Drug Discovery using Active Learning (“PEDAL”™), our proprietary AI-driven platform, offered by our Pittsburgh segment, is designed to
provide high-confidence drug-response predictions. This platform combines our biobank of samples with a one-of-a-kind database of historical tumor data,
and  the  power  of  AI  to  efficiently  build  predictive  models  of  tumor  drug  response.  Our  PEDAL  asset  is  a  unique  technology  that  combines  one  of  the
largest privately held commercial biobanks of tumor samples, AI active machine learning, and multi-omic historical tumor data – complete with on-site
Clinical  Laboratory  Improvement  Amendments  (“CLIA”)  certified  lab  testing  capabilities  to  inform  drug/tumor  model  predictions.  PEDAL  offers
researchers  the  opportunity  to  incorporate  patient  diversity  early,  efficiently,  and  cost-effectively  into  the  drug  discovery  process  by  using  data  from
hundreds of patient samples. PEDAL works by iterative cycles of active learning to guide the testing of patient samples against specific compounds. This
results  in  PEDAL  efficiently  building  comprehensive  predictive  models  of  patient  drug  response  in  a  matter  of  weeks.  This  predictive  model  can  rank
compounds  against  tumor  samples  of  certain  profiles  that  respond  to  specific  drugs  and  can  also  predict  the  set  of  compounds  that  provide  the  best
coverage across patient tumor samples.

We believe leveraging our unique, historical database of tumor drug responses, genomics, biomarkers, digitized pathology slides, and histopathology data
with over 150,000 patient tumor samples to efficiently build AI driven predictive models of tumor drug response will provide actionable insights critical to
new drug development. Through the course of over 15 years of clinical testing of patient tumor responses to drugs, our Pittsburgh lab has amassed a huge
proprietary knowledgebase of data. To provide for our patient-centric approach, this dataset has been rigorously de-identified and aggregated to inform our
proprietary process to create models of tumor drug response.

PEDAL  can  significantly  increase  the  probability  of  clinical  success  by  introducing  patient  diversity  early  in  the  development  process,  while  also
decreasing the time and cost of oncology drug discovery programs. Our large knowledgebase of tumor drug response and other data, together with proven
AI, has created a unique capability for oncology drug discovery, utilizing this highly efficient screening of drug responses against thousands of diverse,
well-characterized  patient  primary  tumor  samples.  With  each  iteration  of  a  PEDAL  campaign,  the  program  learns,  predicts,  and  then  directs  the  most
informative  wet  lab  experimentation,  while  building  the  predictive  model.  This  allows  for  a  unique  and  streamlined  approach  in  which  AI-driven
predictions are tested against samples from this expansive and diverse biobank to more efficiently and effectively narrow down viable drug-tumor pairings.
This  novel  disruptive  approach  is  ideally  suited  to  the  early  part  of  drug  discovery  while  also  being  highly  customizable  to  meet  the  needs  of  our
collaborators. Our patient-centric drug discovery approach provides for the prioritization of drug compound candidates while accounting for patient tumor
diversity.  This  should  dramatically  improve  the  chances  of  successfully  translating  discoveries  into  successful  therapies,  while  simultaneously  lowering
costs through shortened development timelines, and most importantly, enhanced “speed-to-patient” for new therapies. 

A  key  part  of  our  commercialization  strategy  is  the  understanding  that  our  AI-driven  models  of  tumor  drug  response  serve  a  key  unmet  need  of
pharmaceutical,  diagnostic,  and  biotech  industries  for  actionable  multi-omic  insights  into  cancer.  In  collaboration  with  these  companies,  using  the
predictive models, we will accelerate the search for more effective cancer treatments through biomarker discovery, drug screening, drug repurposing, and
ultimately clinical trials with higher probability of success.

PEDAL,  which  incorporates  CORE™,  our  active  machine  learning  program,  with  tumor  profile  data  and  human  tumor  samples,  provides  optimized,
efficient, high-confidence drug-response predictions. Our platform is designed to move molecules forward with a higher probability of clinical success. The
focus  of  our  business  strategy  is  to  leverage  and  expand  our  portfolio  of  proprietary  solutions  to  advance  drug  discovery  and  enable  oncology  drug
development for our biopharma partners.

3D Modeling

Our Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Our 3D tumor-specific models accelerate
the drug development process for our clients and partners by providing drug response predictions with high correlation to clinical response, enabling our
biopharma clients to manage pipeline prioritization more efficiently.

5

 
 
 
 
 
 
 
 
 
 
 
The  3D  models  incorporate  tissue-specific  extracellular  matrices  and  tumor-specific  medium  supplements  allowing  for  a  true  reconstruction  of  tumor
microenvironment. Our approach is compatible with multiple classes of immuno-oncology agents from antibody and antibody-drug conjugates to bi- and
tri-specific  compounds  and  CAR-T  cells.  The  organ-specific  disease  models  provide  3D  reconstruction  of  human  tissues  accurately  representing  each
disease state and mimicking drug response.

Our  3D  platform  maintains  tumor-tumor  and  tumor-stroma  interactions  and  incorporates  both  cellular  and  extracellular  elements  of  tissue
microenvironment  including  soluble  factors  in  an  organ-  and  disease-specific  manner.  It  is  compatible  with  multiple  cell  types,  drug  classes,  and
downstream analysis methods. Our models support proliferation of malignant and non-malignant cellular components of tissues.

Applications  include  providing  efficacy  screening  of  anticancer  compounds,  evaluation  of  mechanisms  of  drug  resistance,  identification  of  new  drug
combinations,  rescue  of  failed  drug  candidates,  assessment  of  off-target  toxicity,  target  discovery  and  biomarker  discovery.  Product  offerings  include
preclinical testing services based on our proprietary models directly to clients in the biopharmaceutical industry.

Clinical Testing

Through our wholly owned subsidiary, Helomics Corporation (“Helomics”), reported under our Pittsburgh segment, we offer a group of clinically relevant,
cancer-related  tumor  profiling  and  biomarker  tests  for  gynecological  cancers  that  determine  how  likely  the  patient  is  to  respond  to  various  types  of
available chemotherapy treatments and which therapies might be indicated by relevant tumor biomarkers.

Clinical diagnostic testing is comprised of our Tumor Drug Response Testing (ChemoFx™), Genomic Profiling Testing (BioSpeciFx), and other biomarker
tests.  The  Tumor  Drug  Response  Testing  test  determines  how  a  patient’s  tumor  specimen  reacts  to  a  panel  of  various  chemotherapy  drugs,  while  the
Genomic and biomarker profiling evaluates the expression and/or status of a particular gene or protein related to a patient’s tumor specimen.

Testing involves obtaining tumor tissue during biopsy or surgery, which is then sent to our CLIA certified laboratory using a special collection kit. Tumor
Drug Response Testing is a fresh tissue platform that uses the patient’s own live tumor cells to help physicians identify effective treatment options for each
gynecologic cancer patient.

Genomic  Profiling  offers  a  select  group  of  clinically  relevant  protein  expression  and  genomic  mutation  tests  associated  with  drug  response  and  disease
prognosis. Physicians can select biomarkers for testing from carefully chosen panels of relevant tests, organized by cancer pathway and tumor type. Results
for these tests are presented in a clear, easy to understand format, including summaries of the clinical relevance of each marker.

BIRMINGHAM

Drug Development Solutions – Formulations for Biologics

Our  Birmingham  segment  focuses  on  contract  services  and  research  for  biopharmaceutical  company  clients  and  academic  collaborators,  focused  on
solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized FDA-approved formulations for vaccines,
antibodies,  and  other  protein  therapeutics  in  a  faster  and  lower  cost  basis  to  its  customers,  as  described  below.  In  addition,  our  Birmingham  segment
enables protein degradation studies, which based on current projections, could be a substantial line of business for the Company.

The primary asset of our Birmingham segment is our proprietary automated High Throughput Self-Interaction Chromatography (“HSC”™) platform. Our
HSC  platform  is  a  self-contained,  automated  system  that  conducts  high-throughput,  self-interaction  chromatography  screens  on  excipients  previously
approved by the FDA for protein formulations. Our technology rapidly measures the solubility of protein in different excipients and excipient combinations
that  promote  improved  protein  solubility  in  solutions.  The  data  generated  from  HSC  screens  are  analyzed  by  a  proprietary  AI  predictive  algorithm  to
identify the optimal combination(s) of buffers, pH, and excipients, resulting in increased solubility and physical stability of proteins. Several of our clients
have seen ten-fold and hundred-fold increases in their protein’s solubility while maintaining physical stability. For biopharmaceutical clients this means
faster development times and quicker progression of molecules into the clinic. For academic collaborators, this means further progression of biochemical
and biology studies necessary to advance fundamental research in areas of unmet medical need.

6

 
 
 
 
 
 
 
 
 
 
 
 
 
 
In  addition,  our  Birmingham  segment  provides  comprehensive  protein  stability  analyses  via  time-dependent  shelf-life  studies  and  forced  degradation
studies  designed  to  quickly  determine  which  of  the  additives  previously  approved  by  the  FDA  will  improve  the  solubility  and  stability  of  proteins  in
solutions.  Services  include  pre-formulation  development,  stability  assessment,  and  biophysical  characterization,  which  evaluate  variables  including  pH,
temperature, humidity, light, viscosity, oxidizing agents, and mechanical stress to determine the most promising additives, formulation of B22 values and
validation of conformation stability. We provide clients with a list of the most promising additives from a set of over 40 different additives that can increase
the solubility and stability of protein formulations.

The Birmingham segment also offers protein solubility kits that allow rapid identification of soluble formulations. We provide four different kits to fulfill
customer  solubility  requirements.  The  kits  are  in  96-well  format  and  provide  the  tools  and  methods  to  compare  relative  solubility  across  88  common
formulations (with 8 controls). Birmingham kits utilize a simple mix and spin protocol that quickly evaluates aggregation behavior as a function of pH, salt,
and additives costing significantly less than if manually determined.

In addition, our Birmingham segment supplies proprietary technologies for bacterial endotoxin detection and removal. Endotoxin is an inherent byproduct
of  bacterial  expression  of  therapeutic  proteins.  However,  therapeutic  proteins  are  required  to  have  extremely  low  endotoxin  levels.  Our  Birmingham
segment  provides  a  product  to  remove  endotoxin  that  works  through  multiple  molecular  interactions  for  efficient  removal  over  a  wide  range  of  buffer
conditions  with  minimal  product  loss.  The  detection  of  endotoxin  can  also  be  adversely  affected  by  the  protein  therapeutic  itself.  To  address  this,
Birmingham provides sample treatment kits to minimize detection interference while using standard detection assays. At our Birmingham facility, we can
manufacture  high-quality  endotoxin  detection  and  removal  products  to  help  our  customers  efficiently  meet  safety  standards.  We  follow  Good
Manufacturing  Practices  (“GMP”),  International  Council  for  Harmonization  (“ICH”)  and  Good  Laboratory  Practice  (“GLP”)  standards  throughout  to
ensure consistent and standardized products and services.

EAGAN

STREAMWAY® System

Through our wholly owned subsidiary, Skyline Medical Inc. (“Skyline Medical”), reported under our Eagan segment, we sell the STREAMWAY System,
as  well  as  proprietary  cleaning  solution  and  filters  for  use  with  the  STREAMWAY  System.  The  STREAMWAY  System  is  an  FDA-cleared,  automated,
patient-to-drain waste fluid disposal system designed for medical environments involving potentially infectious medical waste fluids. We have been granted
patents  for  the  STREAMWAY  System  in  the  United  States,  Canada,  and  Europe.  We  distribute  our  products  to  medical  facilities  where  bodily  and
irrigation  fluids  produced  during  medical  procedures  must  be  contained,  measured,  documented,  and  disposed  of  properly.  Our  products  minimize  the
exposure potential to the healthcare workers who handle such fluids.

Our  STREAMWAY  System  is  a  wall-mounted  system  that  disposes  of  an  unlimited  amount  of  bodily  and  irrigation  fluids  providing  uninterrupted
performance  for  physicians  while  virtually  eliminating  healthcare  workers’  exposure  to  potentially  infectious  fluids  collected  during  surgical  and  other
patient procedures. We also manufacture and sell two disposable products required for the operation of the STREAMWAY System: a bifurcated dual port
procedure filter with tissue trap and a single use bottle of cleaning solution. Both items are utilized on a single procedure basis and must be discarded after
use.  The  disposables  used  for  operation  of  the  STREAMWAY  System  are  a  critical  component  of  our  business  model,  and  we  expect  will  provide
significant recurring revenues. We have exclusive distribution rights to the disposable cleaning solution.

7

 
 
 
 
 
 
 
 
 
The  STREAMWAY  System  virtually  eliminates  exposure  to  blood,  irrigation  fluid,  and  other  potentially  infectious  fluids  found  in  the  healthcare
environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present both an exposure risk and
potential liability. The STREAMWAY System automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead
costs to hospitals and surgical centers; 2) improve compliance with the Occupational Safety and Health Administration (“OSHA”) and other regulatory
agency safety guidelines; 3) improve efficiency in the operating room and radiology and endoscopy departments, thereby leading to greater profitability;
and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into
landfills each year in the United States.

Industry and Market Background and Analysis

Drug Discovery and Development Solutions

The  growing  demand  for  the  improvement  in  the  discovery  and  development  process  of  novel  drug  therapies  is  driving  the  demand  for  AI-empowered
solutions. Growing partnerships and cooperation are expected to fuel global market for AI in drug development. The adoption of AI solutions in the drug
development  process  increases  efficiency,  reduces  cycle  time,  and  increases  the  productivity  and  accuracy  of  the  risky  and  long  process.  Due  to  these
advantages, the importance of AI in drug discovery and development is expected to drive the global market. AI-powered drug discovery is an emerging
approach  that  considers  individual  variability  in  multi-omics,  including  genes,  disease  and  environment  to  develop  effective  therapies.  This  approach
predicts more accurately which treatment, dose, and therapeutic regimen could provide the best possible clinical outcome. Biopharmaceutical companies,
contract  research  organizations,  academia,  and  other  stakeholders  began  integrating  AI-based  solutions  in  their  drug  development  processes  to  enhance
outcomes and curb costs.

We  believe  we  are  uniquely  positioned  with  our  PEDAL  platform  to  provide  early  insights  that  clients  can  use  to  prioritize  drugs  for  development  and
identify patient-centric indications. In addition, the PEDAL platform can be used to re-purpose previously failed drug compounds. We aim to leverage the
PEDAL platform for our biopharma clients and help them prioritize their oncology portfolio. The PEDAL platform supports a biopharma client’s decision
on the drug molecules with a higher likelihood of clinical success. With PEDAL, we look to improve/enhance the way that the biopharma industry carries
out the development of oncology drugs. We believe our platform provides unique financial- and time-saving advantages for pharmaceutical companies.

We believe the passage of the FDA Modernization Act 2.0 will increase the use of non-animal methods to study the mechanisms of diseases and to test the
effectiveness of new drugs. The FDA Modernization Act 2.0 allows for alternatives to animal-testing requirements for the development of drugs and allows
drug  manufacturers  to  opt  out  of  animal  testing  while  utilizing  other  testing  methods  to  develop  drugs,  such  as  cell-based  assays,  organ-on-a-chip
technology, computer models, and other human biology-based test methods. We expect the market to continue to grow due to a shift towards more efficient,
accurate and predictive models.

Infectious and Biohazardous Waste Management

There has long been recognition of the collective potential for ill effects to healthcare workers from exposure to infectious/biohazardous materials. Federal
and  state  regulatory  agencies  have  issued  mandatory  guidelines  for  the  control  of  such  materials,  and  particularly  bloodborne  pathogens.  OSHA’s
Bloodborne Pathogens Standard (29 CFR 1910.1030) requires employers to adopt engineering and work practice controls that would eliminate or minimize
employee exposure to hazards associated with bloodborne pathogens. In 2001, in response to the Needlestick Safety and Prevention Act, OSHA revised the
Bloodborne  Pathogens  Standard.  The  revised  standard  clarifies  and  emphasizes  the  need  for  employers  to  select  safer  needle  devices  and  to  involve
employees in identifying and choosing these devices. The revised standard also calls for the use of “automated controls” as it pertains to the minimization
of healthcare exposure to bloodborne pathogens.

Most  surgical  procedures  produce  potentially  infectious  materials  that  must  be  disposed  of  with  the  lowest  possible  risk  of  cross-contamination  to
healthcare  workers.  Current  standards  of  care  allow  for  these  fluids  to  be  retained  in  canisters  and  located  in  the  operating  room  where  they  can  be
monitored throughout the surgical procedure. Once the procedure is complete these canisters and their contents are disposed using a variety of methods, all
of  which  include  manual  handling  and  result  in  a  heightened  risk  to  healthcare  workers  for  exposure  to  their  contents.  Canisters  are  the  most  prevalent
means  of  collecting  and  disposing  of  infectious  fluids  in  hospitals  today.  Traditional,  non-powered  canisters  and  related  suction  and  fluid  disposable
products are exempt and do not require FDA clearance. 

8

 
 
 
 
 
 
 
 
 
 
 
We expect the hospital surgery market to continue to increase due to population growth, the aging of the population, and expansion of surgical procedures
to new areas (for example, use of the endoscope) which requires more medical fluid management and new medical technology. 

Competition and Competitive Advantages

Drug Discovery Solutions – PEDAL and 3D Modeling

On  average,  new  oncology  drug  compounds  take  10-12  years  to  become  approved  for  use,  from  discovery  to  commercial  launch.  Identifying  those
compounds  is  a  difficult  process  with  a  significant  majority  of  compounds  failing.  This  failure  is  costly  in  time  and  resources,  particularly  when  the
compounds fail during the clinical trial stages. It is estimated that 90-95% of compounds fail between first human dose and launch. One of the reasons for
this high failure rate is the inability of oncology drug compounds in clinical trials to meet the therapeutic end points in a large population.  

AI  companies  addressing  the  needs  in  the  drug  discovery  market  are  looking  at  the  drug  discovery  and  development  challenges  from  different  angles.
However,  we  believe  no  other  company  has  access  to  a  comparable  privately  held  biobank  with  tumor  drug  responses,  genomics,  biomarkers,  digitized
pathology slides, and histopathology data. The ability to pair AI with our biobank provides us with a competitive advantage and creates a barrier to entry
for competitors in the drug response prediction space.

We  believe  this  patient-derived,  highly  curated,  multi-omic  tumor  model  offers  a  better  chance  of  generating  predictive  models  of  drug-response  and
outcomes  than  competitive  approaches  in  the  market  today.  The  information  embodied  in  the  AI-driven  predictive  model  provides  insights  into  each
tumor’s response to different therapeutic options, resulting in the ability to provide actionable insights critical to new drug development, individualizing
patient  treatment,  drug  repurposing,  and  biomarker  development.  Identifying  cohorts  of  patient  tumors  most  responsive  to  candidate  drugs  informs  the
early drug candidate selection process in a patient-centric manner that we do not believe is offered elsewhere. The tumor cohorts identified by our models
can also be analyzed and stratified to optimize patient selection criteria for improved clinical trials. A deeper analysis of these same tumor cohorts found to
be highly responsive to a particular drug candidate can be further utilized for targeted biomarker development and/or targeted assay development.

We  also  fulfill  unmet  needs  in  the  drug  discovery  market  with  the  next-generation  technology  of  our  3D  models,  based  on  extensive  knowledge  of  the
human  tumor  microenvironment  creating  accurate  reconstruction  of  the  organ-specific  3D  tissue  microenvironment  enabling  evaluation  of  therapeutic
agents under conditions mimicking human physiology. The main competitive advantage of our technology is the tumor-specific nature of its systems. 3D
models  replicate  tissue  heterogeneity  and  provide  maintenance  of  primary  human  cells,  organoids,  and  cell  lines  under  the  native  conditions  of  human
disease.  The  3D  models  are  formulated  to  mimic  the  tissue  and/or  disease  of  interest  instead  of  pursuing  a  one-size-fits-all  approach  taken  by  other
companies. Recreating specific tumor microenvironments enables more reliable prediction of tissue response to drugs with varying mechanisms of action.
This same technology can also be used to demonstrate potential toxic drug effect on normal tissues by maintaining an accurate reconstruction of cellular
and extracellular compartments of human tissues.

9

 
 
 
 
 
 
 
 
 
Drug Development Solutions – Formulations for Biologics

Our  HSC  platform  is  a  self-contained,  automated  system  that  conducts  high-throughput,  self-interaction  chromatography  screens  on  FDA  approved
excipients  for  protein  formulations.  The  HSC  system  provides  clear  competitive  advantages.  First,  HSC  measures  the  solubility  in  all  FDA-approved
excipients  and  excipient  combinations  rather  than  a  limited  subset  of  excipients.  The  HSC  also  requires  smaller  sample  sizes  and  decreased  time  and
manpower to optimize formulations. Using data generated from HSC screens, our proprietary predictive algorithm identifies the optimal combination(s) of
buffers, pH, and excipients based on more than 4,000 possible combinations, resulting in increased solubility and physical stability of proteins. The top
predictive  solubilities  are  then  validated  using  experimental  methods  in  combination  with  the  HSC  to  produce  multiple  formulations  to  meet  customer
requirements.

The HSC instrument and its technology has been validated over the past twelve years via industry and academic collaborations. Several of our clients have
seen ten-fold and hundred-fold increases in their protein’s solubility while maintaining physical stability. For biopharmaceutical clients this means faster
development times and quicker progression of molecules into the clinic. Our technologies and services help expedite and streamline biologics development
—improving yield with expression and purification services; helping prepare for clinical trials with ICH stability profiles; meeting safety standards with
endotoxin detection and removal; and manufacturing at our GMP facility.

Infectious and Biohazardous Waste Management

We believe that the STREAMWAY System is unique to the infectious and biohazardous waste management industry because it allows continuous suction
but also provides for unlimited capacity, eliminating the need to interrupt a procedure to change canisters. To our knowledge, the STREAMWAY System is
the only known automated fully closed direct‐to‐drain system that is wall‐mounted and able to collect, measure, and dispose of an unlimited amount of
waste fluid without interruption.

We believe that our virtually hands free direct-to-drain technology (1) significantly reduces the risk of healthcare worker exposure to these infectious fluids
by replacing canisters, (2) further reduces the risk of worker exposure when compared to powered canister technology that requires transport to and from
the operating room, (3) reduces the cost per procedure for handling these fluids, and (4) enhances the surgical team’s ability to collect data to accurately
assess the patient’s status during and after procedures. In addition to the traditional canister method of waste fluid disposal, several other powered medical
devices have been developed that address some of the deficiencies described above. Most of these competing products continue to utilize some variation on
the existing canister technology, and while not directly addressing the canister, most have been successful in eliminating the need for an expensive gel and
its  associated  handling  and  disposal  costs.  Our  existing  competitors  with  products  already  on  the  market  have  a  clear  competitive  advantage  over  us  in
terms  of  brand  recognition  and  market  exposure.  In  addition,  many  of  our  competitors  have  extensive  marketing  and  development  budgets  that  could
overpower an emerging growth company like ours.

Suppliers

We  buy  our  raw  materials  from  several  suppliers  and,  except  as  set  forth  below,  the  loss  of  any  one  supplier  would  not  materially  adversely  affect  our
business. We rely on sole suppliers for certain materials used to perform our molecular diagnostic tests. We also purchase reagents used in our molecular
diagnostic tests from sole-source suppliers. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain
that these strategies will be effective or that the alternative sources will be available in a timely manner. If our current suppliers can no longer provide us
with  the  materials  that  we  need  to  perform  molecular  diagnostic  tests,  if  the  materials  do  not  meet  our  quality  specifications,  or  if  we  cannot  obtain
acceptable substitute materials, there could be an interruption in molecular diagnostic test processing. In the event of the loss of these suppliers, we could
experience delays and interruptions that might adversely affect the financial performance of our business.

We also have single suppliers for the manufacturing of certain of our Skyline Medical products. Alternative suppliers are available in the market; however,
we  could  experience  delays  and  interruptions  that  might  adversely  affect  the  financial  performance  of  our  business  including  time  for  machine  tooling
specific to our products.

10

 
 
 
 
 
 
 
 
 
 
 
We have existing and good relationships with our service vendors.

Research and Development (“R&D”)

We spent $188,305 and $320,320 in 2023 and 2022, respectively, on R&D. 

Intellectual Property

We  believe  that  to  maintain  a  competitive  advantage  in  the  marketplace,  we  must  develop  and  maintain  protection  of  the  proprietary  aspects  of  our
technology. We rely on a combination of patent, trade secret intellectual property rights, and other measures to protect our intellectual property to develop
and  maintain  our  competitive  position.  We  seek  to  protect  our  trade  secrets  and  proprietary  know-how,  in  part,  with  confidentiality  agreements  with
employees, although we cannot be certain that the agreements will not be breached, or that we will have adequate remedies if a breach were to occur.

CORE™

We have been granted an exclusive world-wide license to CORE, our computational drug discovery platform that can predict the main effects of drugs on
disease-associated  targets.  The  licensed  technology  is  protected  by  PCT/US2012/025029,  U.S.  Patent  Application  Number  16/296,088,  China  Patent
Number 201280013276.2, Japan Patent Number 6133789, and Hong Kong Patent Number 1193197.

3D Modeling

Our  technology  is  a  patient-derived  3D  culture  platform  that  recreates  the  complex  human  organ  microenvironment  thereby  preserving  the  critical
interactions  between  a  tumor  and  its  surroundings.  Our  models  replicate  the  extracellular  matrix  of  individual  organs  and  disease-specific  soluble
microenvironment  mimicking  the  biology  of  human  disease,  and  as  such,  demonstrate  high  correlation  with  clinical  response.  Patents  include
US10,501,717 and US11,124,756.

STREAMWAY® System

In general, our patents are directed to a system and method for collecting waste fluid from a surgical procedure while ensuring there is no interruption of
suction during the surgical procedure and no limit on the volume of waste fluid that can be collected. We hold the following granted patents in the United
States on our earlier STREAMWAY System models: US7,469,727 and US8,123,731 (collectively, the “First Generation Patents”). The First Generation
Patents will begin to expire on April 17, 2024.

On January 25, 2014, we filed a non-provisional Patent Cooperation Treaty (“PCT”) Application No. PCT/US2014/013081 claiming priority from the U.S.
Provisional Patent Application, number 61756763 which was filed on January 25, 2013. The PCT allows an applicant to file a single patent application to
seek patent protection for an invention simultaneously in each of the 148-member countries of the PCT, including the United States. We filed both U.S. and
European  national  stage  applications  from  this  PCT  application.  We  have  two  issued  U.S.  patents  claiming  priority  from  the  PCT  application:
US10,253,792 and US10,954,975 (collectively, the “Second Generation Patents”). The Second Generation Patents will begin to expire on January 25, 2034.

As of November 22, 2017, we were informed that the European Patent Office allowed all our claims for application #14743665.3-1651 and on as of July
11,  2018,  we  were  informed  that  the  European  Patent  #EP2948200  was  granted.  European  Patent  #EP2948200  in  the  following  countries:  Belgium,
Germany, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, and Sweden. Further, we filed a European divisional application,
which was granted as European Patent #EP3437666 on March 26, 2020. European Patent #EP3437666 was validated in the following countries: Belgium,
Switzerland,  Cyprus,  Germany,  Spain,  France,  United  Kingdom,  Hungary,  Ireland,  Italy,  Liechtenstein,  North  Macedonia,  Malta,  Netherlands,  Norway,
Poland,  Sweden,  and  Turkey.  Our  PCT  patent  application  is  for  an  enhanced  model  of  the  surgical  fluid  waste  management  system.  We  utilize  this
enhanced technology in the updated version of the STREAMWAY System unit we began selling in 2014.

11

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government Regulation

Our businesses are subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state
levels) and the other jurisdictions in which we conduct business, including some specific to our business, some specific to our industry, and others relating
to conducting business generally (e.g., U.S. Foreign Corrupt Practices Act). We also are subject to inspections and audits by governmental agencies. The
table below highlights key regulatory schemes applicable to our businesses: 

CLIA and State Clinical
Laboratory Licensing

CLIA regulates the operations of virtually all clinical laboratories, requiring that they be certified by the federal government
and  that  they  comply  with  various  technical,  operational,  personnel,  and  quality  requirements  intended  to  ensure  that  the
services provided are accurate, reliable, and timely.

State  laws  may  require  additional  personnel  qualifications  or  licenses,  quality  control,  record  maintenance,  proficiency
testing, or detailed review of our scientific method validations and technical procedures for certain tests.

Violations  of  these  laws  and  regulations  may  result  in  monetary  fines,  criminal  and  civil  penalties  and/or  suspension  or
exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs.

Medicare and Medicaid;
Fraud and Abuse

Diagnostic testing services provided under Medicare and Medicaid programs are subject to complex, evolving, stringent, and
frequently  ambiguous  federal  and  state  laws,  and  regulations,  including  those  relating  to  billing,  coverage,  and
reimbursement.

Anti-kickback laws and regulations prohibit making payments or furnishing other benefits to influence the referral of tests
billed to Medicare, Medicaid, or certain other federal or state healthcare programs.
In  addition,  federal  and  state  anti-self-referral  laws  generally  prohibit  Medicare  and  Medicaid  payments  for  clinical  tests
referred  by  physicians  who  have  an  ownership  or  investment  interest  in,  or  a  compensation  arrangement  with,  the  testing
laboratory, unless specific exceptions are met.

Federal substance abuse legislation enacted in 2018 contains anti-kickback provisions that are, by their terms, applicable to
laboratory testing paid for by all payers. Upon full review of the legislation, we were in compliance at that time and continue
to maintain compliance. We monitor regularly and reflect this in our annual compliance report.

Some states have similar laws that are not limited in applicability to only Medicare and Medicaid referrals and could also
affect tests that are paid for by health plans and other non-governmental payers.
Violations  of  these  laws  and  regulations  may  result  in  monetary  fines,  criminal  and  civil  penalties  and/or  suspension  or
exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs.

FDA

The FDA has potential regulatory responsibility over, among other areas, instruments, software, test kits, reagents and other
devices  used  by  clinical  laboratories  to  perform  diagnostic  testing  in  the  United  States.  The  FDA  may  assert  regulatory
oversight  over  these  areas,  and  legislative  proposals  addressing  FDA  oversight  of  laboratory  developed  tests  have  been
introduced in the past and may be enacted in the future. See “Item 1A. Risk Factors” for a discussion of the possible impact
of such regulatory or legislative developments.

12

 
 
 
 
 
 
 
 
 
 
 
 
 
Environmental, Health and
Safety

We are subject to laws and regulations related to the protection of the environment, the health and safety of employees, and
the  handling,  transportation,  and  disposal  of  medical  specimens,  infectious  and  hazardous  waste,  radioactive  materials,
various aspects of pertinent technologies and methods of protection.

Several organizations maintain oversight function including:
    •   OSHA (Occupational Safety and Health Administration)
    •   EPA (Environmental Protection Agency)
    •   DOT (Department of Transportation)
    •   USPS (US Postal Service)
    •   US Public Health Service
    •   JCAHO (Joint Commission on Accreditation of Healthcare Organizations)
    •   NFPA (National Fire Protection Association)
    •   AIA (American Institute of Architects)
    •   AORN (Association of Operating Room Nurses)

Privacy and Security of
Health and Personal
Information

We  are  subject  to  laws  and  regulations  regarding  protecting  the  security  and  privacy  of  certain  healthcare  and  personal
information,  including:  (1)  the  federal  Health  Insurance  Portability  and  Accountability  Act  and  the  regulations  thereunder,
which  establish  (a)  a  complex  regulatory  framework  including  requirements  for  safeguarding  protected  health  information
and (b) comprehensive federal standards regarding the uses and disclosures of protected health information; (2) state laws;
and (3) the European Union's General Data Protection Regulation.

A  healthcare  provider  may  be  subject  to  penalties  for  non-compliance  and  may  be  required  to  notify  individuals  or  state,
federal,  or  county  governments  if  the  provider  discovers  certain  breaches  of  personal  information  or  protected  health
information.

To date, no regulatory agency has established exclusive jurisdiction over the area of biohazardous and infectious waste in healthcare facilities.

FDA Clearance of STREAMWAY® System under Section 510(k).

The FDA Center for Devices and Radiological Health requires 510(k) submitters to provide information that compares its new device to a marketed device
of a similar type, in order to determine whether the device is substantially equivalent.

We filed the 510(k) submission for clearance of the STREAMWAY System device on March 14, 2009, and received written confirmation on April 1, 2009
that our 510(k) has been cleared by the FDA. Our 510(k) number is K090759.

Following  these  510(k)  clearances  by  the  FDA,  we  continue  to  be  subject  to  the  normal  ongoing  audits  and  reviews  by  the  FDA  and  other  governing
agencies. These audits and reviews are standard and typical in the medical device industry, and we do not anticipate being affected by any extraordinary
guidelines or regulations.

Our subsidiary, Skyline Medical, has successfully passed FDA audits in the past, with no observations or 483 warning letters issued.

Application for Electrical Safety Testing and Certification for STREAMWAY System

We sought and achieved testing and certification to the IEC 60606-1 and IEC 60606-1-2, two internationally recognized standards.

The 60601-1 3rd edition certification for our STREAMWAY System is valid and enables us to continue to market and sell our product domestically and
internationally.

13

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We have contracted with TUV, a nationally recognized testing laboratory-NRTL, to certify our STREAMWAY System to the new 60601-1 3rd Edition in
late 2016. We attained certification to the new standard, and then submitted it to our Notified Body (BSI) for recommendation for our CE Mark, which we
received in June 2017, allowing us to sell products outside of the United States.

Effective November 21, 2016, we received a Medical Device Establishment License to sell the STREAMWAY System and related disposables in Canada.
Our Health Canada Medical Device Establishment License number is 7202.

ISO Certification

Our subsidiary, Skyline Medical, hired BSI (British Standards Institute) to be its Notified Body and to perform audits to ISO 13485:2003 Standards. On
June 1, 2016, we successfully passed the audit of our Quality Management System and received our Certificate of Registration for ISO 13485:2016. Our
certificate number is FM 649810.

Employees and Human Capital Resources

We  had  34  full-time  employees  and  1  part-time  employee  as  of  December  31,  2023.  None  of  our  employees  are  subject  to  a  collective  bargaining
agreement  and  we  believe  our  relations  with  our  employees  are  satisfactory.  Our  human  capital  resources  objectives  include  identifying,  recruiting,
retaining, incentivizing and integrating our existing and additional employees, and we recruit people for positions regardless of gender, ethnicity or other
protected traits.

Executive Offices

Our principal executive offices are located at 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania and our telephone number is (412) 432-1500.

Corporate History

We were originally incorporated in Minnesota on April 23, 2002, and reincorporated in Delaware in 2013. We changed our name from Skyline Medical Inc.
to Precision Therapeutics Inc. on February 1, 2018 and to Predictive Oncology Inc. on June 13, 2019.

Available Information

Our website address is https://predictive-oncology.com. Information contained on our website is not incorporated by reference into this Annual Report on
Form 10-K unless expressly noted.

We  file  reports  with  the  Securities  and  Exchange  Commission  (“SEC”),  which  we  make  available  on  our  website  free  of  charge  at
https://investors.predictive-oncology.com/financial-information. These reports include Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K, each of which is provided on our website as soon as reasonably practicable after we electronically file such materials with,
or furnish them to, the SEC. We also make, or will make, available through our website other reports filed with or furnished to the SEC under the Securities
Exchange Act of 1934, as amended, including our proxy statements and reports filed by officers and directors under Section 16(a) of that Act. In addition,
the SEC maintains a website (https://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC, including us.

14

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ITEM 1A. RISK FACTORS.

You should carefully consider the risks described below before making an investment decision. Our business could be harmed by any of these risks. The
trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks described below are
not  the  only  ones  that  we  may  face.  Additional  risks  that  are  not  currently  known  to  us  or  that  we  currently  consider  immaterial  may  also  impair  our
business, financial condition or results of operations. In assessing these risks, you should also refer to the other information contained in this Form 10-K,
including our financial statements and related notes.

Risk Factors Related to Our Business

There is substantial doubt about our ability to continue as a going concern. We will require significant additional financing to fund operating expenses
and implement our business plan. Such financing, if available, may be dilutive.

We  have  incurred  significant  and  recurring  losses  from  operations  for  the  past  several  years  and  had  an  accumulated  deficit  of  $167,761,883  as  of
December 31, 2023. We had cash and cash equivalents of $8,728,660 as of December 31, 2023 and need to raise significant additional capital to meet our
operating needs. Our short-term obligations as of December 31, 2023 were $3,951,031, consisting primarily of aggregate accounts payable and accrued
expenses of $2,973,729 and operating lease obligations of $517,427. As of December 31, 2023, we also had a short-term note payable of $150,408 that
bears interest at an annual percentage rate of 9.25% and long-term operating lease obligations of $2,188,979 with a weighted average remaining lease term
of 3.99 years. We do not expect to generate sufficient operating revenue to sustain our operations in the near term. During the year ended December 31,
2023,  we  incurred  negative  cash  flows  from  operations  of  $13,189,390.  Although  we  have  attempted  to  improve  our  operating  margin  by  bolstering
revenues and curtailing expenses and continue to seek ways to generate revenue through business development activities, there is no guarantee that we will
be able to improve our operating margin sufficiently or achieve profitability in the near term. These conditions raise substantial doubt about our ability to
continue as a going concern within one year after the date our consolidated financial statements included in this annual report on Form 10-K are issued. We
are evaluating alternatives to obtain the required additional funding to maintain future operations. These alternatives may include, but are not limited to,
equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. These possibilities, to the extent
available, may be on terms that result in significant dilution to our existing stockholders or that result in our existing stockholders losing part or all of their
investment. Despite these potential sources of funding, we may be unable to access financing or obtain additional liquidity under acceptable terms, if at all.
If such financing or adequate funds from operations are not available, we would be forced to limit our business activities and we could default on existing
payment obligations, which would have a material adverse effect on our financial condition and results of operations, and may ultimately be required to
cease our operations and liquidate our business.

The use of AI in our business is subject to risks associated with new and rapidly evolving technologies and industries, may result in reputational harm
or liability, and may not result in the development of commercially viable therapies, drugs or treatments.

Our business model relies on the use of AI to support the development of optimal cancer therapies. Using AI and our proprietary biobank of 150,000+
tumor samples, categorized by patient type, we make optimized, high-confidence drug-response predictions regarding drug compounds to enable a more
informed selection of drug/tumor combinations. While we believe that AI may potentially enable more efficient drug research and clinical development
than the conventional model, our approach is novel and has not yet been widely studied. Our use of AI is subject to risks and challenges associated with
new, disruptive, and rapidly evolving technologies and industries, which may affect its adoption and the success of our business. The algorithms we use
may  be  flawed,  our  datasets  may  be  insufficient  or  contain  biased  information,  and  inappropriate  or  controversial  data  practices  by  us  or  others  could
impair  the  acceptance  of  AI  solutions.  These  deficiencies  could  undermine  the  predictions  or  analysis  that  AI  applications  produce,  subjecting  us  to
competitive harm, legal liability, and brand or reputational harm. Additionally, changes in laws and regulations could impact the usefulness of our solution
and could necessitate modifications in our business to accommodate such changes. The regulatory landscape for AI is continually evolving, and both the
FDA and the European Medicines Agency are in the process of issuing comprehensive guidance on AI software which may change how our product is
regulated.

15

 
 
 
 
 
 
 
 
 
Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we may not attract collaborators or develop
new drugs as quickly or cost-effectively as expected and, therefore, we may not be able to commercialize our approach as expected at this time.

We have entered into, and may enter into additional, collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with
third parties that may not result in the development of commercially viable products or the generation of significant future revenues.

We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships or other arrangements to develop products and
to  pursue  new  markets.  Proposing,  negotiating  and  implementing  collaborations,  in-licensing  arrangements,  joint  ventures,  strategic  alliances  or
partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or
other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or
arrangements  in  a  timely  manner,  on  a  cost-effective  basis,  on  acceptable  terms  or  at  all.  We  have  limited  institutional  knowledge  and  experience  with
respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular,
these  collaborations  may  not  result  in  the  development  of  products  that  achieve  commercial  success  or  result  in  significant  revenues  and  could  be
terminated prior to developing any products. Our ability to generate revenues from these arrangements will depend in part on our collaborators’ abilities to
successfully perform the functions assigned to them in these arrangements.

Additionally,  we  may  not  be  in  a  position  to  exercise  sole  decision-making  authority  regarding  the  transaction  or  arrangement,  which  could  create  the
potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become,
inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement
of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or
control of intellectual property developed during the collaboration. If any conflicts arise with any future collaborators, they may act in their self-interest,
which may be adverse to our best interests, and they may breach their obligations to us. In addition, we may have limited control over the amount and
timing of resources that any future collaborators devote to our or their future products. Disputes between us and our collaborators may result in litigation or
arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual
in  nature  and  will  generally  be  terminable  under  the  terms  of  the  applicable  agreements  and,  in  such  event,  we  may  not  continue  to  have  rights  to  the
products relating to such transaction or arrangement or may need to purchase such rights at a premium.

If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain
those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend
on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may
determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license
agreements could impose various due diligence, commercialization, royalty or other obligations on us. Future licensors may allege that we have breached
our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm
our business prospects.

Our limited operating history with respect to our drug discovery solutions makes evaluation of our business difficult. 

Our drug discovery, drug development and clinical research services were launched with the initial investment in Helomics during the first quarter of 2018
and have not generated significant revenue to date. Our ability to implement a successful business plan with respect to drug discovery, drug development
and clinical research services remains unproven, and we may not ever generate sufficient revenues to sustain our business. We have a limited operating
history  which  makes  it  difficult  to  evaluate  our  performance.  Our  prospects  should  be  considered  in  light  of  these  risks,  and  the  expenses,  technical
obstacles,  difficulties,  market  penetration  rate,  and  delays  frequently  encountered  in  connection  with  the  development  of  new  businesses.  These  factors
include uncertainty as to whether we will be able to:

  • Succeed in uncertain markets;
  • Respond effectively to competitive pressures;
  • Successfully address intellectual property issues of others;
  • Protect and expand our intellectual property rights; and
  • Continue to develop and upgrade our products.

16

 
 
 
 
 
 
 
 
 
 
In connection with developing our drug discovery solutions, we have committed significant capital to investments in early-stage companies, all of which
may  be  lost,  and  our  ability  to  continue  to  commit  capital  in  other  early-stage  companies  will  require  us  to  raise  significant  additional  capital.  Our
entering into new lines of business could result in significant diversion of management resources, all of which may result in failure of our business.

We have committed significant capital and management resources to developing our drug discovery solutions and other new business areas, and we intend
to continue to devote significant capital and management resources to new businesses. Therefore, we could invest significant capital in business enterprises
with no certainty when or whether we will realize a return on these investments. Any investments using cash will deplete our capital resources, meaning we
will be required to raise significant amounts of new capital. We may not be successful in raising sufficient capital, and the terms of any such financing may
be dilutive to our stockholders. We may also acquire technologies or companies by issuing stock or other equity securities rather than, or in addition to,
payment of cash, which may have the result of diluting our stockholders’ investments. Further, the energy and resources of our officers and personnel may
be substantially diverted to new lines of business, which are unproven. If these businesses are unsuccessful or require too great of a financial investment to
be profitable, our business may fail.

We  rely  on  sole  suppliers  for  some  of  the  materials  used  in  our  business,  and  we  may  not  be  able  to  find  replacements  or  transition  to  alternative
suppliers in a timely manner.

We rely on sole suppliers for certain materials used in our business. While we have developed alternate sourcing strategies for these materials and vendors,
we cannot be certain whether these strategies will be effective, or the alternative sources will be available in a timely manner. If these suppliers can no
longer provide us with the materials used in our business, if the materials do not meet required quality specifications, or if we cannot obtain acceptable
substitute materials, an interruption in our products and services provided to customers could occur. Any such interruption may directly impact our revenue
and cause us to incur higher costs.

If we are sued for product liability or errors and omissions liability, we could face substantial liabilities that exceed our resources.

The marketing, sale, and use of our products could lead to product liability claims. These claims could allege that the products failed to perform as they
were designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance
upon, the information we provide. A product liability or errors and omissions liability claim could result in substantial damages and be costly and time
consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot be certain that our insurance would fully
protect us from the financial impact of defending against these types of claims or any judgments, fines, or settlement costs arising out of such claims. Any
product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from
securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our
products  and  solutions.  The  occurrence  of  any  of  these  events  could  have  a  material  adverse  effect  on  our  business,  financial  condition,  and  results  of
operations.

17

 
 
 
 
 
 
 
 
If our R&D and commercialization efforts for our PEDAL platform take longer than expected, the commercial revenues that use this platform could
also be delayed.

Our drug discovery solutions business offers various services to pharma, diagnostics, and biotech companies. These services use our PEDAL platform. This
platform  is  the  subject  of  active  R&D  to  further  improve  them  for  commercial  use  in  order  to  help  our  clients  in  their  drug  discovery,  biomarker,  and
clinical trial activities. We could face delays in this R&D. For example:

  • we may not be able to secure access to and approval to use clinical data from academic hospital partners in a timely manner;
  • clinical testing volume (number of specimens coming to us for testing) may not grow sufficiently to drive additional data generation as well as further

development of the biobank;

  • patient consent to use the patient’s data and tumor material for R&D may not be sufficient to support R&D; and
  • we may not be able to attract and retain the appropriately qualified staff to perform the necessary R&D.

We have a limited operating history with the drug discovery solutions business, particularly in connection with services using our PEDAL platform, as
these are new to the market, which makes it difficult to forecast our future revenues. Although we are committed to the buildout of this business for the
long term, we cannot predict at this time, with any certainty, the future viability of this business unit.

We face significant competition to our STREAMWAY System in the surgical fluid waste management industry, including competition from companies
with considerably greater resources than ours, and if we are unable to compete effectively with these companies, our market share may decline, and our
business could be harmed.

The surgical fluid waste management industry is highly competitive, with numerous competitors ranging from well-established manufacturers to innovative
start-ups. Several of our competitors have significantly greater financial, technological, engineering, manufacturing, marketing, and distribution resources
than we do. Their greater capabilities in these areas may enable them to compete more effectively on the basis of price and production and more quickly
develop new products and technologies.

Companies with significantly greater resources than ours may be able to reverse engineer our products and/or circumvent our intellectual property position.
Such action, if successful, would greatly reduce our competitive advantage in the marketplace.

We believe our ability to compete successfully with our STREAMWAY System depends on a number of factors, including, without limitation, our technical
innovations of unlimited suction and unlimited capacity capabilities, our innovative and advanced research and development capabilities, strength of our
intellectual property rights, sales and distribution channels, and advanced manufacturing capabilities. We plan to employ these and other elements as we
develop our products and technologies, but there are many other factors beyond our control. We may not be able to compete successfully in the future, and
increased competition may result in price reductions, reduced profit margins, loss of market share, and an inability to generate cash flows that are sufficient
to maintain or expand our development and marketing of new products, which could adversely impact the trading price of the shares of our common stock.

If demand for our STREAMWAY System or molecular diagnostic tests is unexpectedly high or if we experience problems in scaling our operations,
there may be supply interruptions or delays that could limit the growth of our revenue.

We  have  contracted  with  a  manufacturing  company  that  follows  ISO  compliance  regulations  of  the  FDA  and  that  can  manufacture  products  at  high
volumes. However, if demand for our product is higher than anticipated, then we or our manufacturing partners may not be able to produce the product in
sufficiently higher quantity to satisfy demand.

Likewise, as demand for our molecular diagnostic tests grows, we will need to continue to scale our testing capacity and processing technology to expand
our  customer  service,  billing,  and  systems  processes  and  to  enhance  our  internal  quality  assurance  program.  We  will  also  need  additional  certified
laboratory  scientists  and  other  scientific  and  technical  personnel  to  process  higher  volumes  of  our  molecular  diagnostic  tests.  We  cannot  guarantee  that
increases in scale, related improvements, and quality assurance will be implemented successfully or that appropriate personnel will be available. Failure to
implement necessary procedures, transition to new processes, or hire the necessary personnel could result in higher costs of processing tests or an inability
to meet demand. We may not be able to perform our testing on a timely basis at a level consistent with demand, and our efforts to scale our operations may
negatively affect the quality of test results.

18

 
 
 
 
 
 
 
 
 
 
 
 
 
If  we  encounter  difficulties  in  scaling  our  operations  as  a  result  of,  among  other  things,  quality  control  and  quality  assurance  issues  and  availability  of
reagents and raw material supplies, we will likely experience reduced sales, increased repair or re-engineering costs, defects, and increased expenses due to
switching  to  alternate  suppliers.  Any  of  these  results  would  reduce  our  revenues  and  gross  margins.  Although  we  attempt  to  match  our  capabilities  to
estimates of marketplace demand, to the extent demand materially varies from our estimates, we may experience constraints in our operations and delivery
capacity,  which  could  adversely  impact  revenue  in  a  given  fiscal  period.  Any  supply  interruptions  or  inadequate  supply  would  have  a  material  adverse
effect on our results of operations.

If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed, and our future prospects and business could suffer,
causing a material adverse effect on our business, financial condition, and results of operations.

We are dependent on a few key executive officers for our success. Our inability to retain those officers would impede our business plan and growth
strategies, which would have a negative impact on our business, financial condition, and results of operations.

Our success depends on the skills, experience, and performance of key members of our management team. Were we to lose one or more members of our
management team for any reason, we would be required to expend significant time and money to find a replacement, which could result in both a delay in
the  implementation  of  our  business  plan  and  the  diversion  of  our  limited  working  capital.  We  may  not  be  able  to  find  satisfactory  replacements  for
members of our management team at all, or on terms that are not unduly expensive or burdensome to us.  Such loss of a key member or members of our
management team without adequate replacements would have a negative impact on our business, financial condition, and results of operations.

Risk Factors Related to Our Intellectual Property

Our business is dependent upon proprietary intellectual property rights, which if we were unable to protect, could have a material adverse effect on our
business. 

We rely on a combination of patent, trade secret and other intellectual property rights, contractual restrictions, and other measures to protect our intellectual
property. We currently own and may in the future own or license additional patent rights or trade secrets in the U.S., with non-provisional patents elsewhere
in the world that cover certain of our products. We rely on patent laws and other intellectual property laws, nondisclosure and other contractual provisions,
and technical measures to protect our products and intangible assets.

If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs
in our attempts to recover or restrict use of our intellectual property. While we apply for patents covering our products and technologies and uses thereof,
we  may  fail  to  apply  for  patents  on  important  products  and  technologies  in  a  timely  fashion,  or  at  all,  or  we  may  fail  to  apply  for  patents  in  relevant
jurisdictions. Others could seek to design around our current or future patented technologies. These intellectual property rights are important to our ongoing
operations and any measure we implement may not be sufficient to protect our intellectual property rights.

Further,  competitors  could  willfully  infringe  upon  our  intellectual  property  rights,  design  around  our  protected  technology,  or  develop  their  own
competitive technologies that arguably fall outside of our intellectual property rights. Others may independently develop similar or alternative products and
technologies or replicate any of our products and technologies. Also, with respect to our trade secrets and proprietary know-how, we cannot be certain that
the  confidentiality  agreements  we  have  entered  into  with  employees  will  not  be  breached,  or  that  we  will  have  adequate  remedies  for  any  breach.  In
addition,  we  may  lose  the  protection  afforded  by  these  rights  through  patent  expirations,  legal  challenges,  or  governmental  action.  If  our  intellectual
property  does  not  adequately  protect  us  against  competitors’  products  and  methods,  our  competitive  position  could  be  adversely  affected,  as  could  our
business and the results of our operations. To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we
would  be  exposed  to  a  greater  risk  of  competition.  If  our  intellectual  property  does  not  provide  adequate  coverage  of  our  competitors’  products,  our
competitive position could be adversely affected, as could our overall business.

19

 
 
 
 
 
 
 
 
 
 
 
If  we  become  subject  to  intellectual  property  actions,  it  could  hinder  our  ability  to  deliver  our  products  and  services  and  our  business  could  be
negatively impacted.

We could be subject to legal or regulatory actions alleging intellectual property infringement or similar claims against us. Companies may apply for or be
awarded patents or have other intellectual property rights covering aspects of our technologies or businesses. Litigation may be necessary for us to enforce
our patents and proprietary rights or to determine the scope, coverage, and validity of the proprietary rights of others. The outcome of any litigation or other
proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on acceptable
terms,  or  at  all.  Moreover,  if  it  is  determined  that  our  products  infringe  on  the  intellectual  property  rights  of  third  parties,  we  could  be  prevented  from
marketing our products. While we are currently not subject to any material intellectual property litigation, any future litigation alleging intellectual property
infringement could be costly, particularly in light of our limited resources. Similarly, if we determine that third parties are infringing on our patents or other
intellectual property rights, our limited resources may prevent us from litigating or otherwise taking actions to enforce our rights. Any such litigation or
inability to enforce our rights could require us to change our business practices, hinder or prevent our ability to deliver our products and services, and result
in a negative impact to our business. Expansion of our business via product line enhancements or new product lines to drive increased growth in current or
new markets may be inhibited by the intellectual property rights of our competitors and/or suppliers. Our inability to successfully mitigate those factors
may significantly reduce our market opportunity and subsequent growth. Any litigation that may be necessary in the future could result in substantial costs
and diversion of resources and could have a material adverse effect on our business, financial condition, and operating results.

If we breach our license agreements it could have a material adverse effect on our commercialization efforts for our product candidates.

A portion of our patent portfolio is in-licensed. As such, we are a party to license agreements and certain aspects of our business depend on patents and/or
patent applications owned by other companies or institutions. The license agreements impose specified diligence, milestone payment, royalty, and other
obligations on us and requires that we meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize
licensed products, in order to maintain the license. Our rights with respect to in-licensed patents and patent applications may be lost if the applicable license
agreement  expires  or  is  terminated  or  if  we  fail  to  satisfy  the  obligations  under  the  License  Agreement.  We  are  likely  to  enter  into  additional  license
agreements to in-license patents and patent applications as part of the development of our business in the future, under which we may not retain control of
the preparation, filing, prosecution, maintenance, enforcement, and defense of such patents. If we are unable to maintain these patent rights for any reason,
our ability to develop and commercialize our product candidates could be materially harmed.

Our licensors may not successfully prosecute certain patent applications, the prosecution of which they control, under which we are licensed and on which
our business depends. Even if patents issue from these applications, our licensors may fail to maintain these patents, may decide not to pursue litigation
against third-party infringers, may fail to prove infringement, or may fail to defend against counterclaims of patent invalidity or unenforceability.

Risks with respect to parties from whom we have obtained intellectual property rights may also arise out of circumstances beyond our control. In spite of
our  best  efforts,  our  licensors  might  conclude  that  we  have  materially  breached  our  intellectual  property  agreements  and  might  therefore  terminate  the
intellectual  property  agreements,  thereby  removing  our  ability  to  market  products  covered  by  these  intellectual  property  agreements.  If  our  intellectual
property agreements are terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek
regulatory approval of, and to market, products similar or identical to ours. Moreover, if our intellectual property agreements are terminated, our former
licensors and/or assignors may be able to prevent us from utilizing the technology covered by the licensed or assigned patents and patent applications. This
could have a material adverse effect on our competitive business position and our financial condition, results of operations and our business prospects.

20

 
 
 
 
 
 
 
 
Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.

Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. Depending upon the timing, duration, and conditions of FDA marketing approval of our
product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent
Term  Restoration  Act  of  1984,  referred  to  as  the  Hatch-Waxman  Amendments,  and  similar  legislation  in  the  European  Union.  The  Hatch-Waxman
Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost
during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval. Only one patent may be extended, and only those claims covering the approved drug, a method for using it,
or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply
prior  to  expiration  of  relevant  patents  or  otherwise  fail  to  satisfy  applicable  requirements.  Moreover,  the  length  of  the  extension  could  be  less  than  we
request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce
our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue
from applicable products could be reduced and could have a material adverse effect on our business.

Further, recent judicial decisions in the U.S. raised questions regarding the award of patent term adjustment (PTA) for patents in families where related
patents have issued without PTA. Thus, it cannot be said with certainty how PTA will be viewed in the future and whether patent expiration dates may be
impacted.

Changes in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents.

In  September  2011,  the  America  Invents  Act  (AIA)  was  enacted  in  the  United  States,  resulting  in  significant  changes  to  the  U.S.  patent  system.  An
important change introduced by the AIA was a transition to a “first-to-file” system for deciding which party should be granted a patent when two or more
patent applications are filed by different parties claiming the same invention, which went into effect on March 16, 2013. Therefore, a third party that now
files a patent application in the USPTO before we do could be awarded a patent covering an invention of ours even if we created the invention before it was
created  by  the  third  party.  While  we  are  cognizant  of  the  time  from  invention  to  filing  of  a  patent  application,  circumstances  could  prevent  us  from
promptly filing patent applications for our inventions.

Among  some  of  the  other  changes  introduced  by  the  AIA  were  changes  that  limit  where  a  patentee  may  file  a  patent  infringement  suit  and  providing
opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16,
2013. Because of a lower burden of proof in USPTO proceedings compared to the burden of proof in U.S. federal courts necessary to invalidate a patent
claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same
evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO
procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.
The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the patent
applications of our existing and future collaborators or licensors and the enforcement or defense of our issued patents.

Depending  on  decisions  by  the  U.S.  Congress,  the  federal  courts,  and  the  USPTO,  the  laws  and  regulations  governing  patents  could  change  in
unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Similarly, there is complexity and uncertainty related to European patent laws. For example, the European Patent Convention was amended in April 2010
to limit the time permitted for filing divisional applications. In addition, the EPO patent system is relatively stringent in the type of amendments that are
allowed during prosecution. These limitations and requirements could adversely affect our ability to obtain new patents in the future that may be important
for our business.

21

 
 
 
 
 
 
 
 
 
We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of
third parties.

We  employ  individuals  who  were  previously  employed  at  other  biotechnology  or  biopharmaceutical  companies.  Although  we  try  to  ensure  that  our
employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we
or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’
former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our
future patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are
successful, litigation could result in substantial cost and be a distraction to our management and other employees. Even if we are successful in defending
against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and
could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of  hearings,  motions  or  other  interim  proceedings  or  developments,  and,  if  securities  analysts  or  investors  perceive  these  results  to  be  negative,  that
perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our
operating losses and reduce our resources available for development activities. Some of our competitors may be able to sustain the costs of this type of
litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation
and  continuation  of  intellectual  property  litigation  or  other  intellectual  property  related  proceedings  could  adversely  affect  our  ability  to  compete  in  the
marketplace.

We may not be able to enforce our intellectual property rights throughout the world.

The  laws  of  some  foreign  countries  do  not  protect  proprietary  rights  to  the  same  extent  as  the  laws  of  the  United  States,  and  many  companies  have
encountered significant challenges in establishing and enforcing their proprietary rights outside of the United States. These challenges can be caused by the
absence  of  rules  and  methods  for  the  establishment  and  enforcement  of  intellectual  property  rights  outside  of  the  United  States.  In  addition,  the  legal
systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially
those relating to healthcare. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other
intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third
parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In
these  countries,  patents  may  provide  limited  or  no  benefit.  Patent  protection  must  ultimately  be  sought  on  a  country-by-country  basis,  which  is  an
expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we
will not have the benefit of patent protection in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs  and  divert  our  efforts  and  attention  from  other  aspects  of  our  business.  Accordingly,  our  efforts  to  protect  our  intellectual  property  rights  in  such
countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability
to obtain adequate protection for our technology and the enforcement of intellectual property.

Beginning  June  1,  2023,  European  patent  applications  and  patents  may  be  subjected  to  the  jurisdiction  of  the  Unified  Patent  Court  (UPC).  Under  the
unitary  patent  system,  European  applications  will  have  the  option,  upon  grant  of  a  patent,  of  becoming  a  Unitary  Patent  which  will  be  subject  to  the
jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents that
remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the
patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.

22

 
 
 
 
 
 
 
Risk Factors Related to Regulation

Our business is subject to intense governmental regulation and scrutiny, both in the U.S. and abroad.

The production, marketing, and R&D of our products is subject to extensive regulation and review by the FDA and other governmental authorities both in
the  United  States  and  abroad.  In  addition  to  testing  and  approval  procedures,  extensive  regulations  also  govern  marketing,  manufacturing,  distribution,
labeling,  and  record  keeping.  If  we  do  not  comply  with  applicable  regulatory  requirements,  violations  could  result  in  warning  letters,  non-approvals,
suspensions  of  regulatory  approvals,  civil  penalties  and  criminal  fines,  product  seizures  and  recalls,  operating  restrictions,  injunctions,  and  criminal
prosecution.

Periodically, legislative or regulatory proposals are introduced that could alter the review and approval process relating to medical products. It is possible
that the FDA will issue additional regulations further restricting the sale of our present or proposed products. Any change in legislation or regulations that
governs the review and approval process relating to our current and future products could make it more difficult and costlier to obtain approval for new
products,  or  to  produce,  market,  and  distribute  existing  products.  Any  such  change  could  also  result  in  a  failure  to  obtain  necessary  approvals  for  our
current or future products, which would negatively impact our financial condition and results of operations.

If the FDA begins to enforce regulation of our molecular diagnostic tests, we could incur substantial costs and delays associated with trying to obtain
pre-market clearance or approval and costs associated with complying with post-market requirements.

Clinical laboratory tests like our molecular diagnostic tests are regulated under CLIA as well as by applicable state laws. The FDA has historically taken
the position that it has the authority to regulate Laboratory Developed Tests (“LDTs”) as medical devices under the Federal Food, Drug, and Cosmetic Act,
but it has a long-standing policy of not exercising general enforcement discretion with regard to LDTs. Accordingly, LDTs have effectively not been subject
to the FDA’s regulation (although reagents, instruments, software, or components provided by third parties and used to perform LDTs may be subject to
regulation). However, in September 2023, the FDA published a proposed rule on LDTs that would end the FDA’s prior policy of enforcement discretion
with respect to LDTs. The proposed rule would phase out the FDA’s enforcement discretion policy in five stages over a four-year period from the effective
date of the rule. In Phase 1 (effective one year after the rule is finalized), enforcement discretion would end with respect to medical device reporting and
correction and removal reporting requirements. In Phase 2 (effective two years post-finalization), enforcement discretion would end with regard to other
device requirements, including registration and listing, labeling, and investigational devices, except for quality systems and premarket review. In Phase 3
(effective three years post-finalization), enforcement discretion would end with regard to quality systems requirements. In Phase 4 (effective three and a
half  years  post-finalization,  but  not  before  October  1,  2027),  enforcement  discretion  would  end  with  regard  to  compliance  with  premarket  review
requirements for high-risk tests (i.e., tests subject to premarket approval). Finally, in Phase 5 (effective four years post-finalization, but not before April 1,
2028), enforcement discretion would end with regard to premarket review requirements for moderate-risk and low-risk tests. Unlike previous proposals, the
proposed rule does not “grandfather in” any existing tests. At this time, the proposed rule has not been finalized, and its ultimate content (including whether
the rule will go into effect at all) remains unknown.

Legislative proposals addressing the FDA’s oversight of LDTs have been introduced in previous Congresses, including the “Verifying Accurate Leading-
edge  IVCT  Development  Act,”  or  VALID  Act,  and  we  expect  that  new  legislative  proposals  will  be  introduced  from  time‑to‑time.  The  likelihood  that
Congress  will  pass  such  legislation  and  the  extent  to  which  such  legislation  may  affect  the  FDA’s  plans  to  regulate  certain  LDTs  as  medical  devices  is
difficult to predict at this time. If the FDA ultimately regulates certain LDTs, whether via final guidance, final regulation, or as instructed by Congress, our
molecular diagnostic tests may be subject to certain additional regulatory requirements. The cost of conducting clinical trials and otherwise developing data
and information to support pre-market applications may be significant. If we are required to submit applications for our currently marketed tests, we may
be required to conduct additional studies, which may be time-consuming and costly and could result in our currently marketed tests being withdrawn from
the market. If our tests are allowed to remain on the market, but there is uncertainty in the marketplace about our tests, and if we are required by the FDA to
label them investigational, or if labeling claims the FDA allows us to make are limited, orders may decline, and reimbursement may be adversely affected.
Continued compliance with the FDA’s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA
and penalties for failure to comply with these requirements.

In sum, we cannot predict the timing or form of any such guidance or regulation, or the potential effect on our existing molecular diagnostic tests or our
tests in development, or the potential impact of such guidance or regulation on our business, financial condition, and results of operations.

If  we  fail  to  comply  with  Federal,  State,  and  foreign  laboratory  licensing  requirements,  we  could  lose  the  ability  to  perform  our  tests  or  experience
disruptions to our business. 

We  are  subject  to  CLIA,  a  federal  law  that  regulates  clinical  laboratories  that  perform  testing  on  specimens  derived  from  humans  for  the  purpose  of
providing  information  for  the  diagnosis,  prevention,  or  treatment  of  disease.  CLIA  regulations  mandate  specific  standards  in  the  areas  of  personnel
qualifications, administration, and participation in proficiency testing, patient test management, and quality assurance. CLIA certification is also required in
order for our business to be eligible to bill Federal and State healthcare programs, as well as many private third-party payors, for our molecular diagnostic
tests. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of
our clinical reference laboratories. Pennsylvania laws also require that we maintain a license and establish standards for the day-to-day operation of our
clinical reference laboratory in Pittsburgh, Pennsylvania. In addition, our Pittsburgh laboratory is required to be licensed on a test-specific basis by certain
other states. If we were unable to obtain or lose our CLIA certificate or State licenses for our laboratories, whether as a result of revocation, suspension, or
limitation, we would no longer be able to perform our molecular diagnostic tests, which could have a material adverse effect on our business, financial
condition, and results of operations. If we were to lose our licenses issued by the States in which we are required to hold licenses, we would not be able to
test specimens from those States. New molecular diagnostic tests we may develop may be subject to new approvals by governmental bodies, and we may
not be able to offer our new molecular diagnostic tests to patients in such jurisdictions until such approvals are received.

23

 
 
 
 
 
 
 
 
 
 
 
 
 
Complying with numerous statutes and regulations pertaining to our molecular diagnostics business is an expensive and time-consuming process, and
any failure to comply could result in substantial penalties.

We are subject to regulation by both the Federal government and the States in which we conduct our molecular diagnostics business, including:

  • The Food, Drug, and Cosmetic Act, as supplemented by various other statutes;
  • The Prescription Drug Marketing Act of 1987, the amendments thereto, and the regulations promulgated thereunder and contained in 21 C.F.R. Parts

203 and 205;

  • CLIA and State licensing requirements;
  • Manufacturing and promotion laws;
  • Medicare and Medicaid billing and payment regulations applicable to clinical laboratories;
  • The  Federal  Anti-Kickback  Statute,  which  prohibits  knowingly  and  willfully  offering,  paying,  soliciting,  or  receiving  remuneration,  directly  or
indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that
is reimbursable, in whole or in part, by a federal healthcare program;

  • The Federal Stark physician self-referral law (and State equivalents), which prohibits a physician from making a referral for certain designated health
services  covered  by  the  Medicare  program,  including  laboratory  and  pathology  services,  if  the  physician  or  an  immediate  family  member  has  a
financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to
the prohibition;

  • The Federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which established comprehensive federal standards with respect
to  the  privacy  and  security  of  protected  health  information  and  requirements  for  the  use  of  certain  standardized  electronic  transactions,  and
amendments made in 2013 to HIPAA under the Health Information Technology for Economic and Clinical Health Act, which strengthen and expand
HIPAA  privacy  and  security  compliance  requirements,  increase  penalties  for  violators,  extend  enforcement  authority  to  state  attorneys  general,  and
impose requirements for breach notification;

  • The  Federal  Civil  Monetary  Penalties  Law,  which  prohibits,  among  other  things,  the  offering  or  transfer  of  remuneration  to  a  Medicare  or  State
healthcare  program  beneficiary  if  the  person  knows  or  should  know  it  is  likely  to  influence  the  beneficiary’s  selection  of  a  particular  provider,
practitioner, or supplier of services reimbursable by Medicare or a State healthcare program, unless an exception applies;

  • The Federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented,

a false or fraudulent claim for payment to the Federal government;

  • Other Federal and State fraud and abuse laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or
discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payor,
including private insurers;

  • The prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other

party;

  • The rules regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up
the  price  of  the  technical  component  or  professional  component  of  a  diagnostic  test  ordered  by  the  physician  or  other  supplier  and  supervised  or
performed by a physician who does not “share a practice” with the billing physician or supplier; and

  • State  laws  that  prohibit  other  specified  practices  related  to  billing,  such  as  billing  physicians  for  testing  that  they  order,  waiving  coinsurance,  co-
payments,  deductibles,  and  other  amounts  owed  by  patients,  and  being  reimbursed  at  a  higher  amount  from  Medicare,  Medicaid,  and  other  Federal
programs, than what we charge other payors.

We  have  implemented  policies  and  procedures  designed  to  comply  with  these  laws  and  regulations.  We  periodically  conduct  internal  reviews  of  our
compliance with these laws. Our compliance is also subject to governmental review. The growth of our business may increase the potential of violating
these laws, regulations, or our internal policies and procedures. The risk that we are found in violation of these, or other laws and regulations is further
increased  by  the  fact  that  many  have  not  been  fully  interpreted  by  the  regulatory  authorities  or  the  courts,  and  their  provisions  are  open  to  a  variety  of
interpretations. Possible violations of Federal or State regulations may spur investigations or enforcement actions by the FDA, Department of Justice, State
agencies,  or  other  legal  authorities,  and  confirmed  violations  may  result  in  substantial  civil,  criminal,  or  other  fees,  penalties  or  sanctions.  Any  action
brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert managements’ attention from the operation of our business. If our operations are found to be in violation of any of these laws and
regulations, we may be subject to civil and criminal penalties, damages, and fines, we could be required to refund payments we received, we could face
possible exclusion from Medicare, Medicaid and other Federal or State healthcare programs, and we could even be required to cease operations. Any of the
foregoing consequences could have a material adverse effect on our business, financial condition, and results of operations.

24

 
 
 
 
 
 
If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.

We are subject to Federal, State, and local laws, rules and regulations governing the use, discharge, storage, handling, and disposal of biological material,
chemicals, and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling, or
disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs, and any related
penalties or fines. This liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and
regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could have a significant
impact on our operating results.

The healthcare regulatory and political framework is uncertain and evolving.

Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and
results of operations. For example, in March 2010, the Patient Protection and Affordable Care Act, (“ACA”), was adopted, which is a healthcare reform
measure  that  provided  healthcare  insurance  for  approximately  30  million  additional  Americans.  The  ACA  includes  a  variety  of  healthcare  reform
provisions  and  requirements  that  became  effective  at  varying  times  through  2018  and  substantially  changed  the  way  healthcare  is  financed  by  both
governmental  and  private  insurers,  which  may  significantly  impact  our  industry  and  our  business.  For  instance,  the  ACA  requires  “Applicable
Manufacturers” to disclose to the Secretary of the Department of Health & Human Services drug sample distributions and certain payments or transfers of
value  to  covered  recipients  (physicians  and  teaching  hospitals)  on  an  annual  basis.  “Applicable  Manufacturers”  and  “Applicable  Group  Purchasing
Organizations” must also disclose certain physician ownership or investment interests. The data submitted will ultimately be made available on a public
website. Based upon the structure of our relationship with our clients, we may be included in the definition of “Applicable Manufacturer” for purposes of
the disclosure requirements or may provide services that include the transfer of drug samples and/or other items of value to covered recipients. As such, we
may  be  required  to  disclose  or  provide  information  that  is  subject  to  disclosure.  There  may  be  certain  risks  and  penalties  associated  with  the  failure  to
properly make such disclosures, including but not limited to the specific civil liabilities set forth in the ACA, which allows for a maximum civil monetary
penalty per “Applicable Manufacturer” of $1,150,000 per year. There may be additional risks and claims made by third parties derived from an improper
disclosure that are difficult to ascertain at this time. 

We cannot predict whether future healthcare initiatives will be implemented at the federal or state level, or how any future legislation or regulation may
affect us.

25

 
 
 
 
 
 
 
Risk Factors Related to the Securities Markets and Ownership of Our Common Stock

Our certificate of incorporation, as amended, provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will
be the exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders’ ability to obtain a judicial forum
viewed by the stockholders as more favorable for disputes with us or our directors, officers, or employees.

Our certificate of incorporation, as amended, provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware shall be
the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the corporation, (2) any action asserting a claim of breach of a
fiduciary  duty  owed  by  any  director  or  officer  of  the  corporation  to  the  corporation  or  the  corporation’s  stockholders,  (3)  any  action  asserting  a  claim
against the corporation arising pursuant to any provision of the General Corporation Law or the corporation’s certificate of incorporation or bylaws, or (4)
any action asserting a claim against the corporation governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought
to  enforce  a  duty  or  liability  created  by  the  Securities  Exchange  Act  of  1934.  It  could  apply,  however,  to  a  suit  that  falls  within  one  or  more  of  the
categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, as amended, inasmuch as Section 22 of the Securities
Act creates concurrent jurisdiction for Federal and State courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule
and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our
stockholders will not be deemed to have waived our compliance with the Federal securities laws and the rules and regulations thereunder.

Any  person  or  entity  purchasing  or  otherwise  acquiring  any  interest  in  any  of  our  securities  shall  be  deemed  to  have  notice  of  and  consented  to  these
provisions. These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum of their choosing for disputes with us or
our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.

If a court were to find the choice of forum provision contained in our certificate of incorporation, as amended, to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and
results  of  operations.  Even  if  we  are  successful  in  defending  against  these  claims,  litigation  could  result  in  substantial  costs  and  be  a  distraction  to  our
management team.

Our common stock could be delisted from the Nasdaq Capital Market, which delisting could hinder your ability to obtain accurate quotations on the
price of our common stock or dispose of our common stock in the secondary market.

On  May  13,  2022,  we  received  a  letter  from  the  Listing  Qualifications  Department  of  Nasdaq  informing  us  that  because  the  closing  bid  price  for  our
common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, we did not comply with the minimum closing bid price requirement for
continued  listing  on  the  Nasdaq  Capital  Market  under  NASDAQ  Marketplace  Rule  5550(a)(2),  requiring  a  minimum  bid  price  of  $1.00  per  share  (the
“Minimum Bid Price Requirement”). The letter stated that we had 180 days, or until November 9, 2022, to regain compliance by maintaining a closing bid
price of at least $1.00 for a minimum of 10 consecutive trading days. This deadline was subsequently extended by Nasdaq to May 8, 2023.

On April 23, 2023, we effected a 20-for-1 reverse stock split to cure this deficiency. As a result, our stock price increased significantly, and we regained
compliance with the Minimum Bid Price Requirement. However, since the reverse stock split, our stock price has declined and, as of March 18, 2024, our
closing stock price was $2.70 per share. If we subsequently fail to meet the Minimum Bid Price Requirement or another requirement for continued listing
on Nasdaq, we could be delisted.

In the event our common stock is delisted from the Nasdaq Capital Market and we are also unable to maintain listing on another alternate exchange, trading
in our common stock could thereafter be conducted through one or more over-the-counter markets. In such event, the liquidity of our common stock would
likely be impaired, not only in the number of shares which could be bought and sold, but also through delays in the timing of the transactions, and there
would likely be a reduction in our coverage by security analysts and the news media, thereby resulting in lower prices for our common stock than might
otherwise prevail.

26

 
 
 
 
 
 
 
 
 
 
 
Limitations on director and officer liability and indemnification of our officers and directors by us may discourage stockholders from bringing a suit
against a director.

Our  certificate  of  incorporation  and  bylaws  provide,  with  certain  exceptions  as  permitted  by  governing  state  law,  that  a  director  or  officer  shall  not  be
personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions that involve intentional misconduct, fraud,
knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing a suit against a director for
breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director. In addition, our
certificate of incorporation and bylaws may provide for mandatory indemnification of directors and officers to the fullest extent permitted by governing
state law.

You may experience dilution as a result of future equity offerings.

We may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. Although no
assurances can be given that we will consummate a future financing, in the event we do, or in the event we sell shares of common stock or other securities
convertible into shares of our common stock in the future, additional and potentially substantial dilution could occur.

The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively impact the price of our
common stock.

As of December 31, 2023, we had 1,806,589 warrants outstanding at a weighted average exercise price of $21.52 per share. We are able to grant stock
options, restricted stock, restricted stock units, stock appreciation rights, bonus stock, and performance awards under our 2012 Stock Incentive Plan. Under
the  2012  Stock  Incentive  Plan,  47,664  shares  were  issuable  under  outstanding  incentive  awards  at  December  31,  2023,  and  94,878  shares  remained
available for issuance pursuant to future incentive grants. The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on
our stock, and negatively impact the price of our common stock.

We do not expect to pay cash dividends for the foreseeable future, and we may never pay dividends; investors must rely on stock appreciation, if any, for
any return on investment in our common stock.

We currently intend to retain any future earnings to support the development and expansion of our business and do not anticipate paying cash dividends in
the foreseeable future. Our payment of any future dividends will be at the discretion of our board of directors after considering various factors, including
but not limited to, our financial condition, operating results, cash needs, growth plans, and the terms of any credit agreements that we may be a party to at
the time. In addition, our ability to pay dividends on our common stock is limited by the Delaware General Corporation Law, which provides that dividends
may  only  be  lawfully  paid  out  of  a  corporation’s  “surplus,”  which  is  generally  defined  as  the  amount  by  which  total  assets  exceed  total  liabilities.
Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, and the availability of a liquid trading
market in our shares as the only way to realize certain returns on their investment.

Our board of directors’ ability to issue undesignated preferred stock and the existence of anti-takeover provisions may depress the value of our common
stock.

Our  authorized  capital  includes  20  million  shares  of  preferred  stock.  Of  this  amount,  2,300,000  shares  have  been  designated  as  series  B  convertible
preferred stock, of which 79,246 shares are outstanding. The remaining authorized shares are undesignated preferred stock. Our board of directors has the
power  to  issue  any  or  all  of  the  shares  of  undesignated  preferred  stock,  including  the  authority  to  establish  one  or  more  series  and  to  fix  the  powers,
preferences,  rights,  and  limitations  of  such  class  or  series,  without  seeking  stockholder  approval.  Further,  as  a  Delaware  corporation,  we  are  subject  to
provisions of the Delaware General Corporation Law regarding business combinations. We may, in the future, consider adopting additional anti-takeover
measures. The authority of our board of directors to issue undesignated stock and the anti-takeover provisions of Delaware law, as well as any future anti-
takeover measures adopted by us, may, in certain circumstances, delay, deter, or prevent takeover attempts and other changes in control not approved by our
board of directors. As a result, our stockholders may lose opportunities to dispose of their shares at favorable prices generally available in takeover attempts
or that may be available under a merger proposal and the market price, voting, and other rights of the holders of common stock may also be affected.

27

 
 
 
 
 
 
 
 
 
 
 
 
Our stock price may be volatile, and you could lose all or part of your investment.

The trading price of our common stock may fluctuate substantially and will depend on several factors, including those described in this “Risk Factors”
section, many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part
of your investment in our securities.

In addition, the stock market in general has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the
operating  performance  of  those  companies.  Broad  market  and  industry  factors,  as  well  as  general  economic,  political  and  market  conditions  such  as
recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance.

Further, in the past, following periods of volatility in the overall market and the market prices of particular companies’ securities, securities class action
litigations have often been instituted against these companies. Litigation of this type, if instituted against us, could result in substantial costs and a diversion
of our management’s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened
litigation could require that we make significant payments.

General Risk Factors

Business disruptions could harm our operations, lead to a decline in revenue and increase our costs.

Our operations could be disrupted by political and/or civil unrest, acts of war or other military actions, such as recent and ongoing conflicts in Israel/Gaza
and Ukraine, epidemics or pandemics, such as a potential resurgence of the COVID-19 pandemic, and other natural or man-made disasters and catastrophic
events. Geopolitical and domestic political developments and other events beyond our control, can increase economic volatility globally and disrupt supply
chains we rely on. Our operations could be harmed and our costs could increase if manufacturing, logistics or other operations are disrupted for any reason,
including  economic,  business,  labor,  environmental,  public  health,  or  political  issues.  We  monitor  and  act  as  necessary  to  mitigate  potential  risks  of
shortages and delays that may impact our ability to obtain new contracts, fulfill product demands and meet our contract obligations. The extent to which
business disruptions may impact our financial condition and results of operations remains uncertain and is dependent on numerous evolving factors.

Our success is dependent on our ability to attract and retain technical personnel, sales and marketing personnel, and other skilled management.

Our success depends to a significant degree on our ability to attract, retain, and motivate highly skilled and qualified personnel. Failure to attract and retain
necessary  technical,  sales  and  marketing  personnel,  and  skilled  management  could  adversely  affect  our  business.  If  we  fail  to  attract,  train,  and  retain
sufficient numbers of these highly qualified people, our business, financial condition, and results of operations could be materially and adversely affected.

28

 
 
 
 
 
 
 
 
 
 
 
Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the
Internal Revenue Code and may be subject to further limitation because of prior or future offerings of our stock or other transactions.  

Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended (the “Code”) contain rules that limit the ability of a company that
undergoes an ownership change, which is generally an increase in the ownership percentage of certain stockholders in the stock of a company by more than
50% over a three-year period, to utilize its net operating loss and tax credit carryforwards and certain built-in losses recognized in years after the ownership
change. These rules generally operate by focusing on ownership changes involving stockholders owning directly or indirectly 5% or more of the stock of a
company and any change in ownership arising from a new issuance of stock by that company. Generally, if an ownership change, as defined by Section 382
of the Code, occurs, the yearly taxable income limitation on the use of net operating loss and tax credit carryforwards and certain built-in losses is equal to
the  product  of  the  applicable  long-term  tax-exempt  rate  and  the  value  of  stock  immediately  before  the  ownership  change.  The  Company  performed  a
Section 382 analysis as of December 31, 2023 which resulted in the limitation and expiration of a substantial portion of the Company’s loss carryforwards.
In addition, the current net operating loss (“NOL”) carryforwards might be further limited by future issuances of our common stock.

Costs incurred because we are a public company may affect our profitability.

As  a  public  company,  we  incur  significant  legal,  accounting,  and  other  expenses  and  are  subject  to  the  SEC’s  rules  and  regulations  relating  to  public
disclosure  that  generally  involve  a  substantial  expenditure  of  financial  resources.    In  addition,  the  Sarbanes-Oxley  Act  of  2002,  as  well  as  rules
subsequently  implemented  by  the  SEC,  require  changes  in  corporate  governance  practices  of  public  companies.  Full  compliance  with  such  rules  and
regulations requires significant legal and financial compliance costs and makes some activities more time-consuming and costlier, which may negatively
impact our financial results. To the extent our earnings suffer as a result of the financial impact of our SEC reporting or compliance costs, our ability to
develop an active trading market for our securities could be harmed.

Shares eligible for future sale may adversely affect the market.

From time to time, certain stockholders may be eligible to sell some or all of their shares of common stock pursuant to Rule 144, promulgated under the
Securities Act, subject to certain limitations. In general, pursuant to Rule 144 as in effect as of the date of this filing, a stockholder (or stockholders whose
shares are aggregated) who has satisfied the applicable holding period and is not deemed to have been one of our affiliates at the time of sale, or at any time
during the three months preceding a sale, may sell their shares of common stock. Any substantial sale, or cumulative sales, of our common stock pursuant
to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on the market price of our securities.

We may be unable to provide stock-based incentives to our employees without an increase in shares available for issuance.

Due to the low number of shares remaining available for issuance, we may be unable to provide stock-based incentives to our employees. Any increase in
shares issuable will be subject to stockholder approval, which may not be obtained. Not obtaining stockholder approval could materially impact our ability
to provide stock-based incentives to our employees, which could mean that we have to pay more cash, which is currently limited.

Acquisitions involve risks that could result in adverse changes to operating results, cash flows, and liquidity.   

We may desire to make strategic acquisitions in the future. However, we may not be able to identify suitable acquisition opportunities, or we may be unable
to obtain the consent of our stockholders and therefore, may not be able to complete such acquisitions. We may pay for acquisitions with our common stock
or with convertible securities, which may dilute stockholders’ investment in our common stock, or we may decide to pursue acquisitions that our investors
may not agree with. In connection with potential acquisitions, we may agree to substantial earn-out arrangements. To the extent we defer the payment of
the purchase price for any acquisition through a cash earn-out arrangement, cash flows could be reduced in subsequent periods.

29

 
 
 
 
 
 
 
 
 
 
 
 
In addition, acquisitions may expose us to operational challenges and risks, including:

  • the ability to profitably manage acquired businesses or successfully integrate the operations of acquired businesses, as well as the acquired business’s

financial reporting and accounting control systems into our existing platforms;

  •  increased indebtedness and contingent purchase price obligations associated with an acquisition;
  •  the  ability  to  fund  cash  flow  shortages  that  may  occur  if  anticipated  revenue  is  not  realized  or  is  delayed,  whether  by  general  economic  or  market

conditions, or unforeseen internal difficulties;

  •  the availability of funding sufficient to meet increased capital needs;
  •  diversion of management’s time and attention from existing operations; and
  •  the ability to retain or hire qualified personnel required for expanded operations.

Completing acquisitions may require significant management time and financial resources because we may need to assimilate widely dispersed operations
with  different  corporate  cultures.  In  addition,  acquired  companies  may  have  liabilities  that  we  failed  to  or  were  unable  to  discover  in  the  course  of
performing  due  diligence  investigations.  Also,  the  indemnification  granted  by  sellers  of  acquired  companies  may  not  be  sufficient  in  amount,  scope,  or
duration  to  fully  offset  the  possible  liabilities  associated  with  businesses  or  properties  we  assume  upon  consummation  of  an  acquisition.  We  may  learn
additional  information  about  our  acquired  businesses  that  could  have  a  material  adverse  effect  on  us,  such  as  unknown  or  contingent  liabilities  and
liabilities  related  to  compliance  with  applicable  laws.  Any  such  liabilities,  individually  or  in  the  aggregate,  could  have  a  material  adverse  effect  on  our
business.  Failure  to  successfully  manage  the  operational  challenges  and  risks  associated  with,  or  resulting  from,  acquisitions  could  adversely  affect  our
results of operations, cash flows, and liquidity. Borrowings or issuances of convertible securities associated with these acquisitions may also result in higher
levels of indebtedness, which could adversely impact our ability to service our debt within the scheduled repayment terms.

Security breaches, loss of data, and other disruptions to our business or the business of our third-party service providers could compromise sensitive
information  related  to  our  business  or  prevent  us  from  accessing  critical  information  and  expose  us  to  liability,  which  could  adversely  affect  our
business and reputation.

Our business requires that we collect and store sensitive data, including protected health and credit card information and proprietary business and financial
information. We face a number of risks relative to the protection of, and the service providers’ protection of, this critical information, including loss of
access,  inappropriate  disclosure,  and  inappropriate  access,  as  well  as  risks  associated  with  our  ability  to  identify  and  audit  such  events.  The  secure
processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy, and we devote significant
resources  to  protecting  such  information.  Although  we  take  measures  to  protect  sensitive  information  from  unauthorized  access  or  disclosure,  our
information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance, or
other  activities.  While  we  do  not  believe  we  have  not  experienced  any  such  attack  or  breach,  if  such  event  would  occur  and  cause  interruptions  in  our
operations,  our  networks  could  be  compromised  and  the  information  we  store  on  those  networks  could  be  accessed  by  unauthorized  parties,  publicly
disclosed, lost, or stolen. Unauthorized access, loss, or dissemination could disrupt our operations, including collecting, processing, and preparing company
financial information, managing the administrative aspects of our business, and damaging our reputation, any of which could adversely affect our business.
In  addition,  the  interpretation  and  application  of  consumer,  health-related,  and  general  data  protection  laws  in  the  United  States  are  often  uncertain,
contradictory, and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could
result  in  government-imposed  fines  or  orders  requiring  that  we  change  our  practices,  which  could  adversely  affect  our  business.  Complying  with  these
various  laws  could  cause  us  to  incur  substantial  costs  or  require  us  to  change  our  business  practices,  systems,  and  compliance  procedures  in  a  manner
adverse to our business. Additionally, many of our employees have the ability to work remotely, which may increase the risk of security breaches, loss of
data, and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations. 

If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in connection with security incidents,
we may suffer loss of reputation, financial loss, and civil or criminal fines or other penalties. In addition, these breaches and other forms of inappropriate
access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.

30

 
 
 
 
 
 
 
 
If our information technology and communications systems fail or we experience a significant interruption in our operations, our reputation, business,
and results of operations could be materially and adversely affected.

The efficient operation of our business is dependent on information technology and communications systems. The failure of these systems to operate as
anticipated could disrupt our business and result in decreased revenue and increased overhead costs. In addition, we do not have complete redundancy for
all  of  our  systems  and  our  disaster  recovery  planning  cannot  account  for  all  eventualities.  Our  information  technology  and  communications  systems,
including  the  information  technology  systems  and  services  that  are  maintained  by  third-party  vendors,  are  vulnerable  to  damage  or  interruption  from
natural  disasters,  fire,  terrorist  attacks,  malicious  attacks  by  computer  viruses  or  hackers,  and  power  loss  or  failure  of  computer  systems,  Internet,
telecommunications or data networks. If these systems or services become unavailable or suffer a security breach, we may expend significant resources to
address these problems, and our reputation, business, and results of operations could be materially and adversely affected.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

Not applicable.

ITEM 1C. CYBERSECURITY.

Our Board of Directors (the “Board”) recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners
and  employees.  The  Board  exercises  oversight  of  our  risk  management  program,  and  cybersecurity  represents  an  important  component  of  our  overall
approach to enterprise risk management (“ERM”). Our cybersecurity policies, standards, processes, and practices are integrated into our ERM program and
are based on frameworks established by the National Institute of Standards and Technology (“NIST”) and other applicable industry standards. In general,
we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, security, and availability of the
information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents
when they occur.

Risk Management and Strategy

As one of the critical elements of our overall ERM approach, our cybersecurity program is focused on the following key areas:

● Governance. As discussed in more detail under the heading “Governance,” the Board maintains an active role concerning cybersecurity risk

management including oversight of the Company’s employee personnel with extensive experience in the field.

● Technical Safeguards and Risk Management Processes. We have implemented a risk management framework to identify, evaluate, and address
cybersecurity risks. This framework includes the deployment of tools to detect potential threats, the maintenance of detailed incident logs, and the
development of risk mitigation strategies. Our cybersecurity measures and policies are subject to regular testing and continuous improvement to
adapt to new threats as they arise.

● Education and Incident Reporting. We have instituted a company-wide security awareness training program to educate employees about
cybersecurity risks and their role in maintaining our security posture. Continuous education and testing support our workforce in remaining
knowledgeable and vigilant to cybersecurity threats. Employees are instructed to report all cybersecurity concerns directly to our internal
information technology (“IT”) team for immediate assessment and response.

● Cybersecurity Incident Response Plan. We maintain a comprehensive incident response plan designed to mitigate the impact of a cybersecurity
incident. This plan includes protocols for internal response, external communication, and remediation efforts to minimize the impact on our
operations and stakeholders.

● Third-Party Risk Management. We maintain a risk-based approach to identifying and overseeing cybersecurity risks presented by third parties,

including vendors, service providers and other external users of our systems, as well as the systems of third parties that could adversely impact our
business in the event of a cybersecurity incident affecting those third-party systems.

31

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We engage in the periodic assessment and testing of our policies, standards, processes, and practices that are designed to address cybersecurity threats and
incidents.  These  efforts  include  a  range  of  activities,  including  audits,  assessments,  vulnerability  testing,  and  other  exercises  focused  on  evaluating  the
effectiveness  of  our  cybersecurity  measures  and  planning.  We  engage  third  parties  to  perform  assessments  on  our  cybersecurity  measures,  including
information security maturity assessments, audits, and independent reviews of our information security control environment and operating effectiveness.
The results of such assessments, audits, and reviews are reported to the Board, and we adjust our cybersecurity policies, standards, processes, and practices
as necessary based on the information provided by these assessments, audits, and reviews.

Governance

The Board oversees the Company’s ERM process, including the management of risks arising from cybersecurity threats. The Board receives reports on
cybersecurity  risks,  which  address  a  wide  range  of  topics  including  recent  developments,  evolving  standards,  vulnerability  assessments,  third-party  and
independent reviews, the threat environment, technological trends, and information security considerations arising with respect to the Company’s peers and
third parties. The Board also receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as
well as ongoing updates regarding any such incident until it has been addressed.

The Senior Director of IT and Cybersecurity, in coordination with our executive officers, work collaboratively across the Company to implement a program
designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance
with  the  Company’s  incident  response  plan.  To  facilitate  the  Company’s  cybersecurity  risk  management  program,  the  Company’s  internal  IT  team  is
deployed  to  work  with  business  functions  across  the  Company  to  address  cybersecurity  threats  and  to  respond  to  cybersecurity  incidents.  The  Senior
Director of IT and Cybersecurity, as leader of the internal IT team, monitors the prevention, detection, mitigation, and remediation of cybersecurity threats
and incidents in real time, and reports such threats and incidents to the executive officers and Board when appropriate.

The Senior Director of IT and Cybersecurity has served in various roles in information technology and information security for more than two decades with
a track record of managing systems compliant with relevant security standards. The Senior Director of IT and Cybersecurity has industry experience and
education aligned with the Company’s work and the data we maintain. The Senior Director of IT and Cybersecurity’s expertise is complemented by that of
the  Company’s  CEO  and  Interim  CFO,  each  with  degrees  in  their  respective  fields  and  extensive  leadership  experience  including  experience  managing
risks at similar companies.

We face a number of cybersecurity risks in connection with our business. Such risks have not materially affected us, including our business strategy, results
of operations or financial condition, to date. For more information about the cybersecurity risks we face, see the risk factor entitled “Security breaches, loss
of data, and other disruptions to our business or the business of our third-party service providers could compromise sensitive information related to our
business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and reputation.” in Item 1A.
Risk Factors.

ITEM 2. PROPERTIES.

Our corporate offices are in Pittsburgh, Pennsylvania. We have leases for office and laboratory space that are effective through February 29, 2028.

We lease office and laboratory space in Birmingham, Alabama. This lease is effective through August 31, 2025.

We lease office and manufacturing space in Eagan, Minnesota. This lease is effective through May 31, 2025.

We expect that the current space will be adequate for our current office and laboratory needs.

32

 
 
 
 
 
 
 
 
 
 
 
 
 
ITEM 3. LEGAL PROCEEDINGS.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable. 

PART II

ITEM  5.  MARKET  FOR  REGISTRANT’S  COMMON  EQUITY,  RELATED  STOCKHOLDER  MATTERS  AND  ISSUER  PURCHASES  OF
EQUITY SECURITIES.

Market Information

Effective June 13, 2019, our common stock was listed on the NASDAQ Capital Market under the symbol “POAI”. Prior to this, effective February 2, 2018,
our common stock was listed on the NASDAQ Capital Market under the symbol “AIPT”. Prior to February 2, 2018, our common stock was listed on The
NASDAQ Capital Market under the symbol “SKLN”.

Holders

As of March 18, 2024, there were approximately 155 stockholders of record of our common stock.

Dividend Policy

We  follow  a  policy  of  retaining  earnings,  if  any,  to  finance  the  expansion  of  our  business.  We  have  not  paid,  nor  do  we  expect  to  declare  or  pay,  cash
dividends on common stock in the foreseeable future.

Securities Authorized for Issuance under Equity Compensation Plans

The information required by this Item 5 regarding securities authorized for issuance under equity compensation plans is incorporated herein by reference to
Item 12 below.

ITEM 6. [RESERVED]

Not Required.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Information Regarding Forward-Looking Statements

This  Annual  Report  on  Form  10-K  contains  “forward-looking  statements”  that  indicate  certain  risks  and  uncertainties,  many  of  which  are  beyond  our
control.  Actual  results  could  differ  materially  and  adversely  from  those  anticipated  in  such  forward-looking  statements  as  a  result  of  certain  factors,
including but not limited to those set forth below and elsewhere in this report. Important factors that may cause actual results to differ from projections
include:

  • Our ability to continue operating beyond twelve months without additional financing;
  • Continued negative operating cash flows;
  • Our capital needs to accomplish our goals, including any further financing, which may be highly dilutive and may include onerous terms;
  • Risks related to recent and future acquisitions, including risks related to the benefits and costs of acquisition;

33

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  • Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated
benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;
  • Risks  related  to  the  initiation,  formation,  or  success  of  our  collaboration  arrangements,  commercialization  activities  and  product  sales  levels  by  our

collaboration partners and future payments that may come due to us under these arrangements,

  • Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;
  • The impact of competition;
  • Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;
  • Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;
  • Risk that we never become profitable if our products and services are not accepted by potential customers;
  • Possible impact of government regulation and scrutiny;
  • Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;
  • Adverse results of any legal proceedings;
  • The volatility of our operating results and financial condition,
  • Management of growth;
  • Risk that our business and operations could be materially and adversely affected by disruptions caused by economic and geopolitical uncertainties as

well as epidemics or pandemics; and

  • Other specific risks that may be alluded to in this report.

All  statements,  other  than  statements  of  historical  facts,  included  in  this  report  regarding  our  growth  strategy,  future  operations,  financial  position,
estimated revenue or losses, projected costs, prospects and plans, and objectives of management are forward-looking statements. When used in this report,
the words “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan,” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of
this report. We do not undertake any obligation to update any forward-looking statements or other information contained herein. Potential investors should
not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in or suggested by
the  forward-looking  statements  in  this  report  are  reasonable,  we  cannot  assure  potential  investors  that  these  plans,  intentions  or  expectations  will  be
achieved. We disclose important factors that could cause actual results to differ materially from expectations in the “Risk Factors” section and elsewhere in
this report. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

Overview

We  are  a  knowledge  and  science-driven  company  that  applies  artificial  intelligence  (“AI”)  to  support  the  discovery  and  development  of  optimal  cancer
therapies, which can ultimately lead to more effective treatments and improved patient outcomes. We use AI and a proprietary biobank of 150,000+ tumor
samples,  categorized  by  tumor  type,  to  provide  actionable  insights  about  drug  compounds  to  improve  the  drug  discovery  process  and  increase  the
probability of drug compound success. We offer a suite of solutions for oncology drug development from early discovery to clinical trials.

Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. By
harnessing the power of machine learning and scientific rigor, we believe that we can improve the probability of success of advancing pharmaceutical and
biological drug candidates with a higher degree of confidence.

We operate in three business areas. In our first area, we provide optimized, high-confidence drug-response predictions through the application of AI using
our proprietary biobank of tumor samples to enable a more informed selection of drug/tumor combinations and increase the probability of success during
development. We also create and develop tumor-specific 3D cell culture models mimicking the physiological environment of human tissue enabling better-
informed  decision-making  during  development.  In  our  second  business  area,  we  provide  services  and  research  using  a  proprietary  self-contained  and
automated  system  that  conducts  high-throughput,  self-interaction  chromatography  screens  using  additives  and  excipients  commonly  included  in  protein
formulations  resulting  in  soluble  and  physically  stable  formulations  of  biologics.  Our  third  business  area  produces  the  United  States  Food  and  Drug
Administration  (“FDA”)-cleared  STREAMWAY®  System  and  associated  products  for  automated  medical  fluid  waste  management  and  patient-to-drain
medical fluid disposal. As of January 1, 2023, we changed our reportable segments to align with these business areas.

34

 
 
 
 
 
 
 
 
We have three reportable segments, which have been delineated by location and business area:

● Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also

creates proprietary 3D culture models used in drug development.

● Birmingham segment: provides contract services and research focused on solubility improvements, stability studies, and protein production.

● Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and

patient-to-drain medical fluid disposal.

Capital Requirements

Since inception, we have been unprofitable. We incurred net losses of $13,983,967 and $25,737,634 for the years ended December 31, 2023, and December
31, 2022, respectively. As of December 31, 2023, and December 31, 2022, we had an accumulated deficit of $167,761,883 and $153,777,916, respectively.

We  have  never  generated  sufficient  revenues  to  fund  our  capital  requirements.  We  have  funded  our  operations  through  a  variety  of  debt  and  equity
instruments.  Since  2017,  we  have  diversified  our  business  by  investing  in  ventures,  including  making  significant  loans  and  investments  in  early-stage
companies. These activities led to the acquisition of Helomics Corporation in April 2019, two transactions to acquire the assets of three businesses in 2020,
and the acquisition of zPREDICTA Inc. (“zPREDICTA”) in November 2021, each of which have accelerated our capital needs. See “Liquidity and Capital
Resources – Liquidity and Plan of Financing; Going Concern” and “Liquidity and Capital Resources – Financing Transactions” below.

Our  future  cash  requirements  and  the  adequacy  of  available  funds  depend  on  our  ability  to  generate  revenues  from  our  oncology  businesses  located  in
Pittsburgh and Birmingham; our ability to continue to sell our Skyline Medical products and services and to reach profitability in all our businesses; and the
availability  of  future  financing  to  fulfill  our  business  plans.  See  “Liquidity  and  Capital  Resources  –  Liquidity  and  Plan  of  Financing;  Going  Concern”
below.

Our  limited  history  of  operations,  especially  in  our  drug  discovery  business,  and  our  change  in  the  emphasis  of  our  business,  starting  in  2017,  makes
prediction of future operating results difficult. We believe that period-to-period comparisons of our operating results should not be relied on as predictive of
our future results.

Results of Operations

Comparison of Year Ended December 31, 2023, with Year Ended December 31, 2022

Revenue
Cost of sales
General and administrative expense
Operations expense
Sales and marketing expense

  $

2023

2022

Difference

1,780,093    $
634,796     
9,428,496     
4,127,268     
1,510,861     

1,505,459    $
505,107     
11,110,735     
3,798,425     
1,358,907     

274,634 
(129,689)
1,682,239 
(328,843)
(151,954)

Revenue. We recorded revenue of $1,780,093 in 2023, compared to $1,505,459 in 2022. Revenues for the years ended December 31, 2023, and December
31, 2022, were primarily derived from our Eagan operating segment. The Eagan operating segment contributed $1,135,101 and $1,063,493 for the years
ended December 31, 2023, and December 31, 2022, respectively, while the Pittsburgh operating segment contributed $492,596 and $358,776, respectively.

35

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
   
   
   
   
 
 
Cost  of  sales.  Cost  of  sales  was  $634,796  and  $505,107  for  the  years  ended  December  31,  2023,  and  December  31,  2022,  respectively.  Cost  of  sales
increased primarily due to costs associated with Pittsburgh contracted services. The gross profit margin declined to 64% in 2023 from 66% in 2022. The
decline in gross profit margin was primarily due to costs related to contracted services provided by our Pittsburgh operating segment.

General and administrative expense. General and administrative (“G&A”) expenses primarily consist of management salaries, professional fees, consulting
fees,  depreciation  and  amortization,  office  rents,  and  general  office  expenses.  G&A  expenses  decreased  by  $1,682,239  to  $9,428,496  in  2023  from
$11,110,735 in 2022. The decrease was primarily due to decreases in staff-related expenses of approximately $1,980,000. Additional decreases included
lower  amortization  expense  related  to  acquired  intangible  assets  impaired  in  the  prior  year.  These  decreases  were  offset  by  higher  professional  fees
including consultants supporting our management team and investor relations as well as other G&A expenses.

Operations  expense.  Operations  expenses  primarily  consist  of  expenses  related  to  product  development,  prototyping  and  testing.  Operations  expenses
increased by $328,843 to $4,127,268 in 2023 compared to $3,798,425 in 2022. The increase in operations expenses in 2023 was primarily due to higher
cloud  computing  expenses  and  other  expenses  related  to  our  AI  business  provided  by  our  Pittsburgh  operating  segment,  offset  by  lower  research  and
development expenses related to office closures.

Sales and marketing expense. Sales and marketing expenses consist of expenses required to market and sell our products including staff-related expenses
for individuals performing this work. Sales and marketing expenses increased by $151,954 to $1,510,861 in 2023 compared to $1,358,907 in 2022. The
increase in 2023 was primarily due to approximately $209,000 higher staff-related expenses resulting from the addition of headcount supporting our sales
and marketing efforts, offset by lower spend on other marketing activities.

Loss on goodwill impairment. Upon closing our acquisition of zPREDICTA on November 24, 2021, we recorded related goodwill of $7,231,093. During
the year ended December 31, 2022, we determined that the goodwill was impaired primarily due to declines in our market capitalization and recorded an
impairment loss of $7,231,093. Accordingly, goodwill related to zPREDICTA was $0 at both December 31, 2023, and December 31, 2022. zPREDICTA
was merged with Predictive Oncology at the end of 2022 and is now reported as part of the Pittsburgh operating segment. See Note 5 – Intangible Assets to
our audited consolidated financial statements included in this annual report on Form 10-K.

Loss on finite-lived intangible asset impairment. During the year ended December 31, 2023, we incurred no losses on impairment of finite-lived intangible
assets.  During  the  year  ended  December  31,  2022,  we  incurred  a  loss  on  impairment  of  finite-lived  intangible  assets  of  $3,349,375.  The  impairment
recorded related to the finite-lived intangible assets obtained with our acquisition of zPREDICTA in 2021 and was primarily due to declines in projected
future cash flows. The value of the intangible assets of zPREDICTA following the impairment was $0 at December 31, 2022. zPREDICTA was merged
with Predictive Oncology at the end of 2022 and is now reported as part of the Pittsburgh operating segment. See Note 5 – Intangible Assets to our audited
consolidated financial statements included in this annual report on Form 10-K.

Loss  on  impairment  of  tangible  long-lived  assets.  We  recorded  a  loss  on  impairment  of  property  and  equipment  of  $162,905  during  the  year  ended
December  31,  2023.  We  prepared  an  undiscounted  cash  flow  for  our  Birmingham  asset  group  as  of  June  30,  2023,  to  evaluate  long-lived  assets,  then
completed  a  fair  value  assessment  which  resulted  in  the  impairment.  We  then  allocated  the  impairment  to  the  assets  of  the  affected  asset  group.  We
recorded a loss on impairment of property and equipment of $185,469 during the year ended December 31, 2022. The impairment was primarily due to a
decline in projected future cash flows. We completed a fair value assessment which resulted in an impairment. We then allocated the impairment to the
assets of each of the affected asset groups. See Note 4 – Property and Equipment to our audited consolidated financial statements included in this annual
report on Form 10-K.

Other income. We earned other income of $152,776 in 2023 compared to $185,646 in 2022. Other income primarily consists of interest income and, in the
year ended December 31, 2022, gains associated with equipment abandoned in connection with a sublease and losses on asset disposals. The decrease in
other income was primarily due to lower interest income.

36

 
 
 
 
 
 
 
 
 
 
Other expense. We incurred other expenses of $64,967 in 2023 compared to $5,275 in 2022. Other expenses primarily consist of interest expense and, in
the year ended December 31, 2023, losses on a note receivable deemed uncollectible. The increase in other expenses was primarily due to writing off a note
receivable deemed uncollectible.

Gain on derivative instruments. We recorded a gain of $12,457 in 2023 compared to a gain of $115,647 in 2022, primarily related to the changes in fair
market value on derivatives.

Income Taxes. We incurred zero income tax expense in 2023 and 2022 due to losses in both years.

Liquidity and Capital Resources

Cash Flows

On December 31, 2023, we had $8,728,660 in cash and cash equivalents. Cash and cash equivalents decreased by $13,342,863 from the prior year due to
the following factors.

Net  cash  used  in  operating  activities  was  $13,189,390  in  2023,  compared  to  net  cash  used  of  $12,370,800  in  2022.  Cash  used  in  operating  activities
increased  in  2023  primarily  due  to  cash  operating  losses  as  well  as  changes  in  working  capital  including  decreases  in  accrued  expenses  and  contract
liabilities, offset by an increase in accounts payable.

Net cash used in investing activities was $302,371 in 2023, compared to $475,697 in 2022. Cash used in investing activities decreased in 2023 primarily
due to a decrease in the acquisition of property and equipment.

Net  cash  provided  by  financing  activities  was  $148,898  in  2023  compared  to  $6,715,405  in  2022.  Cash  provided  by  financing  activities  in  2023  was
primarily related to proceeds from financing insurance premiums over the insured period with a short-term note payable while the cash provided in 2022
was primarily proceeds from the issuance of common stock and warrants.

Liquidity and Plan of Financing; Going Concern

We have incurred significant and recurring losses from operations for the past several years and, as of December 31, 2023, had an accumulated deficit of
$167,761,883.  We  had  cash  and  cash  equivalents  of  $8,728,660  as  of  December  31,  2023,  and  need  to  raise  significant  additional  capital  to  meet  our
operating needs. Our short-term obligations as of December 31, 2023, were $3,951,031, consisting primarily of aggregate accounts payable and accrued
expenses of $2,973,729 and operating lease obligations of $517,427. As of December 31, 2023, we also had a short-term note payable of $150,408 that
bears interest at an annual percentage rate of 9.25% and long-term operating lease obligations of $2,188,979 with a weighted average remaining lease term
of 3.99 years. We do not expect to generate sufficient operating revenue to sustain our operations in the near term. During the year ended December 31,
2023,  we  incurred  negative  cash  flows  from  operations  of  $13,189,390.  Although  we  have  attempted  to  improve  our  operating  margin  by  bolstering
revenues and curtailing expenses and continue to seek ways to generate revenue through business development activities, there is no guarantee that we will
be able to improve our operating margin sufficiently or achieve profitability in the near term. These conditions raise substantial doubt about our ability to
continue as a going concern within one year after the date our consolidated financial statements included in this annual report on Form 10-K are issued. We
are evaluating alternatives to obtain the required additional funding to maintain future operations. These alternatives may include, but are not limited to,
equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. These possibilities, to the extent
available, may be on terms that result in significant dilution to our existing stockholders or that result in our existing stockholders losing part or all of their
investment.  Despite  these  potential  sources  of  funding,  we  may  be  unable  to  access  financing  or  obtain  additional  liquidity  when  needed  or  under
acceptable terms, if at all. If such financing or adequate funds from operations are not available, we would be forced to limit our business activities and we
could default on existing payment obligations, which would have a material adverse effect on our financial condition and results of operations, and may
ultimately be required to cease our operations and liquidate our business. The consolidated financial statements for the year ended December 31, 2023,
included in this annual report on Form 10-K have been prepared assuming we will continue as a going concern and do not include any adjustments that
might result from the outcome of this uncertainty.

37

 
 
 
 
 
 
 
 
 
 
 
 
 
Financing Transactions

We have funded our operations through a combination of debt and equity instruments including short-term borrowings, and a variety of debt and equity
offerings. We have no off-balance sheet transactions. There were no financing transactions during the year ended December 31, 2023.

May 2022 Offerings

On May 16, 2022, the Company issued and sold an aggregate of 191,864 shares of its common stock, at a purchase price of $12.00 per share to several
institutional and accredited investors in a registered direct offering (the “First Offering”). Pursuant to the securities purchase agreement, the Company also
agreed  to  issue  to  these  purchasers  unregistered  warrants  to  purchase  up  to  an  aggregate  of  191,864  shares  of  common  stock  (the  “Warrants”)  in  a
concurrent private placement. The Warrants have an exercise price equal to $14.00 per share, will become exercisable six months from the date of issuance,
and will expire five and one-half years from the date of issuance.

In addition, in a concurrent registered direct offering (the “Second Offering”), on May 16, 2022, the Company issued and sold to several institutional and
accredited investors an aggregate of 408,136 shares of its common stock, at a purchase price of $12.00 per share. The Company also entered into a warrant
amendment  agreement  (the  “Warrant  Amendment”)  with  each  of  the  purchasers  in  the  Second  Offering.  Under  the  Warrant  Amendment,  the  Company
agreed  to  amend  certain  existing  warrants  to  purchase  up  to  816,272  shares  of  common  stock  that  were  previously  issued  in  2020  and  2021  to  those
purchasers, with exercise prices ranging from $20.00 to $40.00 per share (the “Existing Warrants”), were amended to: (i) lower the exercise price of the
Existing Warrants to $14.00 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until six months following the closing
date of the Second Offering, and (iii) extend the original expiration date of the Existing Warrants by five and one-half years following the close of the
Second Offering.

In each case, the Company paid to the placement agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the
offering and a management fee equal to 1% of the aggregate gross proceeds received by the Company in the offering and provided the placement agent
expense  allowance  of  $65,000  for  non-accountable  and  other  out-of-pocket  expenses.  In  addition,  the  Company  granted  to  the  placement  agent  or  its
assigns  warrants  to  purchase  7.5%  of  the  shares  sold  to  investors  in  the  offering  at  an  exercise  price  equal  to  125%  of  the  price  of  the  shares  in  the
transaction, or $15.00 per share, with a term of five years (the “Agent Warrants”). The Agent Warrants become exercisable six months after issuance.

Equity Line

On October 24, 2019, the Company entered into an equity purchase agreement with an investor, providing for an equity financing facility. According to the
terms  and  subject  to  the  conditions  in  the  purchase  agreement,  the  investor  was  committed  to  purchase  shares  having  an  aggregate  value  of  up  to
$15,000,000 of the Company’s common stock for a period of up to three years. The Company issued to the investor 5,233 commitment shares at a fair
market value of $450,000 for entering into the agreement. From time to time during the three-year commitment period, provided that the closing conditions
were  satisfied,  the  Company  could  provide  the  investor  with  put  notices  to  purchase  a  specified  number  of  shares  subject  to  certain  limitations  and
conditions and at specified prices, which generally represent discounts to the market price of the common stock. During the year ended December 31, 2022,
the Company issued 15,750 shares of its common stock valued at $236,009 pursuant to the equity line. In connection with the May 2022 offerings, the
Company agreed not to access the remaining balance for a period of one year after the closing date, or May 18, 2022. The equity line expired on October
23, 2022.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our audited consolidated Financial Statements, which have
been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). The preparation of these financial statements requires
management  to  make  estimates  and  assumptions  that  affect  the  reported  amounts  of  assets  and  liabilities  as  of  the  date  of  our  financial  statements,  the
reported  amounts  of  revenues  and  expenses  during  the  reporting  periods  presented,  as  well  as  our  disclosures  of  contingent  assets  and  liabilities.  We
evaluate our estimates and assumptions on an on-going basis.

38

 
 
 
 
 
 
 
 
 
 
 
 
We base our estimates and assumptions on our historical experience and on various other information available to us at the time that these estimates and
assumptions  are  made.  We  believe  that  these  estimates  and  assumptions  are  reasonable  under  the  circumstances  and  form  the  basis  for  our  making
judgments about the carrying values of our assets and liabilities that are not readily apparent from other sources.  Actual results and outcomes could differ
from our estimates.

Our significant accounting policies are described in Note 1 – Summary of Significant Accounting Policies in Notes to Consolidated Financial Statements of
this Annual Report on Form 10-K. We believe that the following discussion addresses our critical accounting estimates and reflects those areas that require
more significant judgments and use of estimates and assumptions in the preparation of our audited consolidated Financial Statements.

Revenue Recognition

We  generate  revenues  from  Contract  Research  Organization  (“CRO”)  services  related  to  the  development  of  3D  tumor-specific  in  vitro  models  for
oncology drug discovery and research. We also generate revenues from CRO services related to development of protein formulations and performance of
protein stability analyses. The specific pattern of revenue recognition for CRO services is determined on a case-by-case basis according to the facts and
circumstances  applicable  to  a  given  contract.  We  evaluate  each  product  or  service  promised  in  a  contract  to  determine  whether  it  represents  a  distinct
performance  obligation.  Determining  whether  services  are  considered  distinct  performance  obligations  that  should  be  accounted  for  separately  versus
together  may  require  significant  judgment.  Contracts  for  CRO  services  generally  contain  one  performance  obligation  to  perform  research  and  deliver
appropriate data or reporting. Revenues from CRO services are generally recognized at the point in time when data and reports are provided to customers.
See Note 1 – Summary of Significant Accounting Policies in Notes to Consolidated Financial Statements of this Annual Report on Form 10-K for further
details of our revenue recognition policies.

We also have a collaboration arrangement, under which we have utilized our active learning technology, proprietary biobank, and know-how to provide
predictive  models  of  tumor  responses  to  various  drug  compounds.  This  collaboration  arrangement  includes  sales-based  royalties,  under  which  our
collaboration partner is obligated to pay us revenue sharing fees that are based on the net revenue from the collaboration partner’s commercialized drugs.
The percentage of net revenue varies depending on the stage of development. The revenue sharing fees represent variable consideration, which requires us
to estimate the expected value of revenue sharing fees and extent to which those estimates are constrained. These estimates are reassessed at each reporting
period. To date, we have not recognized revenues related to revenue sharing fees pursuant to our collaboration arrangement. See Note 11 – Collaborative
Agreement in Notes to Consolidated Financial Statements of this Annual Report on Form 10-K for further details of our collaboration arrangement.

Stock-Based Compensation.  

We  account  for  stock-based  compensation  under  the  fair  value  recognition  and  measurement  provisions  for  share-based  payments  of  U.S.  GAAP.  We
recognize compensation expense for these service-based equity-classified awards over their requisite service period and adjust for forfeitures as they occur.
We estimate the fair value of stock-based payment awards on the date of grant using the Black-Scholes option-pricing model which requires the input of
significant assumptions including an estimate of the average period of time employees and directors will retain vested stock options before exercising them,
the estimated volatility of our common stock price over the expected term, and the risk-free interest rate.

When an option or warrant is granted in place of cash compensation for services, we deem the value of the service rendered to be the value of the option or
warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine
without utilizing an option pricing model. For that reason, we also use the Black-Scholes option-pricing model to value options and warrants granted to
non-employees,  which  requires  the  input  of  significant  assumptions  including  an  estimate  of  the  average  period  that  investors  or  consultants  will  retain
vested  stock  options  and  warrants  before  exercising  them,  the  estimated  volatility  of  our  common  stock  price  over  the  expected  term,  and  the  risk-free
interest rate. In the case of options to employees, we estimated the life to be the legal term.

39

 
 
 
 
 
 
 
 
 
 
 
Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognizes
that.  We  have  been  traded  on  the  NASDAQ  Capital  Market  exchange  since  2015  and  have  experienced  significant  volatility  in  our  stock  price.  The
assumptions we use in calculating the fair value of stock-based payment awards represent our best estimates, which involve inherent uncertainties and the
application of management's judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be
materially different in the future. See Note 9 – Stockholders’ Equity, Stock Options, and Warrants in Notes to Consolidated Financial Statements of this
Annual Report on Form 10-K for further details of our stock-based compensation.

Goodwill Impairment

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired.
Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination. Goodwill is an indefinite-lived
intangible asset and is not amortized.

Goodwill  is  tested  on  an  annual  basis  for  impairment  at  the  reporting  unit  level  as  of  December  31,  or  whenever  events  or  changes  in  circumstances
indicate  that  the  carrying  amount  may  not  be  fully  recoverable.  To  determine  whether  goodwill  is  impaired,  annually  or  more  frequently  if  needed,  we
perform a multi-step impairment test. We first have the option to assess qualitative factors to determine if it is more likely than not that the carrying value
of a reporting unit exceeds its estimated fair value. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When
performing  quantitative  testing,  we  first  estimate  the  fair  values  of  our  reporting  units  using  discounted  cash  flows.  To  determine  fair  values,  we  are
required  to  make  assumptions  about  a  wide  variety  of  internal  and  external  factors.  Significant  assumptions  used  in  the  impairment  analysis  include
financial  projections  of  free  cash  flow  (including  significant  assumptions  about  operations  including  the  rate  of  future  revenue  growth,  capital
requirements,  and  income  taxes),  long-term  growth  rates  for  determining  terminal  value  and  discount  rates.  Comparative  market  multiples  are  used  to
corroborate the results of the discounted cash flow test. These assumptions require significant judgement. Pursuant to ASU 2017-04, Simplifying the Test
for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting
unit,  including  goodwill.  To  the  extent  the  carrying  amount  of  goodwill  exceeds  the  implied  goodwill,  the  difference  is  the  amount  of  the  goodwill
impairment. We also complete a reconciliation between the implied equity valuation prepared and our market capitalization. The majority of the inputs used
in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are
considered Level 1 inputs.

Long-lived Asset Impairment

We  review  long-lived  assets,  including  finite-lived  intangible  assets  and  long-lived  tangible  assets,  for  impairment  whenever  events  or  changes  in
circumstances indicate the carrying amount may not be recoverable. Identifying and evaluating such events or changes in circumstances involves judgment.
Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the
medical device marketplace and a significant adverse change in the business climate in which we operate.

The  recoverability  of  an  asset  to  be  held  and  used  is  determined  by  comparing  the  carrying  amount  to  the  estimated  undiscounted  future  cash  flows
expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated undiscounted future cash flows, we record an impairment
charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a
value  determined  utilizing  discounted  cash  flow  techniques.  See  Note  4  –  Property  and  Equipment  and  Note  5  –  Intangible  Assets  to  our  audited
consolidated financial statements included in this annual report on Form 10-K.

Income Taxes

Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating
loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported
amounts of assets and liabilities and their tax bases. Deferred income taxes are subject to certain limitations under Section 382. Deferred tax assets are
reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be
realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes
the  financial  statement  benefit  of  a  tax  position  only  after  determining  that  the  relevant  tax  authority  would  more  likely  than  not  sustain  the  position
following  an  audit.  For  tax  positions  meeting  the  more-likely-than-not  threshold,  the  amount  recognized  in  the  consolidated  financial  statements  is  the
largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

40

 
 
 
 
 
 
 
 
 
 
 
Recent Accounting Developments

See “Recent Accounting Pronouncements” and “Recently Adopted Accounting Standards” under Note 1 - Summary of Significant Accounting Policies in
Notes to Consolidated Financial Statements of this Annual Report on Form 10-K.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not required.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Our financial statements and supplementary data are included beginning on pages F-1 of this report.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), defines the term “disclosure controls and procedures” as those
controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange
Act  is  recorded,  processed,  summarized  and  reported  within  the  time  periods  specified  in  the  SEC’s  rules  and  forms  and  that  such  information  is
accumulated  and  communicated  to  our  management,  including  our  principal  executive  and  principal  financial  officers,  or  persons  performing  similar
functions, as appropriate to allow timely decisions regarding required disclosure.

Management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, has evaluated the effectiveness of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as of December 31, 2023. Based on that
evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-
15(e) and 15d-15(e) under the Exchange Act) were effective as of December 31, 2023.

Management’s Report on Internal Control Over Financial Reporting

We are responsible for establishing and maintaining adequate internal control over financial reporting. As defined in the securities laws, internal control
over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by our
Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i)
pertain  to  the  maintenance  of  records  that  in  reasonable  detail  accurately  and  fairly  reflect  the  acquisitions  and  dispositions  of  our  assets;  (ii)  provide
reasonable  assurance  that  transactions  are  recorded  as  necessary  to  permit  preparation  of  financial  statements  in  accordance  with  generally  accepted
accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii)
provide  reasonable  assurance  regarding  prevention  or  timely  detection  of  unauthorized  acquisition,  use  or  disposition  of  our  assets  that  could  have  a
material  effect  on  the  financial  statements.  Because  of  its  inherent  limitations,  internal  control  over  financial  reporting  may  not  prevent  or  detect
misstatements.

41

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Under the supervision and with the participation of our management, including our Chief Executive Officer and Interim Chief Financial Officer, we carried
out an evaluation of the effectiveness of our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of
1934)  as  of  December  31,  2023  based  on  the  criteria  in  “Internal  Control  -  Integrated  Framework  (2013)”  issued  by  the  Committee  of  Sponsoring
Organizations of the Treadway Commission (“COSO”) in 2013. Based upon this evaluation, we concluded that our internal control over financial reporting
was effective as of December 31, 2023.

The  rules  of  the  SEC  do  not  require,  and  this  Annual  Report  on  Form  10-K  does  not  include,  an  attestation  report  of  an  independent  registered  public
accounting firm regarding internal control over financial reporting.

Material Weakness Remediation Activities

In connection with management’s assessment of controls over financial reporting during the year ended December 31, 2022, we determined that we had not
maintained adequate accounting resources with a sufficient understanding of U.S. GAAP to allow us to properly identify and account for new complex
transactions. To remediate this material weakness, we reevaluated our overall staffing levels within the accounting department and, as a result, during the
second  quarter  of  2023  we  hired  an  additional  resource  with  qualifications  that  include  a  high  level  of  experience  with  complex  technical  accounting
transactions  and  application  of  U.S.  GAAP.  We  have  improved  our  procedures  for  evaluating  complex  accounting  transactions  as  well  as  our  reporting
procedures through the involvement of this additional resource.

During the quarter ended September 30, 2023, we determined that we had a material weakness as we had not maintained effective information technology
general controls in the areas of user access management, administrative user access, and segregation of duties within our financial information systems and
other  financial  reporting  controls  that  are  relevant  to  our  preparation  of  financial  statements.  As  a  result  of  those  segregation  of  duties  deficiencies,  the
related manual business process controls were determined to be ineffective. To remediate this material weakness, we evaluated logical access, including
administrative user access, eliminated certain segregation of duties conflicts, and implemented additional compensating controls. During the fourth quarter
of  2023,  we  designed,  implemented,  and  tested  logical  access  controls  to  monitor  user  access  and  manage  changes  to  user  access.  We  also  designed,
implemented, and tested information technology application controls to enforce proper segregation of duties.

Remediation of Material Weaknesses

During  the  fourth  quarter  of  2023,  with  the  assistance  of  an  external  consulting  company,  we  tested  and  adopted  changes  to  our  internal  control  over
financial  reporting  related  to  our  remediation  efforts  described  above  that  materially  affected,  or  are  reasonably  likely  to  materially  affect,  our  internal
control over financial reporting. Based on the actions taken, as well as the evaluation of the design, implementation, and operating effectiveness of the new
controls, we determined that the material weaknesses have been remediated as of December 31, 2023.

Changes in Internal Control Over Financial Reporting

Except  for  the  changes  described  above,  there  were  no  changes  in  our  internal  control  over  financial  reporting  (as  defined  in  Rule  13a-15(f)  under  the
Securities Exchange Act of 1934) during the three months ended December 31, 2023, that materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

None.

42

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

PART III

The Board may be increased or decreased from time to time by resolution of the stockholders or the Board. Our Board presently consists of seven directors.
Directors are elected at each annual meeting, and each director shall serve until his or her term expires, his or her earlier death, or a successor is elected and
qualified  or  until  the  director  resigns  or  is  removed.  Directors  are  elected  by  a  plurality  of  votes  cast  at  a  meeting  at  which  a  quorum  is  present.  Any
vacancies may be filled by the vote of a majority of the Board of Directors, although less than a quorum, and any such person elected to fill a vacancy shall
serve as a director for a term that coincides with the term of the class to which such director shall have been elected. See “Classified Board of Directors”
below.

The Board does not intend to alter the manner in which it evaluates candidates for the Board based on whether or not the candidate was recommended by a
stockholder.  To  submit  a  candidate  for  consideration  for  nomination,  stockholders  must  submit  such  nomination  in  writing  to  our  Secretary  at  91  43rd
Street, Suite 110, Pittsburgh, PA 15201.

Executive Officers and Directors of the Registrant

The following table identifies the individuals who serve as our executive officers and directors as of March 18, 2024:

Name

Age

  Position Held

Raymond F. Vennare

Josh Blacher

Chuck Nuzum

71

51

75

  Chief Executive Officer and Chairman of the Board of Directors

Interim Chief Financial Officer

  Director

Member  of  the  Audit,  Compensation,  Nominating  and  Governance,  and  Merger  &  Acquisition
Committees

Daniel E. Handley, Ph.D.

64

  Director

Member of the Nominating and Governance Committee

Gregory S. St. Clair, Sr.

58

  Director

Member of the Audit and Compensation Committees

Nancy Chung-Welch, Ph.D.

63

  Director

Member of the Audit, Compensation, and Merger & Acquisition Committees

Matthew J. Hawryluk, Ph.D.

46

  Director

Member of the Compensation and Merger & Acquisition Committees

Veena Rao, Ph.D.

56

  Director

Member of the Audit, Nominating and Governance, and Merger & Acquisition Committees

Our directors serve until their successors are elected and have duly qualified.

There are no family relationships among our directors and executive officers. Our executive officers are appointed by our Board of Directors and serve at
the Board’s discretion.

43

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classified Board of Directors

Our Certificate of Incorporation and Bylaws provide for the division of the members of our Board of Directors into three classes, with the term of each
class expiring in different years. The term of our Class I directors expires in 2025, the term of our Class II directors expires in 2026, and the term of our
Class III directors expires in 2024. The class of directors up for election or reelection will be elected to three-year terms. The current directors are divided
into classes as follows:

CLASS I
(term expiring in 2025)
Chuck Nuzum
Daniel E. Handley

CLASS II
(term expiring in 2026)
Matthew J. Hawryluk
Nancy Chung-Welch
Gregory S. St. Clair, Sr.

CLASS III
(term expiring in 2024)
Raymond F. Vennare
Veena Rao

The Board of Directors met eight times in fiscal year 2023.

Business Experience

Raymond F. Vennare. Mr. Vennare was appointed as our Chief Executive Officer and as Chairman of the Board effective November 1, 2022. Mr. Vennare
brings  more  than  thirty  years  of  experience  to  his  work  as  an  accomplished  senior  executive,  board  director  and  biotechnology  entrepreneur.  As  a
professional who has built and managed companies on behalf of institutional investors, private foundations and research institutions, he is recognized as an
expert in the practice of company creation, technology commercialization, business development and corporate governance. Mr. Vennare is currently (and
has been since 2015) Chairman of the Board of Cvergenx, Inc., a genomic informatics company developing decision-support tools for radiation oncology,
and since 2019 has been on the Board of Directors of Cvergenx Technologies India Private, Ltd. Mr. Vennare was CEO of Cvergenx, Inc., from 2015 until
2022 when he resigned as CEO of Cvergenx upon accepting his position as CEO and Chairman of the Board for Predictive Oncology Inc. He also serves as
a  trusted  and  confidential  advisor  to  clients  as  diverse  as  nationally  ranked  universities  and  philanthropic  foundations  to  multi-national  publicly  traded
companies and early-stage start-ups. Previously Mr. Vennare was Co-founder, President and CEO of ThermalTherapeutic Systems, Inc. (Medical Device);
President  and  Chief  Executive  Officer  of  ImmunoSite,  Inc.  (Diagnostics);  Senior  Vice  President  and  Chief  Information  Officer,  TissueInformatics,  Inc.
(Bioinformatics); Founder, President and Partner in VSInteractive (Information Technology) and, Founder and President of the Fine Art Inventory Network
(On-line Commerce). From June 2018 to December 2020, he was Vice Chairman of Guangzhou INDA Biotechnology Company, Ltd. Mr. Vennare has a
Master’s Degree in Business and Ethics from Duquesne University, a Master’s Degree in Art History and Museum Studies from Case Western Reserve
University and a Bachelor’s Degree from the University of Pittsburgh.

Josh Blacher. Mr. Blacher was appointed as our Interim Chief Financial Officer effective September 30, 2023. Mr. Blacher has served as a consultant with
Danforth Advisors, LLC since September 2022 and as Managing Partner of Columbus Circle Capital LLC (“Columbus Circle Capital”) since August 2019.
During his tenure at Columbus Circle Capital, Mr. Blacher has served as CFO at several public and private companies. Prior to his tenure at Columbus
Circle Capital, Mr. Blacher served as Chief Business Officer at Inmed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial
Officer  of  Therapix  Biosciences  (Nasdaq:  TRPX)  from  April  2017  to  April  2018,  and  as  Chief  Financial  Officer  at  Galmed  Pharmaceuticals  (Nasdaq:
GLMD) from October 2014 to March 2017. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and a Master of Business Administration from
Columbia Business School.

Daniel E. Handley M.S., Ph.D. Dr. Handley was appointed to the Board on February 19, 2020. He serves as a Professor and the Director of the Clinical
and Translational Genome Research Institute of Southern California University of Health Sciences. Previously, he was the Chief Scientific Officer of the
Clinical  and  Translational  Genome  Research  Institute,  a  Florida  501(c)3  non-profit  corporation.  During  that  time,  he  also  held  a  courtesy  faculty
appointment in the Department of Biological Sciences at Florida Gulf Coast University. He previously served as the Chief Scientific Officer for Advanced
Healthcare  Technology  Solutions,  Inc.,  Life-Seq,  LLC,  as  a  senior  researcher  at  the  Procter  &  Gamble  Co.,  a  senior  administrator,  researcher,  and
laboratory manager at the David Geffen UCLA School of Medicine, and as a founding biotechnology inventor for the National Genetics Institute. He holds
a B.A. in Biophysics from Johns Hopkins University, an M.S. in Logic and Computation from Carnegie Mellon University, a Ph.D. in Human Genetics
from  the  University  of  Pittsburgh.  He  completed  his  post-doctoral  training  at  Magee-Women’s  Research  Institute  researching  advanced  genomic
technologies  applied  to  fetal  and  maternal  health.  He  is  a  decorated  veteran  of  the  U.S.  Navy,  having  served  as  a  nuclear  propulsion  instructor  and  a
submarine nuclear reactor operator.

44

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chuck Nuzum. Mr. Nuzum was appointed to the Board on July 9, 2020. Mr. Nuzum has extensive experience as a CFO that ranges from private start-ups
to  large  publicly  traded  companies.  Mr.  Nuzum  presently  provides  financial  consulting  services  on  a  project  basis  to  companies  such  as  McKesson,
BioMarin, AutoDesk and Squire Patton Boggs, mentors start-up companies and serves on the Board of Directors of several companies. Previously he was
co-founder and CFO of the Tyburn Group, a financial services company that creates and delivers prepaid payroll and general-purpose card programs for
customers. For the four years prior, Mr. Nuzum served as the Controller of Dey, L.P., a large pharmaceutical manufacturing subsidiary of Merck KGaA.
Prior to that he was co-founder, Executive Vice President and CFO of SVC Financials Services, one of the first companies in the field to integrate a mobile
money  solution  for  global  distribution,  Vice  President  of  Finance  and  Administration  at  Tiburon,  Inc.,  a  leader  in  public  safety  and  justice  information
systems, and CFO of Winebid.com the world’s leading e-commerce wine auction company. For more than two decades, Mr. Nuzum was CFO of Loomis
Fargo & Co., the well-known international provider of ATM systems, armored cars and other security services. Mr. Nuzum, a Certified Public Accountant,
earned his BA at the University of Washington at Seattle.

Gregory  S.  St.  Clair.  Mr.  St.  Clair  was  appointed  to  the  Board  on  July  9,  2020.  Mr.  St.  Clair  is  the  Founder  and  Managing  Member  of  SunStone
Consulting, LLC, a healthcare consulting firm that has served healthcare providers throughout the United States since 2002. As frequently sought experts
on  issues  related  to  compliance,  reimbursement  and  revenue  integrity,  Mr.  St.  Clair  and  his  team  are  constantly  on-call  to  assist  clients  as  they  address
financial  challenges  through  creative  solutions  to  the  nation’s  health  systems.  Previously,  Mr.  St.  Clair  worked  as  a  national  vice  president  for  CGI,
ImrGlobal, and Orion Consulting and as national director for Coopers & Lybrand. He holds a B.S. in both Accounting and Finance from Juniata College in
Huntington, Pennsylvania.

Nancy  Chung-Welch,  Ph.D.  Dr.  Chung-Welch  was  appointed  to  the  Board  on  July  9,  2020.  Dr.  Chung-Welch  is  currently  an  independent  consultant
advising life science companies and their institutional investors on life science companies, technologies and industries with an emphasis on the research
product/tools  market.  Previously  she  was  a  Director,  Business  Development  at  Cell  Signaling  Technology  and  was  Director,  Business  Development  at
Thermo Fisher Scientific and Technical Marketing Manager for Fisher Scientific. She has over 25 years of marketing and business development experience
in  the  life  sciences  market.  Dr.  Chung-Welch  has  a  balanced  blend  of  business  and  technical/analytical  strengths  to  provide  sound  foundation  for
technology/IP  assessments  and  external  partnerships.  She  has  a  strong  record  of  domestic  and  international  experience  in  business  and  customer  needs
analysis, technology assessment, licensing, distribution deals, partnerships, strategic alliances, strategic customer relationships, mergers/acquisitions. She
previously served as Instructor in Surgery and Assistant in Physiology at Harvard Medical School and the Massachusetts General Hospital with expertise in
basic  science  research,  including  cell  biology,  tissue  culture,  vascular  physiology,  genomics,  proteomics,  and  lab  automation  applications.  She  is  also  a
hands-on marketing executive and has conceptualized, launched, and managed products and services in the laboratory, medical, biotech/pharma, academic
and government markets. She received her Ph.D. in Vascular Physiology and Cell Biology from Boston University.

Matthew J. Hawryluk, Ph.D. Dr. Hawryluk was appointed to the Board on November 29, 2022, to fill the vacancy created by a retirement in October
2022. Dr. Hawryluk was appointed to the Board as a Class II director. Dr. Hawryluk has served as Executive Vice President and Chief Business Officer of
Gritstone bio, Inc. since November 2015. Since March 2020, Dr. Hawryluk has served as an Advisory Board Member of PathAI, Inc. Prior to Gritstone,
from  April  2011  to  October  2015,  Dr.  Hawryluk  held  positions  of  increasing  responsibility  at  Foundation  Medicine,  Inc.,  then  a  public  molecular
diagnostics company (subsequently acquired by Roche), most recently serving as Vice President, Corporate and Business Development. Previously, he held
roles in business development, marketing, and product management across multiple divisions of Thermo Fisher Scientific, Inc. Dr. Hawryluk received a
B.S. from the University of Notre Dame, a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine and an
M.B.A. at Carnegie Mellon University’s Tepper School of Business as a Swartz Entrepreneurial Fellow.

45

 
 
 
 
 
 
Veena Rao, Ph.D. Dr. Rao was appointed to the Board on May 2, 2023. Dr. Rao is an experienced commercial and technical leader with over 25 years of
experience in the areas of drug development, med tech, medical devices, and digital health, having held a number of roles in both large and small company
environments. She has a background in technology innovation, licensing, and corporate business development in addition to having led launch and go-to-
market teams for novel drug and medical device products. Dr. Rao currently serves as President and Chief Business Officer of Portal Instruments, a needle-
free drug delivery company, a position she has held since December 2022. Previously, Dr. Rao served as Chief Commercial Officer at Beta Bionics from
February 2021 until August 2022, and as Head of Corporate Development & Strategy at Beta Bionics from October 2020 until February 2021. Prior to Beta
Bionics, Dr. Rao spent over a decade at Eli Lilly and Company with a number of commercial and technical roles including as Vice President of External
Innovation for the Lilly Device team. Dr. Rao has also served on the Board of Directors of Thermalin, Inc, and advisor to the PharmStars program, and an
advisor to Digbi Health. Dr. Rao has a B.S. in Chemical Engineering from the University of Minnesota, a PhD in Chemical Engineering from Stanford
University and an MBA from the University of Virginia Darden School of Business.

Board Committees

The Board of Directors has a standing Audit Committee, Compensation Committee, Nominating and Governance Committee, and Merger & Acquisition
Committee.

Below is a description of each committee of the Board of Directors as such committees are presently constituted.

Audit Committee; Audit Committee Financial Expert

The Audit Committee oversees the Company’s corporate accounting and financial reporting processes and audits of its financial statements.

The functions of the Audit Committee, as governed by its charter, include, among other things:

● serving as an independent and objective party to monitor the Company’s financial reporting process and internal control system;

● coordinating, reviewing and appraising the audit efforts of the Company’s independent auditors and management and, to the extent the Company
has an internal auditing or similar department or persons performing the functions of such department (“internal auditing department” or “internal
auditors”), the internal auditing department; and

● communicating directly with the independent auditors, financial and senior management, the internal auditing department, and the Board of

Directors regarding the matters related to the committee’s responsibilities and duties.

Both  our  independent  registered  public  accounting  firm  and  management  periodically  meet  privately  with  the  Audit  Committee.  Our  Audit  Committee
currently  consists  of  Mr.  Nuzum,  as  the  chairperson,  Dr.  Chung-Welch,  Mr.  St.  Clair,  and  Dr.  Veena  Rao.  Each  Audit  Committee  member  is  a  non-
employee director of the Board. The Board of Directors reviews the NASDAQ listing standards definition of independence for Audit Committee members
on an annual basis and has determined that all current members of our Audit Committee are independent (as independence is currently defined in Rule
5605(a)(2) of the NASDAQ listing standards). The Board has determined that Mr. Nuzum meets the criteria as an “audit committee financial expert,” as
defined in Item 407(d)(5)(ii) of Regulation S-K under the Securities Act of 1933, as amended. The Audit Committee met seven times in fiscal year 2023.

46

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compensation Committee

The  Compensation  Committee  of  the  Board  of  Directors  currently  consists  of  four  directors:  Mr.  Nuzum,  as  the  chairperson,  Dr.  Chung-Welch,  Mr.  St.
Clair and Dr. Hawryluk. All members of the Compensation Committee are “non-employee directors” for purposes of Rule 16b-3 under the Exchange Act
and  “independent”  as  independence  is  currently  defined  in  Rule  4200(a)(15)  of  the  NASDAQ  listing  standards.  The  Compensation  Committee  met
six times in fiscal year 2023.

The functions of the Compensation Committee include, among other things:

● approving the annual compensation packages, including base salaries, incentive compensation, deferred compensation and stock-based

compensation, for our executive officers;

● administering our stock incentive plans, and subject to Board approval in the case of executive officers, approving grants of stock, stock options

and other equity awards under such plans;

● approving the terms of employment agreements for our executive officers;

● developing, recommending, reviewing and administering compensation plans for members of the Board of Directors;

● reviewing and discussing the Company’s compensation discussion and analysis with management; and

● preparing any compensation committee report required to be included in the annual proxy statement.  

All Compensation Committee approvals regarding compensation to be paid or awarded to our executive officers are rendered with the full power of the
Board, though not necessarily reviewed by the full Board.

Our Chief Executive Officer may not be present during any Board or Compensation Committee voting or deliberations with respect to his compensation.
Our Chief Executive Officer may, however, be present during any other voting or deliberations regarding compensation of our other executive officers but
may not vote on such items of business. 

Compensation Committee Interlocks and Insider Participation

No member of the Compensation Committee who served as such during the year ended December 31, 2023, has been an executive officer or employee of
ours  while  serving  on  the  Committee  or  had  a  relationship  requiring  disclosure  under  Item  404  of  Regulation  S-K  promulgated  under  the  Securities
Exchange Act of 1934, as amended. None of our officers currently serves, or has served during the last completed year, on the Compensation Committee or
the Board of Directors of any other entity that has one or more officers serving as a member of the Board of Directors or the Compensation Committee.

Nominating and Governance Committee

The Nominating and Governance Committee of the Board of Directors currently consists of Dr. Handley, as the chairperson, Mr. Nuzum and Dr. Rao. All
members  of  the  Nominating  and  Governance  Committee  are  “independent  directors,”  as  such  term  is  defined  by  the  NASDAQ  Market  Listing  Rule
5605(a)(2),  and  free  from  any  relationship  that,  in  the  opinion  of  the  Board,  would  interfere  with  the  exercise  of  his  or  her  independent  judgment  as  a
member of the Committee. There were no meetings of the Nominating and Governance Committee during fiscal year 2023.

In furtherance of its purpose, the Nominating and Governance Committee:

● evaluates the composition, organization and governance of the Board, determines future requirements and make recommendations to the Board for

approval;

● determines desired Board and committee skills and attributes and criteria for selecting new directors;

47

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
● reviews candidates for Board membership consistent with the Committee’s criteria for selecting new directors or as recommended by our

stockholders. Annually, the Committee recommends a slate of nominees to the Board for consideration at our annual stockholders’ meeting;

● develops a plan for, and consults with the Board regarding, management succession; and

● advises the Board generally on corporate governance matters. 

In addition, the Committee, if and when deemed appropriate by the Board or the Committee, develops and recommends to the Board a set of corporate
governance principles applicable to the Company, and reviews and reassesses the adequacy of such guidelines annually and recommends to the Board any
changes deemed appropriate. The Committee also advises the Board on (1) committee member qualifications, (2) appointments, removals and rotation of
committee members, (3) committee structure and operations (including authority to delegate to subcommittees), and (4) committee reporting to the Board.
Finally,  the  Committee  performs  any  other  activities  consistent  with  its  charter,  our  Certification  of  Incorporation,  Bylaws  and  governing  law  as  the
Committee or the Board deems appropriate.

The Committee has the authority to obtain advice and seek assistance from internal or external legal, accounting or other advisors. The Committee has the
sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve such search firm’s fees
and other retention terms.

Merger & Acquisition Committee

The  Merger  &  Acquisition  Committee  of  the  Board  of  Directors  currently  consists  of  Mr.  Nuzum,  Dr.  Chung-Welch,  Dr.  Rao,  and  Dr.  Hawryluk.  The
Merger & Acquisition Committee advises the Company with respect to any considered mergers, acquisitions, joint ventures and/or consolidations of any
type.

Diversity

The Nominating and Governance Committee of the Board of Directors considers and makes recommendations to the Board on all matters pertaining to the
effectiveness of the Board, such as the size and composition of the Board; including the recognition of Equal Opportunity (which is the policy of treating
Directors  and  others  without  discrimination,  especially  on  the  basis  of  their  sex,  ethnicity,  religion,  disability,  national  origin,  sexual  orientation  or
identification, veteran status, race or age). Pursuant to Rules 5605(f) and 5606 of the NASDAQ listing standards, we have made our board diversity matrix
available on our website at https://predictive-oncology.com/ under the “For Investors” and “Corporate Governance” tabs.

Delinquent Section 16(a) Reports

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our officers and directors, and persons who own more than ten percent of a
registered  class  of  our  equity  securities,  to  file  reports  of  ownership  and  changes  in  ownership  of  such  securities  with  the  Securities  and  Exchange
Commission. Based solely on review of the copies of Forms 3 and 4 and amendments thereto filed with the SEC during the fiscal year ended December 31,
2023 and Forms 5 and amendments thereto filed with the SEC with respect to such fiscal year, or written representations that no Forms 5 were required, we
believe that there were no instances where the list of our officers, directors and greater than ten percent beneficial owners failed to file on a timely basis all
Section 16(a) filing requirements during the fiscal year ended December 31, 2023.

48

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code of Ethics

We  have  adopted  a  Code  of  Ethics  that  applies  to  all  directors,  officers  (including  our  principal  executive  officer,  principal  financial  officer,  principal
accounting officer or controller, and persons performing similar functions), and employees of the Company. Our Code of Ethics satisfies the requirements
of Item 406(b) of Regulation S-K and is included as an exhibit to this Annual Report on Form 10-K.

Recoupment of Incentive Compensation Policy

We have adopted a Recoupment of Incentive Compensation Policy that applies to certain executive compensation in the event of an accounting restatement
to correct a material error. Our policy satisfies the requirements as defined in Rule 5608(d) of the Nasdaq Marketplace Rules and is included as an exhibit
to this Form 10-K.

ITEM 11. EXECUTIVE COMPENSATION.

Overview

This section describes the material elements of the compensation awarded to, earned by or paid to (i) each individual who served as our principal executive
officer  during  2023,  (ii)  our  two  most  highly  compensated  other  executive  officers  who  were  serving  as  executive  officers  at  the  end  of  2023  and  who
received more than $100,000 in the form of salary and bonus during such year, and (iii) up to two additional individuals for whom disclosure would have
been  provided  pursuant  to  (ii)  above  but  for  the  fact  that  the  individual  was  not  serving  as  an  executive  officer  at  the  end  of  2023.  We  refer  to  these
individuals as our “Named Executive Officers.” Our named executive officers are:

● Raymond F. Vennare, Chief Executive Officer;
● Bob Myers, former Chief Financial Officer; and
● Pamela Bush, former Chief Business Officer.

We did not have any other executive officers, as determined in accordance with SEC rules, during 2023. 

Summary Compensation Table for Fiscal 2023 and 2022

The  following  table  provides  information  regarding  the  compensation  awarded  to  or  earned  by  each  of  the  Named  Executive  Officers  during  the  fiscal
years ended December 31, 2023 and December 31, 2022:

Name and
Principal
Position

Raymond F.
Vennare, CEO  

Bob Myers (4)

Pamela Bush (8) 

Year

Salary

Bonus

(1)
Stock
Awards

(1)
Option
Awards

All Other
Compensation  

Total
Compensation  

2023
2022

2023
2022

2023
2022

  $
  $

  $
  $

  $
  $

525,000 
  $
87,500(2)  $

316,360 
374,900 

402,917 
- 

  $
  $

  $
  $

- 
  $
34,125(3)  $

- 

  $
110,430(6)  $

- 
- 

  $
  $

-    $
-    $

-    $
-    $

-    $
-    $

-    $
-    $

-    $
-    $

-    $
-    $

- 
- 

  $
  $

131,316(5)  $
26,538(7)  $

- 
- 

  $
  $

525,000 
121,625 

447,676 
511,868 

402,917 
- 

(1)These amounts have been calculated in accordance with FASB ASC Topic 718. Pursuant to SEC rules, the amounts shown exclude the impact of
estimated forfeitures related to service-based vesting conditions. For a discussion of the assumptions relating to our valuations of these stock awards
and  stock  options,  please  see  Notes  1  and  9  to  the  financial  statements  included  in  this  Annual  Report  on  Form  10-K.  These  amounts  reflect  our
accounting  expense  for  these  stock  awards  and  stock  options  and  do  not  correspond  to  the  actual  value  that  may  be  recognized  by  the  Named
Executive Officer.

49

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
   
     
 
     
 
     
       
       
 
     
 
 
 
 
   
     
 
     
 
     
       
       
 
     
 
 
 
 
 
   
     
 
     
 
     
       
       
 
     
 
 
 
 
 
 
(2)Effective November 1, 2022, Mr. Vennare was named Chief Executive Officer. Mr. Vennare received an annual salary of $525,000.

(3)Reflects a discretionary bonus for performance in 2022 that was paid to Mr. Vennare on March 15, 2023.

(4)Effective September 30, 2023, Mr. Myers resigned as the Company’s Chief Financial Officer.

(5)Includes severance payments of $89,583 and an accrued vacation payment of $36,798 paid to Mr. Myers in 2023 pursuant in accordance with his

Employment Agreement and a Separation Agreement and Mutual Release dated September 30, 2023, between Mr. Myers and the Company.

(6)Reflects a discretionary bonus for performance in 2022 that was paid to Mr. Myers in 2023.

(7)Reflects  the  grant  date  fair  value  of  restricted  stock  units  (RSUs)  granted  on  May  17,  2021.The  RSUs  comprise  a  Long-Term  Incentive  Program

(“LTIP”) structured to reward performance. See “Long Term Incentive Plan for Executive Officers” below.

(8)Effective  February  1,  2023,  Dr.  Bush  was  named  Chief  Business  Officer  and  received  an  annual  salary  of  $410,000.  The  amount  in  the  table
represents Dr. Bush’s salary for the entire year, including prior to becoming an executive officer. Dr. Bush left the Company effective February 15,
2024.

Outstanding Equity Awards at Fiscal Year-end for Fiscal 2023

The following table sets forth certain information regarding outstanding equity awards held by the named executive officers as of December 31, 2023:

Name

Grant Date

Options

Number of
Securities
Underlying
Options
Exercisable

Number of
Securities
Underlying
Options
Unexercisable

Raymond F. Vennare

Bob Myers

Pamela Bush

-     

6/22/2017     
4/4/2019     

12/21/2021     

-     

1,521     
830     

500     

Executive Compensation Components for Fiscal 2023

Option
Exercise
Price

Option
Expiration
Date

-     

-    $
-    $

-    $

-     

- 

30.80   
30.80   

6/22/2027 
4/4/2029 

20.60   

12/1/2031 

Base Salary. Base salary is an important element of our executive compensation program as it provides executives with a fixed, regular, non-contingent
earnings stream to support annual living and other expenses. As a component of total compensation, we generally set base salaries at levels believed to
attract and retain an experienced management team that will successfully grow our business and create stockholder value. We also utilize base salaries to
reward individual performance and contributions to our overall business objectives but seek to do so in a manner that does not detract from the executives’
incentive to realize additional compensation through our bonus and equity incentive programs.

The Compensation Committee reviews the Chief Executive Officer’s salary at least annually. The Compensation Committee may recommend adjustments
to the Chief Executive Officer’s base salary based upon the Compensation Committee’s review of his current base salary, incentive cash compensation and
equity-based compensation, as well as his performance and comparative market data. The Compensation Committee also reviews other executives’ salaries
throughout the year, with input from the Chief Executive Officer. The Compensation Committee may recommend adjustments to other executives’ base
salary based upon the Chief Executive Officer’s recommendation and the reviewed executives’ responsibilities, experience, and performance, as well as
comparative market data.

50

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
   
 
 
 
   
   
   
   
 
 
     
       
       
       
       
 
   
 
     
       
       
       
       
 
 
 
 
 
     
       
       
       
       
 
 
 
 
 
 
In  utilizing  comparative  data,  the  Compensation  Committee  seeks  to  recommend  salaries  for  each  executive  at  a  level  that  is  appropriate  after  giving
consideration  to  experience  for  the  relevant  position  and  the  executive’s  performance.  The  Compensation  Committee  reviews  performance  for  both  our
Company (based upon achievement of strategic initiatives) and each individual executive. Based upon these factors, the Compensation Committee may
recommend adjustments to base salaries to better align individual compensation with comparative market compensation, to provide merit-based increases
based upon individual or company achievement, or to account for changes in roles and responsibilities.

Bonuses. Bonuses may be paid at the discretion of the Compensation Committee and as approved by the Board of Directors based on the Compensation
Committee’s determination of the performance of the executive officer.

Stock Options and Other Equity Grants. Consistent with our compensation philosophies related to performance-based compensation, long-term stockholder
value creation and alignment of executive interests with those of stockholders, we may make periodic grants of long-term incentive compensation in the
form of stock options or other equity-based incentive award to our executive officers, directors, and others in the organization.

Stock options provide executive officers, directors, and other employees with the opportunity to purchase common stock at a price fixed on the grant date
regardless of future market price. A stock option becomes valuable only if the common stock price increases above the option exercise price and the holder
of the option remains employed or appointed during the period required for the option shares to vest. This provides an incentive for an option holder to
remain  employed  or  appointed  by  us.  In  addition,  stock  options  link  employees’  compensation  to  stockholders’  interests  by  providing  an  incentive  to
increase stockholder value. Under our Amended and Restated 2012 Stock Incentive Plan (the “2012 Plan”), we may also make grants of common stock,
restricted stock awards, restricted stock units, performance stock awards, and stock appreciation rights to executive officers, directors, and other employees.
Restricted stock units represent the right to receive shares of our common stock (or, in some cases, the value thereof in cash) upon vesting, with vesting
generally  being  time-based,  based  on  achievement  of  certain  perform  metrics,  or  both.  We  adopted  the  2012  Plan  to  give  us  flexibility  in  the  types  of
awards that we could grant to our executive officers, directors, and other employees. In 2020, 2021, and 2022, our stockholders approved amendments to
the 2012 Plan to increase the share reserve under the 2012 Plan by 37,500 shares, 75,000 shares, and 125,000 shares, respectively. As of December 31,
2023, there were stock options to purchase 47,664 shares of common stock outstanding under the 2012 Plan and 94,878 shares remain available for future
equity awards.

Limited Perquisites; Other Benefits. We provide our employees, including our executive officers, with a full complement of employee benefits, including
health and dental insurance, short term and long-term disability insurance, life insurance, a 401(k) plan, FSA flex plan and Section 125 plan.

Long Term Incentive Plan for Executive Officers

On May 17, 2021, the Committee adopted and approved a 2021 Long Term Incentive Plan (the “LTIP”) to provide incentives to the Company’s executive
officers  over  the  three-year  performance  period  consisting  of  fiscal  years  2021,  2022  and  2023.  Under  the  LTIP,  in  May  2021,  the  Company  granted
restricted stock units (“RSUs”) to the Company’s then-current CFO, Bob Myers, under the 2012 Plan.

The LTIP awards consisted of 7,500 RSUs (target). These RSUs required continued employment of the executive through January 1, 2024, and therefore
were terminated before vesting as a result of Mr. Myers’ departure from the Company in 2023.

51

 
 
 
 
 
 
 
 
 
 
Employment Contracts

Employment Agreement with Current Chief Executive Officer

On October 13, 2022, the Company and Raymond F. Vennare, the Company’s current Chief Executive Officer, entered into an Employment Agreement (the
“Agreement”), effective as of November 1, 2022, the first date of Mr. Vennare’s employment. Pursuant to the Agreement, Mr. Vennare is entitled to an
annual base salary of $525,000. He will also be eligible (i) to receive an annual cash bonus equal to up to 50% of his salary, or at the discretion of the
Compensation Committee (the “Committee”) of the Company’s Board of Directors, a higher percentage based on his performance (prorated for 2022) and
(ii)  to  participate  in  a  long-term  incentive  plan  to  be  adopted  and  maintained  by  the  Committee.  Mr.  Vennare  will  also  be  eligible  to  participate  in  the
standard employee benefit plans generally available to executive employees of the Company, and, at the discretion of the Committee, to receive grants of
stock options or other equity awards. Any grants of equity awards, including those above, will be made from the Company’s Amended and Restated 2012
Stock Incentive Plan or successor plans.

Under the Agreement, Mr. Vennare’s employment by the Company is at-will. If his employment is terminated by the Company without “cause” or if he
voluntarily resigns with “good reason” (in each case as defined in the Agreement), then Mr. Vennare will be entitled to receive from the Company payment
of his base salary then in effect through his last date of employment, plus accrued, unused vacation pay. In addition, Mr. Vennare will be entitled to (a)
severance pay in an amount equal to 12 months of his base salary then in effect, less applicable taxes and withholdings; and (b) a bonus payment on a pro-
rata basis through the date of his termination.

The Agreement also contains customary provisions with respect to confidentiality and intellectual property, in addition to ones prohibiting Mr. Vennare
from soliciting the Company’s employees and from engaging in certain activities that are competitive with the Company for a period of 12 months after
termination of his employment.

Employment Agreement with former Chief Financial Officer.

Effective September 30, 2023, Mr. Bob Myers resigned as the Chief Financial Officer. Mr. Myers served as Chief Financial Officer since July 1, 2012,
under an employment agreement entered on August 13, 2012, which was amended on August 20, 2018. Under the agreement the employment of Mr. Myers
was at will.

Mr.  Myers’  annual  base  salary  was  $345,000  until  March  1,  2022,  at  which  time  Mr.  Myers  received  an  increase  in  his  base  salary  resulting  in  an
annualized base salary of $380,880. On September 23, 2020, Mr. Myers was awarded a one-time, special interim grant of retention equity awards for 2020
of  5,000  restricted  stock  units  payable  in  shares  of  common  stock  and  vesting  in  equal  annual  installments  over  three  years,  subject  to  continued
employment,  with  accelerated  vesting  upon  certain  events,  including  involuntary  termination  without  cause,  voluntary  termination  for  good  reason  or
retirement after at least eighteen months upon at least six months’ notice. Mr. Myers received an increase in his base salary on March 1, 2023, resulting in
an annualized base salary of $430,000. Base salary for Mr. Myers could have been adjusted by us but could not have been reduced except in connection
with a reduction imposed on substantially all employees as part of a general reduction. He would have also been eligible to receive an annual incentive
bonus for each calendar year at the end of which he remained employed by us, subject to the attainment of certain objectives.

On May 17, 2021, Mr. Myers received 7,500 restricted stock units (target) pursuant to the 2021 Long Term Incentive Plan (the “LTIP”). See “Long Term
Incentive Plan for Executive Officers” above. Also, under the long-term incentive program, the officer would receive annual grants of restricted stock units
on January 1 of each calendar year starting in 2021. Each grant would consist of 2,500 restricted stock units with vesting of each grant over three years
based on performance and continued employment.

Mr.  Myers  was  entitled  to  five  (5)  weeks  of  paid  vacation  per  each  calendar  year  earned  ratably  over  each  calendar  year,  to  be  taken  at  such  times  as
employee and Company determined and provided that no vacation time would unreasonably interfere with the duties required to be rendered by employee.

52

 
 
 
 
 
 
 
 
 
 
 
 
Under the agreement, if his employment was terminated without “cause” or if he terminated his employment for “good reason,” in each case as defined in
his employment agreement, he would be entitled to receive severance pay in an amount equal to twelve months of base salary, less applicable taxes and
withholdings. In that event, he would receive a bonus payment on a pro-rata basis through the date of termination and any accrued, unused vacation pay.
The  severance  pay,  bonus  payment,  and  other  consideration  were  conditioned  upon  the  executive’s  execution  of  a  full  and  final  release  of  liability.  Mr.
Myers left the Company in September 2023, and the Company and Mr. Myers entered into a Separation Agreement and Mutual Release on September 30,
2023, that restated the severance payments he was entitled to pursuant to his agreement, provided for the release of liability described above, and in which
the Company limited the non-compete provision of the employment agreement to provide that it would only apply to activities related to the discovery,
characterization, or evaluation of chemical or biological compositions for the diagnosis or treatment of disease.

Potential Payments Upon Termination or Change of Control

Most of our stock option agreements provide for an acceleration of vesting in the event of a change in control as defined in the agreements and in the 2012
Plan.  However,  the  stock  option  agreements  awarded  to  Bob  Myers  provided  that  upon  the  termination  of  his  employment  without  cause  or  for  good
reason, his options would become fully vested, and the vested shares may be purchased for up to five years after such termination (or such lesser period for
the option if the remaining period of the option was less than five years after such termination). In addition, in the event of such employee’s retirement,
death  or  disability,  such  employee’s  options  would  become  fully  vested,  and  the  vested  shares  may  be  purchased  for  the  entire  remaining  period  of  the
option. Also, see “Employment Contracts” above for a description of certain severance compensation arrangements.

Director Compensation

Effective June 17, 2021 the Board adopted a Director Compensation Program under which the members of the Board of Directors receive quarterly awards
of  common  stock  and  cash  as  compensation  for  their  services  as  directors  and  annual  awards  of  common  stock  and  cash  for  services  as  committee
members.  These  awards  were  implemented  to  replace  a  previous  program  of  quarterly  stock  option  grants  to  directors.  The  June  2020  annual  common
stock award remains in place as described below.

The compensation program pays all of the compensation in the form of stock and cash awards (with the cash component payable in additional shares at the
election of the director. The cash component is equal to 28% of the total value of the award (or 38.9% of the share component of the award), intended to
pay the tax on the full award.

Each director receives a quarterly award of $8,333 payable on the last day of the quarter, consisting of (i) shares with a value of $6,000 and (ii) $2,333 in
cash (or additional shares).

For each board committee, each director receives an additional annual award of $11,112, consisting of (i) shares with a value of $8,000 and (ii) $3,112 in
cash (or additional shares), payable on December 31.

Starting  in  2022,  director  compensation  became  limited  to  Non-Employee  Directors  (directors  who  are  not  employees  of  Predictive  Oncology  or  any
subsidiary and who do not receive regular long-term cash compensation as consultants).

Effective as of January 25, 2023, under an Amended and Restated Director Compensation Program, the Lead Independent Director, will also receive an
annual award of $11,112, consisting of (i) shares with a value of $8,000 and (ii) $3,112 in cash (or additional shares).

Effective on June 16, 2020, the Board instituted an annual common stock award for all the directors under which they will receive $7,000 in value of newly
issued  shares  of  common  stock,  par  value  $0.01  per  year  annually  for  three  years,  if  they  are  serving  as  a  director  at  the  annual  appointment  date.
Additionally, the directors will receive a $3,000 cash payment per year annually for three years, if they are serving as a director at the annual appointment
date.

53

 
 
 
 
 
 
 
 
 
 
 
 
 
Director Compensation Table for Fiscal 2023

The following table summarizes the compensation paid to each individual who served as a director during the fiscal year ended December 31, 2023:

Charles Nuzum Sr. (2)
Daniel Handley (3)
Greg St. Clair Sr. (4)
Nancy Chung-Welch (5)
Matthew J. Hawryluk (6)
Veena Rao (7)

David S. Smith (8)

Fees Paid or
Earned in
Cash

Stock Awards
(1)

Option
Awards

Total

  $
  $
  $
  $
  $
  $

  $

63,893    $
29,444    $
32,890    $
51,668    $
40,556    $
49,335    $

35,006    $
25,001    $
32,670    $
25,001    $
25,001    $
24,002    $

2,333    $

6,000    $

-    $
-    $
-    $
-    $
-    $
-    $

-    $

98,899 
54,445 
65,560 
76,669 
65,557 
73,337 

8,333 

(1)Represents grant date fair value of stock awards granted during 2023 as determined pursuant to FASB ASC 718, Stock Compensation.
(2)Reflects 7,653 shares of common stock received in 2023 for serving on the Board.
(3)Reflects 5,468 shares of common stock received in 2023 for serving on the Board.
(4)Reflects 6,923 shares of common stock received in 2023 for serving on the Board.
(5)Reflects 5,468 shares of common stock received in 2023 for serving on the Board.
(6)Reflects 5,468 shares of common stock received in 2023 for serving on the Board.
(7)Reflects 5,849 shares of common stock received in 2023 for serving on the Board.
(8)Reflects 918 shares of common stock received in 2023 for serving on the Board. Mr. Smith resigned from the Board effective May 2, 2023.

ITEM  12.  SECURITY  OWNERSHIP  OF  CERTAIN  BENEFICIAL  OWNERS  AND  MANAGEMENT  AND  RELATED  STOCKHOLDER
MATTERS.

Equity Compensation Plan Information

The following table presents the equity compensation plan information as of December 31, 2023:

Number of
securities
to be issued upon
exercise of
outstanding
restricted stock,
warrants and
options
(a)

Weighted-
average
exercise
price of
outstanding
options,
warrants
(b)

Number of
securities
remaining
available for
future issuance
under
equity
compensation
plans (excluding
securities reflected
in
column (a))
(c)

Equity compensation plans approved by security holders (1)
Equity compensation plans not approved by security holders

47,664    $
-    $

82.23     
-     

94,878 
- 

(1)Consists of outstanding options under the 2008 Equity Incentive Plan and the 2012 Stock Incentive Plan. The remaining share authorization under the

2008 Equity Incentive Plan was rolled over to the current 2012 Stock Incentive Plan.

54

 
 
 
 
 
 
   
   
   
 
 
     
       
       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
   
   
 
 
 
Security Ownership of Certain Beneficial Owners and Management

The following table sets forth as of March 8, 2024, certain information regarding beneficial ownership of our common stock by:

  ● each person, or group of affiliated persons, who are known by us to beneficially own more than 5% of the outstanding shares of common stock;

  ● each of our directors and director nominees;

  ● each of the Named Executive Officers, as identified in this Annual Report on Form 10-K; and

  ● all of our current executive officers (as that term is defined under the rules and regulations of the SEC) and directors as a group.

We have determined beneficial ownership in accordance with Rule 13d-3 under the Exchange Act. Beneficial ownership generally means having sole or
shared voting or investment power with respect to securities. We are not aware of any beneficial owners of more than 5% of our issued and outstanding
common stock as of March 8, 2024.

Unless  otherwise  indicated  in  the  footnotes  to  the  table,  each  stockholder  named  in  the  table  has  sole  voting  and  investment  power  with  respect  to  the
shares of common stock set forth opposite the stockholder’s name. We have based our calculation of the percentage of beneficial ownership on 4,062,853
shares of our common stock outstanding on March 8, 2024. Unless otherwise noted below, the address for each person or entity listed in the table is c/o
Predictive Oncology Inc., 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201.

Name of Beneficial Owner (1)

Raymond F. Vennare

Josh Blacher

Chuck Nuzum (2)

Gregory St. Clair (3)

Daniel Handley (4)

Nancy Chung-Welch (5)

Matthew J. Hawryluk

Veena Rao

All directors and executive officers as a group (8 persons)

Amount and
Nature of
Beneficial
Ownership

    Percent of Class  

7,122     

-     

28,653     

19,266     

16,308     

18,974     

7,135     

5,849     

103,307     

0.18%

0.00%

0.71%

0.47%

0.40%

0.47%

0.18%

0.14%

2.54%

(1) Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding,
relationship, or otherwise has or shares: (1) voting power, which includes the power to vote, or to direct the voting of shares; and (2) investment
power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than
one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially
owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which
the  information  is  provided.  In  computing  the  percentage  ownership  of  any  person,  the  amount  of  shares  outstanding  is  deemed  to  include  the
number  of  shares  beneficially  owned  by  such  person  (and  only  such  person)  by  reason  of  these  acquisition  rights.  As  a  result,  the  percentage  of
outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the
number of shares of common stock actually outstanding.

(2) Includes options to purchase 2,014 shares that are exercisable within 60 days of March 8, 2024.
(3) Includes options to purchase 1,332 shares that are exercisable within 60 days of March 8, 2024.
(4) Includes options to purchase 1,643 shares that are exercisable within 60 days of March 8, 2024.
(5) Includes options to purchase 2,014 shares that are exercisable within 60 days of March 8, 2024.

55

 
 
 
 
 
 
 
 
 
 
 
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
     
       
 
   
 
 
 
 
 
 
 
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

The  Audit  Committee  has  the  responsibility  to  review  and  approve  all  transactions  to  which  a  related  party  and  we  may  be  a  party  prior  to  their
implementation, to assess whether such transactions meet applicable legal requirements. Pursuant to the Charter of the Audit Committee, every transaction
that  must  be  disclosed  pursuant  to  Item  404(a)  of  Regulation  S-K  promulgated  under  the  Exchange  Act  must  be  reviewed  and  approved  by  the  Audit
Committee.

During the year ended December 31, 2023, there were no related party transactions.

Information regarding director independence is disclosed under Item 10, above.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

In connection with the audit of the fiscal 2023 and 2022 financial statements, we entered into an engagement agreement with BDO USA, P.C. (2023) and
Baker Tilly US, LLP (2022), which set forth the terms by which they performed audit services for us.

The following table represents aggregate fees billed to us by BDO USA, P.C. (“BDO”), the Company’s independent public accounting firm for the fiscal
year  ended  December  31,  2023,  for  services  rendered  with  respect  to  the  fiscal  year  ended  December  31,  2023,  and  by  Baker  Tilly  US,  LLP  (“Baker
Tilly”), the Company’s independent public accounting firm for the fiscal year ended December 31, 2022, for services rendered with respect to the fiscal
year  ended  December  31,  2022.  Fees  are  approved  by  the  Audit  Committee  on  an  engagement-by-engagement  basis.  All  fees  described  below  were
approved by the Audit Committee.

Audit Fees (1)
Audit-Related Fees
Tax Fees (2)
All Other Fees (3)

2023

2022

392,006    $
-     
-     
-     
392,006    $

337,558 
- 
29,875 
102,250 
469,683 

  $

  $

(1)Audit Fees were principally for services rendered for the audit and/or review of our consolidated financial statements. Also includes fees for services
rendered in 2022 in connection with the filing of registration statements and other documents with the SEC, the issuance of accountant consents and
comfort letters.

(2)Tax Fees consist of fees billed in the indicated year for professional services performed by Baker Tilly with respect to tax compliance during 2022.

(3)Other Fees in 2022 consisted of fees for professional services performed by Baker Tilly with respect to an assessment of the Company’s security and

compliance activities.

56

 
 
 
 
 
 
 
 
 
 
 
   
 
   
   
   
 
 
 
 
 
 
 
 
ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES.

PART IV

The following exhibits and financial statements are filed as part of, or are incorporated by reference into, this report:

(1) Financial Statements

The following financial statements are filed with this Annual Report on Form 10-K and can be found beginning at page F-1 of this report:

● Reports of Independent Registered Public Accounting Firms (BDO USA, P.C., Minneapolis, Minnesota, PCAOB Firm ID #243) (Baker Tilly US,

LLP, Minneapolis, Minnesota, PCAOB Firm ID #23);

● Consolidated Balance Sheets as of December 31, 2023, and December 31, 2022;

● Consolidated Statements of Net Loss for the Years Ended December 31, 2023, and December 31, 2022;

● Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023, to December 31, 2022;

● Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, and December 31, 2022; and

● Notes to Consolidated Financial Statements.

(2) Financial Statement Schedules

All schedules for which provision is made in the applicable accounting regulations of the SEC have been omitted because the information required to be
shown in the schedules is not applicable or is included elsewhere in the financial statements and Notes to Consolidated Financial Statements.

(3) Exhibits

Exhibit
Number

Description

2.1

3.1

3.2

3.3

3.4

3.5

Agreement and Plan of Merger dated November 24, 2021 by and among the Company, Golden Gate Acquisition, Inc., zPREDICTA, Inc.
and Tom Kelly, as Representative (Filed on December 1, 2021 as an exhibit to our Current Report on Form 8-K, and incorporated herein by
reference).

Certificate  of  Incorporation  (Filed  on  December  19,  2013  as  an  exhibit  to  our  Current  Report  on  Form  8-K,  and  incorporated  herein  by
reference).

Certificate of Amendment to Certificate of Incorporation to effect reverse stock split and reduction in authorized share capital filed with the
Delaware  Secretary  of  State  on  October  20,  2014.  (Filed  on  October  24,  2014  as  an  exhibit  to  our  Current  Report  on  Form  8-K,  and
incorporated herein by reference)

Certificate of Amendment to Certificate of Incorporation regarding increase in share capital, filed with the Delaware Secretary of State on
July  24,  2015.  (Filed  on  June  30,  2015  as  an  appendix  to  our  Information  Statement  on  Schedule  14C,  and  incorporated  herein  by
reference).

Certificate of Amendment to Certificate of Incorporation to increase authorized share capital, filed with the Delaware Secretary of State on
September 16, 2016. (Filed on September 16, 2016 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate of Amendment to Certificate of Incorporation to effect reverse stock split and reduction in authorized share capital, filed with the
Delaware  Secretary  of  State  on  October  26,  2016.  (Filed  on  October  27,  2016  as  an  exhibit  to  our  Current  Report  on  Form  8-K,  and
incorporated herein by reference).

57

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6

3.7

3.8

3.9

3.10

3.11

3.12

3.13

3.14

3.15

3.16

3.17

3.18

3.19

Certificate of Amendment to Certificate of Incorporation regarding increase in share capital, filed with the Delaware Secretary of State on
January 26, 2017. (Filed on January 27, 2017 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate of Amendment to Certificate of Incorporation to effect reverse stock split, filed with the Delaware Secretary of State on January
2, 2018. (Filed on January 2, 2018 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate of Amendment to Certificate of Incorporation to effect name change, filed with the Delaware Secretary of State on February 1,
2018. (Filed on February 6, 2018 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. (Filed on August 20,
2015 as an exhibit to our Registration Statement on Form S-1 (File No. 333-198962), and incorporated herein by reference.

Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock. (Filed on November 29, 2017 as
an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate  of  Amendment  to  Certificate  of  Incorporation  dated  March  22,  2019.  (Filed  on  March  22,  2019  as  an  exhibit  to  our  Current
Report on Form 8-K, and incorporated herein by reference).

Certificate of Designation Of Preferences, Rights And Limitations of Series D Convertible Preferred Stock. (Filed on April 1, 2020 as an
exhibit to our Annual Report on Form 10-K, and incorporated herein by reference).

Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock Effective June 13, 2019. (Filed on
June 19, 2019 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate  of  Amendment  of  Certificate  of  Incorporation,  changing  name  from  Precision  Therapeutics  Inc.  to  Predictive  Oncology  Inc.
(Filed on June 13, 2019 as an exhibit to our Current Report on Form 8-K, and incorporated herein by reference).

Certificate of Amendment of Certificate of Incorporation, amending number of shares of common stock and preferred stock, effecting a
reverse stock split. (Filed on October 28, 2019 as an exhibit to our Current Report on Form 8-K).

Certificate of Amendment to the Certificate of Incorporation, doubling number of shares of common stock and preferred stock due to stock
split. (Filed on August 19, 2021 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.)

Certificate of Designation of Series F Preferred Stock (Filed on March 16, 2023 as an exhibit to the Form 8-A and incorporated herein by
reference.)

Certificate of Amendment to Certificate of Incorporation (Filed on April 20, 2023 as an exhibit to our Current Report on Form 8-K and
incorporated herein by reference.)

Second Amended and Restated Bylaws of the Company, effective as of September 9, 2022 (Filed on September 30, 2022 as an exhibit to
our Registration Statement on Form S-1 (File No. 333-267689).

58

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1

4.2

4.3

4.4

4.5

4.6

4.7

4.8

4.9

4.10

4.11

4.12

4.13

4.14

4.15

4.16

Form of specimen certificate evidencing shares of Series B Convertible Preferred Stock. (Filed on August 10, 2015 as an exhibit to our
Registration Statement on Form S-1/A (File No. 333-198962) and incorporated herein by reference.)

Form of Unit Purchase Option issued February 27, 2019. (Filed on March 1, 2019 as an exhibit to our Current Report on Form 8-K and
incorporated herein by reference.)

Form of Common Stock Purchase Warrant issued March 29, 2019. (Filed on April 2, 2019 as an exhibit to our Current Report on Form 8-K
and incorporated herein by reference.)

Form of Unit Purchase Option for the Purchase of Units issued March 29, 2019. (Filed on April 2, 2019 as an exhibit to our Current Report
on Form 8-K and incorporated herein by reference.)

Common Stock Purchase Warrant Issued to Oasis Capital, LLC dated September 27, 2019. (Filed on September 30, 2019 as an exhibit to
our Current Report on Form 8-K and incorporated herein by reference.)

Form of Specimen Common Stock Certificate. (Filed on October 3, 2019 as an exhibit to our Registration Statement on Form S-3 (File No.
333-234073) and incorporated herein by reference.)

Form of Common Stock Purchase Warrant Issued on or about October 1, 2019. (Filed on October 10, 2019 as an exhibit to our Current
Report on Form 8-K and incorporated herein by reference.)

Common Stock Purchase Warrant issued to Oasis Capital, LLC dated February 5, 2020. (Filed on February 7, 2020 as an exhibit to our
Current Report on Form 8-K and incorporated herein by reference.)

Description  of  Registrant’s  Securities.  (Filed  on  March  31,  2022  as  an  exhibit  to  our  Annual  Report  on  Form  10-K  for  the  year  ended
December 31, 2021 and incorporated herein by reference.)

Common  Stock  Purchase  Warrant  issued  to  Oasis  Capital,  LLC  dated  March  6,  2020.  (Filed  on  April  6,  2020  as  an  exhibit  to  our
Registration Statement on Form S-3 (File No. 333-237581) and incorporated herein by reference.)

Form of Helomics Common Stock Purchase Warrant issued April 4, 2019. (Filed on January 24, 2019 as Annex H to Amendment No. 2 to
Form S-4 (File No. 333-228031) and incorporated herein by reference.) 

Form of Common Stock Purchase Warrant issued January 12, 2021. (Filed on January 12, 2021 as an exhibit to our Current Report on Form
8-K and incorporated herein by reference.)

Form of Common Stock Purchase Warrant issued January 19, 2021. (Filed on January 21, 2021 as an exhibit to our Current Report on Form
8-K and incorporated herein by reference.)

Form of Placement Agent Warrant to H.C. Wainwright & Co., LLC or its designees in connection with certain financing transactions in
2020 and 2021. (Filed on January 29, 2021 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.)

Form of Common Stock Purchase Warrant dated February 10, 2021. (Filed on February 12, 2021 as an exhibit to our Current Report on
Form 8-K and incorporated herein by reference.)

Form of Common Stock Purchase Warrant dated February 23, 2021. (Filed on February 22, 2021 as an exhibit to our Current Report on
Form 8-K and incorporated herein by reference.)

59

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.17

4.18

10.1**

10.2**

10.3**

10.4**

10.5**

Form of Common Stock Purchase Warrant dated June 16, 2021. (Filed on June 16, 2021 as an exhibit to our Current Report on Form 8-K
and incorporated herein by reference.)

Form  of  Placement  Agent  Warrant  dated  June  16,  2021.  (Filed  on  June  16,  2021  as  an  exhibit  to  our  Current  Report  on  Form  8-K  and
incorporated herein by reference.)

Employment Agreement with Robert Myers dated August 11, 2012. (Filed on November 5, 2012 as an exhibit to our Registration Statement
on Form S-1/A and incorporated herein by reference.)

Amended  and  Restated  2012  Stock  Incentive  Plan.  (Filed  on  October  18,  2022  as  an  appendix  to  our  definitive  proxy  statement  on
Schedule 14A and incorporated herein by reference.)

Form of Stock Option Agreement for Employees under Amended and Restated 2012 Stock Incentive Plan (Filed on March 31, 2022 as an
exhibit to our Annual Report on Form 10-K and incorporated herein by reference).

Form of Stock Option Agreement for Executive Officers under Amended and Restated 2012 Stock Incentive Plan (Filed on March 31, 2022
as an exhibit to our Annual Report on Form 10-K and incorporated herein by reference).

Form of Stock Option Agreement for Directors under Amended and Restated 2012 Stock Incentive Plan (Filed on March 31, 2022 as an
exhibit to our Annual Report on Form 10-K and incorporated herein by reference).

10.6

Securities  Purchase  Agreement  by  and  among  the  Company  and  the  Investors  dated  March  15,  2020.  (Filed  on  March  16,  2020  as  an
exhibit to our Current Report on Form 8-K and incorporated herein by reference.)

10.7**

10.8**

Employment Offer Letter dated September 30, 2022, by and between the Company and Raymond F. Vennare. (Filed on September 22, 2022
as an exhibit to our Current Report on Form 8-K).

Employment Agreement dated effective November 1, 2022, by and between the Company and Raymond F. Vennare. (Filed on October 20,
2022 as an exhibit to our Current Report on Form 8-K).

10.9*

Separation Agreement and Mutual Release dated effective September 30, 2023, by and between the Company and Bob Myers.

14.1

Code of Ethics. (Filed on April 16, 2012 as an exhibit to our Annual Report on Form 10-K and incorporated herein by reference.)

21.1*

Subsidiaries of the Registrant

23.1*

Consent of Independent Registered Public Accounting Firm:  BDO USA, P.C.

23.2*

Consent of Independent Registered Public Accounting Firm:  Baker Tilly US, LLP

31.1*

Certification of Principal Executive Officer required by Rule 13a-14(a)

31.2*

Certification of Principal Financial Officer required by Rule 13a-14(a)

32.1***

Section 1350 Certification

97*

Policy Relating to Recovery of Erroneously Awarded Compensation

60

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101.INS*

Inline XBRL Instance Document

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
**Compensatory Plan or arrangement required to be filed pursuant to Item 15(b) of Form 10-K. 
***Furnished herewith.

ITEM 16. FORM 10-K SUMMARY.

None.

61

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-
K to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

Dated: March 28, 2024

Predictive Oncology Inc.

By  /s/ Raymond F. Vennare
  Raymond F. Vennare
  Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.

Signatures

  Title

/s/ Raymond F. Vennare
Raymond F. Vennare

  Chief Executive Officer

(Principal executive officer)

/s/ Josh Blacher
Josh Blacher

/s/ Chuck Nuzum
Chuck Nuzum

/s/ Daniel E. Handley
Daniel E. Handley

/s/ Gregory St. Clair Sr.
Gregory St. Clair Sr.

/s/ Nancy Chung-Welch
Nancy Chung-Welch

/s/ Matthew Hawryluk
Matthew Hawryluk

/s/ Veena Rao
Veena Rao

Interim Chief Financial Officer
(Principal financial and accounting officer)

  Director

  Director

  Director

  Director

  Director

  Director

62

March 28, 2024

March 28, 2024

March 28, 2024

March 28, 2024

March 28, 2024

March 28, 2024

March 28, 2024

March 28, 2024

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The audited consolidated financial statements for the periods ended December 31, 2023, and December 31, 2022, are included on the following pages:

INDEX TO FINANCIAL STATEMENTS

Financial Statements:
Reports of Independent Registered Public Accounting Firms (BDO USA, P.C., Minneapolis, Minnesota, PCAOB Firm ID #243) (Baker Tilly
US, LLP, Minneapolis, Minnesota, PCAOB Firm ID #23)
Consolidated Balance Sheets
Consolidated Statements of Net Loss
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements

Page

F-1
F-4
F-5
F-6
F-8
F-9

63

 
 
 
 
 
 
 
 
 
 
 
 
Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors
Predictive Oncology Inc.
Pittsburgh, Pennsylvania

Opinion on the Consolidated Financial Statements

We  have  audited  the  accompanying  consolidated  balance  sheet  of  Predictive  Oncology  Inc.  (the  “Company”)  as  of  December  31,  2023,  the  related
consolidated  statements  of  net  loss,  stockholders’  equity,  and  cash  flows  for  the  year  then  ended,  and  the  related  notes  (collectively  referred  to  as  the
“consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company at December 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles
generally accepted in the United States of America.

We also have audited the adjustments to the 2022 consolidated financial statements to retrospectively apply the changes in the share and per share amounts
to reflect the reverse stock split and in the change in the reportable segments, as discussed in Notes 1 and 14, respectively. In our opinion, such adjustments
are  appropriate  and  have  been  properly  applied.  We  were  not  engaged  to  audit,  review,  or  apply  any  procedures  to  the  2022  consolidated  financial
statements of the Company other than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the
2022 consolidated financial statements taken as a whole.

Going Concern Uncertainty

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in
Note  1  to  the  consolidated  financial  statements,  the  Company  has  suffered  recurring  losses  from  operations  and  has  an  accumulated  deficit  that  raises
substantial  doubt  about  its  ability  to  continue  as  a  going  concern.  Management’s  plans  in  regard  to  these  matters  are  also  described  in  Note  1.  The
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

F-1

 
 
 
 
 
 
 
 
 
 
 
 
 
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance  about  whether  the  consolidated  financial  statements  are  free  of  material  misstatement,  whether  due  to  error  or  fraud.  The  Company  is  not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion.

Our  audit  included  performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  consolidated  financial  statements,  whether  due  to  error  or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis
for our opinion.

Critical Audit Matter

The  critical  audit  matter  communicated  below  is  a  matter  arising  from  the  current  period  audit  of  the  consolidated  financial  statements  that  was
communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated
financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below,
providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

Revenue Recognition – Evaluation of Contract Terms in Certain Contracts with Customers

The  Company  has  revenues  of  $1,780,093  for  the  year  ended  December  31,  2023.  As  described  in  Note  1  of  the  consolidated  financial  statements,  the
Company derives its revenues primarily from Contract Research Organization (“CRO”) services, sales of medical device products, or maintenance plan
services. The Company recognizes revenue in accordance with the five-step process outlined in ASC 606.

We identified the evaluation of contract terms in  certain contracts with customers as a critical audit matter, due to the significant judgment by management
in identifying and evaluating terms and conditions in contracts that impact revenue recognition. Auditing these elements involved especially subjective and
complex auditor judgments due to the nature and extent of audit effort required.

The primary procedures we performed to address this critical audit matter included:

● Examination of management’s identification and evaluation of the terms and conditions in certain contracts, including management’s

determination of the impact of those terms and conditions on revenue recognition.

● Testing the completeness and accuracy of management’s application of the terms and conditions in certain contracts to how revenue was

recognized, by examining revenue arrangements on a test basis.

/s/ BDO USA, P.C.

We have served as the Company's auditor since 2023.

Minneapolis, Minnesota
March 28, 2024

F-2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report Of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Predictive Oncology Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet and the related consolidated statements of net loss, stockholders' equity, and cash flows of
Predictive  Oncology,  Inc.  (the  "Company")  for  the  year  ended  December  31,  2022,  and  the  related  notes  (collectively  referred  to  as  the  "consolidated
financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company the
year  ended  December  31,  2022,  and  the  results  of  their  operations  and  their  cash  flows  for  the  year  ended  December  31,  2022  in  conformity  with
accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance  about  whether  the  consolidated  financial  statements  are  free  of  material  misstatement,  whether  due  to  error  or  fraud.  The  Company  is  not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.

Our  audit  included  performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  consolidated  financial  statements,  whether  due  to  error  or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provided a reasonable basis
for our opinion.

/s/ Baker Tilly US, LLP

We served as the Company's auditor from 2020 to 2023.

Minneapolis, Minnesota
March 21, 2023

F-3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSOLIDATED FINANCIAL STATEMENTS

PREDICTIVE ONCOLOGY INC.
CONSOLIDATED BALANCE SHEETS

ASSETS

December 31,
2023

December 31,
2022

Current assets:
Cash
Accounts receivable
Inventories
Prepaid expense and other assets
Total current assets

Property and equipment, net
Intangibles, net
Lease right-of-use assets
Other long-term assets
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable
Note payable
Accrued expenses and other liabilities
Derivative liability
Contract liabilities
Lease liability
Total current liabilities

Other long-term liabilities
Lease liability – net of current portion
Total liabilities
Commitments and contingencies

  $

  $

  $

8,728,660    $
333,697     
494,374     
521,700     
10,078,431     

1,233,910     
252,457     
2,728,355     
124,096     
14,417,249    $

1,342,027    $
150,408     
1,631,702     
1,376     
308,091     
517,427     
3,951,031     

5,459     
2,188,979     
6,145,469     

22,071,523 
331,196 
430,493 
526,801 
23,360,013 

1,833,255 
253,865 
211,893 
75,618 
25,734,644 

943,452 
- 
2,229,075 
13,833 
602,073 
94,237 
3,882,670 

- 
86,082 
3,968,752 

Stockholders’ equity:
Preferred stock, 20,000,000 shares authorized inclusive of designated below
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding
as of December 31, 2023, and December 31, 2022
Common stock, $.01 par value, 200,000,000 shares authorized, 4,062,853 and 3,938,160 shares outstanding
as of December 31, 2023, and December 31, 2022, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity

792     

792 

40,629     
175,992,242     
(167,761,883)    
8,271,780     

39,382 
175,503,634 
(153,777,916)
21,765,892 

Total liabilities and stockholders’ equity

  $

14,417,249    $

25,734,644 

See accompanying notes to consolidated financial statements.

F-4

 
 
 
 
 
 
 
 
   
 
   
 
     
 
 
     
       
 
   
   
   
   
 
     
       
 
   
   
   
   
 
     
       
 
   
 
     
 
 
     
       
 
   
   
   
   
   
   
 
     
       
 
   
   
   
   
     
 
 
     
       
 
     
       
 
     
       
 
   
   
   
   
   
 
     
       
 
 
 
PREDICTIVE ONCOLOGY INC.
CONSOLIDATED STATEMENTS OF NET LOSS

Revenue
Cost of sales
Gross profit

Operating expenses:

General and administrative expense
Operations expense
Sales and marketing expense
Loss on impairment of goodwill
Loss on impairment of finite-lived intangible assets
Loss on impairment of property and equipment

Total operating expenses
Total operating loss
Other income
Other expense
Gain on derivative instruments
Net loss

Net loss per common share – basic and diluted

Weighted average shares used in computation – basic and diluted

  $

Year Ended December 31, 
2022
2023

1,780,093    $
634,796     
1,145,297     

1,505,459 
505,107 
1,000,352 

9,428,496     
4,127,268     
1,510,861     
-     
-     
162,905     
15,229,530     
(14,084,233)    
152,776     
(64,967)    
12,457     
(13,983,967)   $

11,110,735 
3,798,425 
1,358,907 
7,231,093 
3,349,375 
185,469 
27,034,004 
(26,033,652)
185,646 
(5,275)
115,647 
(25,737,634)

(3.48)   $

(6.98)

4,014,848     

3,685,954 

  $

  $

See accompanying notes to consolidated financial statements.

F-5

 
 
 
 
 
 
 
 
 
   
 
   
   
 
     
       
 
     
       
 
   
   
   
   
   
   
   
   
   
   
   
 
     
       
 
 
     
       
 
   
 
 
PREDICTIVE ONCOLOGY INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED
DECEMBER 31, 2023

Series B Preferred

Series F Preferred

Common Stock

Shares

    Amount    

Shares

    Amount    

Shares

    Amount

Additional
Paid-In
Capital

    Accumulated    

Deficit

Total

79,246    $

792     

-    $

-      3,938,160    $

39,382    $ 175,503,634    $ (153,777,916)   $ 21,765,892 

-     

-     

-     

-     

98,193     

982     

488,344     

-     

489,326 

-     

-     

-     

-     

-     

-     

2,038     

-     

2,038 

-     

-     

79,404     

794     

-     

-     

(794)    

-     

-     

-     

-     

-     

25,343     

253     

(253)    

-     

-     

(79,404)    

(794)    

-     

-     

794     

-     

-     

- 

- 

- 

-     
-     

-     
-     

79,246    $

792     

-     
-     

-    $

-     
-     

1,157     
-     

12     
-     

(1,521)    
-     

(1,509)
(13,983,967)     (13,983,967)

-     

-      4,062,853    $

40,629    $ 175,992,242    $ (167,761,883)   $ 8,271,780 

See accompanying notes to consolidated financial statements.

F-6

Balance at
12/31/2022
Shares issued
to non-
employees
Vesting
expense, net
of forfeitures    
Series F
Preferred
Stock
dividend
Reverse stock
split round up
to whole
shares
Series F
Preferred
redemption
Share
issuance to
CFO for
vesting of
RSUs, net of
repurchase to
cover
withholding
tax
Net loss
Balance at
12/31/2023

 
 
 
 
 
 
   
   
   
 
 
 
 
   
   
   
 
   
   
   
   
   
   
   
   
 
 
PREDICTIVE ONCOLOGY INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED
DECEMBER 31, 2022

Series B Preferred

Common Stock

Shares

    Amount

Shares
792      3,280,750    $

    Amount

Additional
Paid-In
Capital

    Accumulated    

Deficit

Total

32,808    $ 168,272,366    $ (128,040,282)   $ 40,265,684 

Balance at 12/31/2021
Issuance of shares and warrants pursuant
to May 2022 private placement, net
Shares issued pursuant to Equity Line
Share issuance to consultant and other
Vesting expense and option repricing
Net loss
Balance at 12/31/2022

79,246    $

-     
-     
-     
-     
-     
79,246    $

-     
-     
-     
-     
-     

600,000     
15,750     
29,838     
11,822     
-     
792      3,938,160    $

6,000     
158     
297     
119     
-     

6,507,050 
236,009 
356,124 
138,659 
(25,737,634)     (25,737,634)
39,382    $ 175,503,634    $ (153,777,916)   $ 21,765,892 

6,501,050     
235,851     
355,827     
138,540     
-     

-     
-     
-     
-     

See accompanying notes to consolidated financial statements.

F-7

 
 
 
 
 
   
   
 
 
 
 
   
   
   
   
 
   
   
   
   
   
   
   
 
 
PREDICTIVE ONCOLOGY INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Vesting expense
Common stock issued to non-employees
Gain on valuation of equity-linked instruments and derivative liability
Loss on impairment of goodwill
Loss on impairment of finite-lived intangible assets
Loss on impairment of property and equipment
Loss on property and equipment disposal

Changes in assets and liabilities:

Accounts receivable
Inventories
Prepaid expense and other assets
Accounts payable
Accrued expenses and other liabilities
Contract liabilities
Other long-term liabilities

Net cash used in operating activities:

Cash flows from investing activities:
Purchase of property and equipment
Acquisition of intangibles
Net cash used in investing activities:

Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net
Proceeds from issuance of common stock pursuant to equity line
Repurchase of common stock upon vesting of restricted stock units
Proceeds from note payable
Repayment of note payable
Net cash provided by financing activities

Net decrease in cash 
Cash at beginning of period
Cash at end of period
Supplemental disclosure for cash flow information:
Cash payments for interest
Non-cash transactions:
Adjustment to goodwill for acquisition of zPREDICTA contract liabilities
Right-of-use assets obtained in exchange for lease liabilities
Series F Preferred Stock dividend
Common stock issued to settle accrued board of directors’ and advisory board compensation
Redemption of Series F Preferred Stock
Common stock issued in connection with reverse stock split
Common stock issued to management upon vesting of restricted stock units

  $

  $

  $

See accompanying notes to unaudited consolidated financial statements.

F-8

Year Ended December 31,
2022
2023

  $

(13,983,967)   $

(25,737,634)

739,316     
2,038     
299,430     
(12,457)    
-     
-     
162,905     
903     

(2,501)    
(63,881)    
(43,377)    
398,575     
(397,851)    
(293,982)    
5,459     
(13,189,390)    

(276,352)    
(26,019)    
(302,371)    

-     
-     
(1,510)    
364,721     
(214,313)    
148,898     

(13,342,863)    
22,071,523     
8,728,660    $

1,313,075 
166,312 
356,125 
(115,647)
7,231,093 
3,349,375 
185,469 
14,346 

23,000 
(42,808)
78,425 
(78,322)
869,987 
41,819 
(25,415)
(12,370,800)

(419,869)
(55,828)
(475,697)

6,507,050 
236,009 
(27,654)
- 
- 
6,715,405 

(6,131,092)
28,202,615 
22,071,523 

13,904    $

3,821 

-    $
2,997,181     
794     
189,896     
(794)    
253     
4,934     

373,303 
- 
- 
- 
- 
- 
- 

 
 
 
 
 
 
 
 
 
   
 
     
       
 
     
       
 
   
   
   
   
   
   
   
   
 
     
       
 
     
       
 
   
   
   
   
   
   
   
   
 
     
       
 
     
       
 
   
   
   
 
     
       
 
     
       
 
   
   
   
   
   
   
 
     
       
 
   
   
     
       
 
     
       
 
   
   
   
   
   
   
 
 
PREDICTIVE ONCOLOGY INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

Predictive  Oncology  Inc.  (“Predictive  Oncology”)  is  a  knowledge  and  science-driven  company  that  applies  artificial  intelligence  (“AI”)  to  support  the
discovery  and  development  of  optimal  cancer  therapies,  which  can  ultimately  lead  to  more  effective  treatments  and  improved  patient  outcomes.  The
Company uses AI and a proprietary biobank of 150,000+ tumor samples, categorized by patient type, to provide actionable insights about drug compounds
to improve the drug discovery process and increase the probability of drug compound success. The Company offers a suite of solutions for oncology drug
development from early discovery to clinical trials.

Predictive  Oncology’s  mission  is  to  change  the  landscape  of  oncology  drug  discovery  and  enable  the  development  of  more  effective  therapies  for  the
treatment of cancer. By harnessing the power of machine learning and scientific rigor, the Company believes that it can improve the probability of success
of advancing pharmaceutical and biological drug candidates with a higher degree of confidence.

The Company operates in three business areas. In its first area, the Company provides optimized, high-confidence drug-response predictions through the
application  of  AI  using  its  proprietary  biobank  of  tumor  samples  to  enable  a  more  informed  selection  of  drug/tumor  combinations  and  increase  the
probability  of  success  during  drug  development.  The  Company  also  creates  and  develops  tumor-specific  3D  cell  culture  models  mimicking  the
physiological  environment  of  human  tissue  enabling  better-informed  decision-making  during  development.  In  its  second  business  area,  the  Company
provides  services  and  research  using  a  proprietary  self-contained  and  automated  system  that  conducts  high-throughput,  self-interaction  chromatography
screens using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations of biologics. The
Company’s  third  business  area  produces  the  United  States  Food  and  Drug  Administration  (“FDA”)-cleared  STREAMWAY®  System  and  associated
products  for  automated  medical  fluid  waste  management  and  patient-to-drain  medical  fluid  disposal.  As  of  January  1,  2023,  the  Company  changed  its
reportable segments to align with these business areas.

The Company has three reportable segments, which have been delineated by location and business area, as further described in Note 14 – Segments:

● Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also

creates proprietary 3D culture models used in drug development.

● Birmingham segment: provides contract services and research focused on solubility improvements, stability studies, and protein production.

● Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and

patient-to-drain medical fluid disposal.

Going Concern

The Company has incurred significant and recurring losses from operations for the past several years and, as of December 31, 2023, had an accumulated
deficit  of  $167,761,883.  The  Company  had  cash  and  cash  equivalents  of  $8,728,660  as  of  December  31,  2023  and  needs  to  raise  significant  additional
capital to meet its operating needs. The Company’s short-term obligations as of December 31, 2023 were $3,951,031, consisting primarily of aggregate
accounts payable and accrued expenses of $2,973,729 and operating lease obligations of $517,427. As of December 31, 2023, the Company also had a
short-term note payable of $150,408 that bears interest at an annual percentage rate of 9.25% and long-term operating lease obligations of $2,188,979 with
a weighted average remaining lease term of 3.99 years. The Company does not expect to generate sufficient operating revenue to sustain its operations in
the  near  term.  During  the  year  ended  December  31,  2023,  the  Company  incurred  negative  cash  flows  from  operations  of  $13,189,390.  Although  the
Company has attempted to improve its operating margin by bolstering revenues and curtailing expenses and continues to seek ways to generate revenue
through  business  development  activities,  there  is  no  guarantee  that  the  Company  will  be  able  to  improve  its  operating  margin  sufficiently  or  achieve
profitability in the near term. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the
date the financial statements are issued. The Company is evaluating alternatives to obtain the required additional funding to maintain future operations.
These alternatives may include, but are not limited to, equity financing, issuing debt, entering into other financing arrangements, or monetizing operating
businesses or assets. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing stockholders
or that result in the Company’s existing stockholders losing part or all of their investment. Despite these potential sources of funding, the Company may be
unable  to  access  financing  or  obtain  additional  liquidity  when  needed  or  under  acceptable  terms,  if  at  all.  If  such  financing  or  adequate  funds  from
operations are not available, the Company would be forced to limit our business activities and the Company could default on existing payment obligations,
which would have a material adverse effect on its financial condition and results of operations, and may ultimately be required to cease its operations and
liquidate its business. The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern and
do  not  include  any  adjustment  relating  to  the  recoverability  and  classification  of  recorded  asset  amounts  and  classification  of  liabilities  that  might  be
necessary should the Company be unable to continue in existence.

F-9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reverse Stock Split

On April 19, 2023, the Company completed a one-for-twenty reverse stock split that was effective for trading purposes on April 24, 2023. All numbers of
shares and per-share amounts in this report have been adjusted to reflect the reverse stock split (“Reverse Split”).

Accounting Policies and Estimates

The  preparation  of  financial  statements  in  conformity  with  accounting  principles  generally  accepted  in  the  United  States  of  America  (“U.S.  GAAP”)
requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of
contingent  assets  and  liabilities  at  the  date  of  the  financial  statements  and  during  the  reporting  period.  Actual  results  could  materially  differ  from  those
estimates.

Principles of Consolidation

The Company has two wholly owned subsidiaries, Helomics Corporation and Skyline Medical, Inc., as of and for the year ended December 31, 2023. The
Company had multiple wholly owned subsidiaries for the year ended December 31, 2022. The consolidated financial statements include the accounts of the
Company and these wholly owned subsidiaries after elimination of intercompany transactions and balances as of and for the years ended December 31,
2023, and 2022.

Reclassifications

Certain  reclassifications  have  been  made  to  the  prior  year’s  consolidated  financial  statements  to  conform  to  the  current  year  presentation.  The
reclassifications had no effect on previously reported results of operations, cash flows or stockholders’ equity.

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board
(the “FASB”). Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact
on the consolidated financial statements of the Company.

In  November  2023,  the  FASB  issued  ASU  2023-07,  “Segment  Reporting  (Topic  280):  Improvements  to  Reportable  Segment  Disclosures.”  This  ASU
updates reportable segment disclosures by expanding the frequency and extent of segment disclosures. This ASU will become effective for the Company’s
fiscal year beginning January 1, 2024, and for the Company’s interim periods beginning in the Company’s fiscal year 2025. Early adoption is permitted and
requires the retrospective adoption method. Management is currently evaluating this ASU to determine its impact on the Company’s disclosures.

F-10

 
 
 
 
 
 
 
 
 
 
 
 
 
In  December  2023,  the  FASB  issued  ASU  2023-09,  “Income  Taxes  (Topic  740):  Improvements  to  Income  Tax  Disclosures.”  This  ASU  requires  more
detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as
expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply
them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently
evaluating this ASU to determine its impact on the Company’s disclosures.

Recently Adopted Accounting Standards

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses.” This ASU added a new impairment model (known as the current
expected  credit  loss  (“CECL”)  model)  that  is  based  on  expected  losses  rather  than  incurred  losses.  Under  the  new  guidance,  an  entity  recognizes  as  an
allowance its estimate of expected credit losses. The CECL model applies to most debt instruments, trade receivables, lease receivables, financial guarantee
contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to
measure expected credit losses on assets that have a low risk of loss. The Company adopted the provisions of ASU 2016-13 on January 1, 2023, using the
modified-retrospective approach, and its adoption did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options and Derivatives and Hedging – Contracts in Entity’s
Own Equity” (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It
also  amends  the  accounting  for  certain  contracts  in  an  entity’s  own  equity  that  are  currently  accounted  for  as  derivatives  because  of  specific  settlement
provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the
diluted EPS computation. As a smaller reporting company pursuant to Rule 12b-2 of the Securities Exchange Act of 1934, as amended, ASU 2020-06 is
effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. Early adoption is permitted, including
interim  periods  within  those  fiscal  years.  Entities  should  adopt  the  guidance  as  of  the  beginning  of  its  annual  fiscal  year  and  are  allowed  to  adopt  the
guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company early adopted ASU 2020-
06 on January 1, 2023, and its adoption did not have a material impact on the Company’s financial statements.

In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs” (“ASU 2022-04”). ASU 2022-04 was issued to enhance the
transparency of supplier finance programs used by an entity in connection with the purchase of goods and services. The standard requires entities that use
supplier finance programs to disclose the key terms, including a description of payment terms, the confirmed amount outstanding under the program at the
end of each reporting period, a description of where those obligations are presented on the balance sheet, and an annual rollforward, including the amount
of  obligations  confirmed  and  the  amount  paid  during  the  period.  The  guidance  does  not  affect  the  recognition,  measurement,  or  financial  statement
presentation of obligations covered by supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years, except for the required rollforward information, which is effective for fiscal years beginning after December 15,
2023. The Company adopted ASU 2022-04 on January 1, 2023, using the retrospective approach, and its adoption did not have a material impact on the
Company’s financial statements.

Cash 

The Company considers all highly liquid instruments with maturities when purchased of three months or less to be cash equivalents. The Company places
its cash with high quality financial institutions and believes its risk of loss is limited to amounts in excess of that which is insured by the Federal Deposit
Insurance Corporation.

F-11

 
 
 
 
 
 
 
 
 
Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts
through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts.

Amounts recorded in accounts receivable on the consolidated balance sheets include amounts billed and currently due from customers. The amounts due
are stated at their net estimated realizable value. An allowance is maintained to provide for the estimated amount of receivables that will not be collected.
The  Company  determines  the  allowance  based  on  historical  experience  as  well  as  external  business  factors  expected  to  impact  collectability  such  as
economic  factors.  The  Company  reviews  customers’  credit  history  before  extending  unsecured  credit  and  establishes  an  allowance  based  upon  factors
surrounding the credit risk of specific customers, historical trends, and other information. Invoices are generally due 30 days after presentation. Accounts
receivable over 30 days is generally considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written
off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer. The allowance for
accounts receivable balance was $0 as of both December 31, 2023, and 2022. 

Fair Value Measurements

As outlined in ASC 820, Fair Value Measurement, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction  between  market  participants  at  the  measurement  date.  The  accounting  standards  ASC  820  establishes  a  three-level  fair  value  hierarchy  that
prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data in making fair value measurements, when available. Fair value measurements are classified according to the
lowest level input that is significant to the valuation.

The fair values of the Company’s derivative liabilities were determined based on Level 3 inputs. The Company generally uses the Black Scholes method
for determining the fair value of warrants classified as liabilities on a recurring basis. In addition, the Company uses the Monte Carlo method and other
acceptable valuation methodologies when valuing the conversion feature and other embedded features classified as derivatives on a recurring basis. See
Note 2 – Fair Value Measurements and Note 8 – Derivatives.

When comparing the carrying amount of an asset group to its fair value as part of a long-lived asset impairment analysis, the Company estimates the fair
value of the asset group by making assumptions about the long-lived assets comprising the asset group. The majority of the inputs used by the Company to
estimate the fair value of the long-lived assets are unobservable and thus are considered to be Level 3 inputs. See Note 4 – Property and Equipment and
Note 5 – Intangible Assets.

When performing quantitative testing related to goodwill impairment analysis, the Company estimates the fair values of its reporting units using discounted
cash  flows.  To  determine  fair  values,  the  Company  is  required  to  make  assumptions  about  a  wide  variety  of  internal  and  external  factors.  Significant
assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including
the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. The
majority  of  the  inputs  used  in  the  discounted  cash  flow  model  are  unobservable  and  thus  are  considered  to  be  Level  3  inputs.  See  Note  5  – Intangible
Assets.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis.  

F-12

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property and Equipment

Property  and  equipment  are  stated  at  cost  less  accumulated  depreciation.  Depreciation  of  property  and  equipment  is  computed  using  the  straight-line
method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: 

Computers, software, and office equipment
Leasehold improvements (1)
Manufacturing tooling
Laboratory equipment
Demo equipment

3
1
3
4

Years
-
-
-
-
3

10
2
7
10

(1) Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Upon retirement or sale of property and equipment, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the
resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Finite-lived Intangible Assets

Finite-lived  intangible  assets  consist  of  patents  and  trademarks,  licensing  fees,  developed  technology,  acquired  software,  customer  relationships,  and
tradenames, and are amortized over their estimated useful life. Accumulated amortization is included in Intangibles, net in the accompanying consolidated
balance sheets.

Long-lived Assets

The  Company  reviews  long-lived  assets  for  impairment  in  accordance  with  ASC  360,  Property,  Plant  and  Equipment,  whenever  events  or  changes  in
circumstances  indicate  the  carrying  amount  may  not  be  recoverable.  Events  or  changes  in  circumstances  that  indicate  the  carrying  amount  may  not  be
recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate
in which the Company operates.

The  recoverability  of  an  asset  to  be  held  and  used  is  determined  by  comparing  the  carrying  amount  to  the  estimated  undiscounted  future  cash  flows
expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated undiscounted future cash flows, the Company records an
impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if
any, or a value determined utilizing discounted cash flow techniques.

Goodwill

In  accordance  with  ASC  350,  Intangibles – Goodwill and Other,  goodwill  is  calculated  as  the  difference  between  the  acquisition  date  fair  value  of  the
consideration transferred and the fair value of net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets
acquired in a business combination. Goodwill is not amortized but is tested on an annual basis for impairment at the reporting unit level as of December 31,
or whenever events or changes in circumstances indicate that the carrying amount may not be fully recoverable.

To determine whether goodwill is impaired, the Company performs a multi-step impairment test, either on an annual basis, or more frequently if needed.
The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its
estimated  fair  value.  The  Company  may  also  elect  to  skip  the  qualitative  testing  and  proceed  directly  to  the  quantitative  testing.  When  performing
quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is
required  to  make  assumptions  about  a  wide  variety  of  internal  and  external  factors.  Significant  assumptions  used  in  the  impairment  analysis  include
financial  projections  of  free  cash  flow  (including  significant  assumptions  about  operations  including  the  rate  of  future  revenue  growth,  capital
requirements,  and  income  taxes),  long-term  growth  rates  for  determining  terminal  value  and  discount  rates.  Comparative  market  multiples  are  used  to
corroborate  the  results  of  the  discounted  cash  flow  test.  These  assumptions  require  significant  judgement.  Pursuant  to  ASC  350,  the  single  step  is  to
determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the
carrying amount of goodwill exceeds the fair value, the difference is the amount of the goodwill impairment. The Company also completes a reconciliation
between the implied equity valuation prepared and the Company’s market capitalization. The majority of the inputs used in the discounted cash flow model
are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. See Note
5 – Intangible Assets.

F-13

 
 
 
 
 
 
 
   
     
     
 
   
     
     
 
   
     
     
 
   
     
     
 
   
 
     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leases

At  inception  of  a  contract  a  determination  is  made  whether  an  arrangement  meets  the  definition  of  a  lease.  A  contract  contains  a  lease  if  there  is  an
identified asset and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current
and noncurrent operating lease liabilities on our consolidated balance sheets.

ROU  assets  represent  our  right  to  use  an  underlying  asset  for  the  duration  of  the  lease  term  and  lease  liabilities  represent  our  obligation  to  make  lease
payments  arising  from  the  lease.  Recognition  on  the  commencement  date  is  based  on  the  present  value  of  lease  payments  over  the  lease  term  using  an
incremental borrowing rate. Leases with a term of 12 months or less at the commencement date are not recognized on the consolidated balance sheet and
are expensed as incurred. 

The  Company  has  lease  agreements  with  lease  and  non-lease  components,  which  are  accounted  for  as  a  single  lease  component  for  all  asset  classes.
Variable lease payments generally represent the Company’s share of the landlord’s expenses and are recorded when incurred. Leases are accounted for at a
portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.

Collaboration Arrangements

The  Company  enters  into  collaboration  arrangements  with  oncology  drug  development  partners,  under  which  the  Company  utilizes  its  active  learning
technology, proprietary biobank, and know-how to provide predictive models of tumor responses to various drug compounds and treatments of partners.
Consideration  under  these  contracts  may  include  an  upfront  payment,  development  and  regulatory  milestones  and  other  contingent  payments,  expense
reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments.

The  Company  analyzes  its  collaboration  arrangements  to  assess  whether  they  are  within  the  scope  of  ASC  808,  Collaborative  Arrangements,  which
includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and
exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of
ASC  808,  the  Company  assesses  whether  the  payments  between  the  Company  and  its  collaboration  partner  fall  within  the  scope  of  other  accounting
literature.  If  the  Company  concludes  that  payments  from  the  collaboration  partner  to  the  Company  would  represent  consideration  from  a  customer,  the
Company  accounts  for  those  payments  within  the  scope  of  Accounting  Standards  Codification  (“ASC”)  606,  Revenue  from  Contracts  with  Customers.
However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents
such  payments  as  a  reduction  of  research  and  development  expense  or  general  and  administrative  expense,  based  on  where  the  Company  presents  the
underlying expense.

F-14

 
 
 
 
 
 
 
 
 
Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in
an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company recognizes revenue
in accordance with the five-step process outlined in ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects
the  taxes  from  the  customers  and  remits  the  entire  amount  to  the  governmental  authorities.  Sales  taxes  are  excluded  from  revenue  and  expenses.
Advertising costs incurred in the Company’s efforts to obtain new customers are expensed as incurred.

Revenues from Services

The Company generates revenues from Contract Research Organization (“CRO”) services related to the development of 3D tumor-specific in vitro models
for  oncology  drug  discovery  and  research.  The  organ-specific  disease  models  provide  3D  reconstruction  of  human  tissues  accurately  representing  each
disease state and mimicking drug response. Revenue from development of 3D models is reported under the Pittsburgh reportable segment.

The Company also generates revenues from CRO services related to development of protein formulations and performance of protein stability analyses.
Using  the  Company’s  proprietary  High  Throughput  Self-Interaction  Chromatography  (“HSC”)  platform,  the  Company  conducts  screens  on  excipients
previously  approved  by  the  FDA  to  develop  protein  formulations  with  increased  solubility  and  physical  stability.  The  Company  also  provides
comprehensive protein stability analyses via time-dependent shelf-life studies and forced degradation studies designed to quickly determine which of the
additives  previously  approved  by  the  FDA  will  improve  the  solubility  and  stability  of  proteins  in  solutions.  Revenues  from  development  of  protein
formulations and performance of protein stability analyses are reported under the Birmingham reportable segment.

The specific pattern of revenue recognition for CRO services is determined on a case-by-case basis according to the facts and circumstances applicable to a
given contract. The Company may execute a master service agreement with a customer that provides terms and conditions for the relationship between the
Company and the customer. Detailed Statements of Work (SOWs) are then prepared to outline the specific services to be provided. The SOW and master
service  agreement,  if  applicable,  form  the  contract  with  the  customer  under  ASC  606.  The  Company  evaluates  each  product  or  service  promised  in  a
contract to determine whether it represents a distinct performance obligation. Determining whether services are considered distinct performance obligations
that should be accounted for separately versus together may require significant judgment. Contracts for CRO services generally contain one performance
obligation  to  perform  research  and  deliver  appropriate  data  or  reporting.  The  Company  typically  requires  partial  payment  for  CRO  services  prior  to
performance  of  the  research  service  with  the  remainder  of  the  transaction  price  due  30  days  after  delivery  of  data  or  reporting.  Revenues  from  CRO
services are generally recognized at the point in time when data and reports are provided to customers.

The Company also generates revenues from services provided under maintenance plans related to the Company’s STREAMWAY System. Customers may
purchase maintenance plans, which require the Company to service the customer’s STREAMWAY System for a period of one year. Payment due under the
maintenance plan is typically due at the start of the service period. The maintenance plan is considered a separate performance obligation from the sale of
the  STREAMWAY  System,  is  charged  separately  from  the  product  sale,  and  is  recognized  over  time  (ratably  over  the  one-year  period)  as  maintenance
services are provided. A time-elapsed output method is used to measure progress toward complete satisfaction of the performance obligation because the
Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the
transfer  of  services  to  its  customers.  Revenues  from  maintenance  plans  related  to  the  Company’s  STREAMWAY  System  are  reported  under  the  Eagan
reportable segment.

F-15

 
 
 
 
 
 
 
 
 
Revenues from Product Sales

The Company generates revenues from the sale of medical device products consisting primarily of sales of the STREAMWAY System (i.e., hardware), as
well  as  sales  of  the  proprietary  cleaning  fluid  and  filters  for  use  with  the  STREAMWAY  System  (i.e.,  disposables).  Currently,  the  Company  sells  its
medical device products directly to hospitals and other medical facilities using employed sales representatives. Purchase orders, which are governed by
sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-
alone selling price for the arrangements. The sales agreement is a dually executed agreement providing explicit terms and conditions supporting the sale of
the STREAMWAY System and related products and services. The Company considers the combination of a purchase order and sales agreement providing
its terms and conditions to form the contract with the customer in all cases.

Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time following the transfer of control
of  such  products  to  the  customer.  Transfer  of  control  may  occur  when  products  are  shipped  from  the  Company’s  facilities  (“FOB  origin”,  which  is  the
Company’s standard shipping terms) or upon delivery at the customer’s facilities (“FOB Destination”), dependent on the shipping terms specified in the
contract with the customer. Transfer of control may also occur prior to shipment under bill and hold arrangements. In such arrangements, the Company
recognizes  revenue  when  the  bill-and-hold  arrangement  has  a  substantive  reason,  the  product  is  identified  separately  as  belonging  to  the  customer,  the
product is ready for physical transfer to the customer, and the Company does not have the ability to use the product or direct it to another customer. The
Company’s standard payment terms for its customers purchasing medical devices are generally 30 to 60 days after the Company transfers control of the
product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from
the Company. All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned
for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods
sold. Revenues from the sale of medical device products are reported under the Eagan reportable segment.

Royalty Revenue and Variable Consideration

The  Company  has  a  collaboration  arrangement  that  includes  sales-based  royalties,  under  which  our  collaboration  partner  is  obligated  to  pay  revenue
sharing fees that are based on the net sales of the collaboration partner’s commercialized drugs. The Company would recognize royalty revenue when the
underlying sales occur based on its best estimate of sales of the drugs. To date, the Company has not recognized revenues related to revenue sharing fees
pursuant to its collaboration arrangement. See Note 11 – Collaboration Agreement.

Warranty

The Company generally provides one-year warranties against defects in materials and workmanship on product sales and will either repair the products or
provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate
performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a
claim for warranty or a product defect.

Contract Balances

The  Company  records  a  receivable  when  it  has  an  unconditional  right  to  receive  consideration  after  the  performance  obligations  are  satisfied.  As  of
December  31,  2023,  and  2022,  accounts  receivable  totaled  $333,697  and  $331,196,  respectively.  As  of  December  31,  2021,  accounts  receivable  totaled
$354,196.

Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have
been  met.  The  Company’s  contract  liabilities  related  primarily  to  3D  services  and  maintenance  plans  were  $313,550  and  $602,073  as  of  December  31,
2023, and 2022, respectively. The Company’s long-term contract liabilities are reported in Other long-term liabilities in the consolidated balance sheets.
The Company's contract liabilities as of December 31, 2023 primarily represent its remaining performance obligations. The Company recognized revenue
of $277,767 primarily related to 3D services earned during the year ended December 31, 2023, that was included in contract liabilities as of December 31,
2022. As of December 31, 2021, contract liabilities totaled $186,951.

F-16

 
 
 
 
 
 
 
 
 
 
 
 
Practical Expedients

The Company has elected not to determine whether contracts with customers contain significant financing components as contracts are generally for less
than one year. The Company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
The Company recognizes shipping and handling costs at point of sale.

Stock-Based Compensation

The  Company  accounts  for  stock-based  compensation  expense  in  accordance  with  ASC  718,  Compensation—Stock Compensation,  which  requires  the
Company to measure and recognize compensation expense in the financial statements based on the fair value at the date of grant for stock-based awards.
The Company recognizes compensation expense for service-based equity-classified awards over their requisite service period and adjusts for forfeitures as
they occur.

ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company
uses  the  Black-Scholes  option-pricing  model  which  requires  the  input  of  significant  assumptions  including  an  estimate  of  the  average  period  of  time
employees and directors will retain vested stock options before exercising them, the estimated volatility of the Company’s common stock price over the
expected term, and the risk-free interest rate.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of
the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult
to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and
warrants  granted  to  non-employees,  which  requires  the  input  of  significant  assumptions  including  an  estimate  of  the  average  period  that  investors  or
consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company’s common stock price over the
expected term, and the risk-free interest rate. In the case of options granted to employees, the Company estimates the life to be the legal term.

The  Company  also  has  certain  awards  which  vest  upon  a  combination  of  the  satisfaction  of  service-based  and  performance-based  conditions.  The
performance-based conditions generally are satisfied upon achieving specified performance targets, such as financial or operating metrics, and/or market
performance of the Company’s common stock. For performance-based awards, the Company generally recognizes expense over the requisite service period
unless there is a compelling reason to make it shorter and when performance-based conditions are considered probable to be satisfied. For market-based
awards, the Company determines the grant-date fair value utilizing a Monte Carlo valuation model, which incorporates various assumptions including stock
price volatility, expected term and risk-free interest rates.

Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognizes
that. The Company’s common stock has been traded on the NASDAQ Capital Market exchange since 2015 and the Company has experienced significant
volatility  in  its  stock  price.  The  assumptions  used  in  calculating  the  fair  value  of  stock-based  payment  awards  represent  the  Company’s  best  estimates,
which  involve  inherent  uncertainties  and  the  application  of  management's  judgment.  As  a  result,  if  factors  change  and  the  Company  uses  different
assumptions, its stock-based compensation expense could be materially different in the future.

On January 1, 2023, the Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) that will apply if reclassification of contracts from
equity to liabilities is necessary. If the Company is unable to demonstrate it has sufficient authorized shares, shares will be allocated based on the earliest
issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC
815, stock-based awards issued to the Company’s employees are not subject to the sequencing policy.

F-17

 
 
 
 
 
 
 
 
 
 
 
Research and Development

Research  and  development  costs  are  charged  to  operations  as  incurred.  Research  and  development  costs,  included  within  operations  expense  in  the
accompanying consolidated statements of net loss were $188,305 and $320,320 for the years ended December 31, 2023, and 2022, respectively.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are
determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when
necessary to reduce deferred tax assets to the amounts expected to be realized.

The  Company  reviews  income  tax  positions  expected  to  be  taken  in  income  tax  returns  to  determine  if  there  are  any  income  tax  uncertainties.  The
Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by
taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Under  Internal  Revenue  Code  Section  382,  certain  stock  transactions  that  significantly  change  ownership  could  limit  the  amount  of  net  operating
carryforwards  that  may  be  utilized  on  an  annual  basis  to  offset  taxable  income  in  future  periods.  Consequently,  the  Company  performed  a  Section  382
analysis at December 31, 2023, which resulted in the limitation and expiration of a substantial portion of the Company’s loss carryforwards. In addition, the
current net operating loss (“NOL”) carryforwards might be further limited by future issuances of our common stock. See Note 10 – Income Taxes.

Tax years after 2003 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with
financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. As of December 31, 2023, the Company
had $142,118 of credit risk for cash amounts held in a single institution that are in excess of amounts insured by the Federal Deposit Insurance Corporation.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not limited to, development
by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance
with regulations of the Food and Drug Administration, Clinical Laboratory Improvement Amendments, and other governmental agencies.

The Company is also subject to general economic and geopolitical uncertainties caused by inflation, rising interest rates, supply chain disruptions, tight
labor  markets,  wage  inflation,  pricing  volatility  for  certain  goods  and  services,  banking  and  financial  sector  disruptions,  instability  and  volatility  in  the
global  markets,  disruptions  from  a  global  pandemic,  and  geopolitical  conflict.  The  impacts  of  economic  and  other  global  events  could  have  a  material
adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks related to the Company.

The  Company  has  evaluated  all  its  activities  and  concluded  that  no  other  subsequent  events  have  occurred  that  would  require  recognition  in  the
consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as described above and in Note 15 – Subsequent
Events.

F-18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE 2 – FAIR VALUE MEASUREMENTS

The following table summarizes the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis:

December 31, 2023
Liabilities:

Derivatives

December 31, 2022
Liabilities:

Derivatives

NOTE 3 – INVENTORIES

Inventory balances consist of the following:

Raw materials
Work-in-process
Finished goods
Total

NOTE 4 – PROPERTY AND EQUIPMENT

The Company’s property and equipment consist of the following:

Computers, software, and office equipment
Leasehold improvements
Laboratory equipment
Manufacturing tooling
Demo equipment
Total
Less: Accumulated depreciation
Total Property and Equipment, Net

Fair Value

Level 1

Level 2

Level 3

  $

1,376    $

-    $

-    $

1,376 

Fair Value

Level 1

Level 2

Level 3

  $

13,833    $

-    $

-    $

13,833 

As of
December 31,
2023

As of
December 31,
2022

239,998    $
-     
254,376     
494,374    $

133,183 
6,694 
290,616 
430,493 

As of
December 31,
2023

As of
December 31,
2022

480,882    $
506,162     
3,670,097     
133,285     
31,554     
4,821,980     
(3,588,070)    
1,233,910    $

463,292 
535,527 
3,559,362 
121,120 
31,554 
4,710,855 
(2,877,600)
1,833,255 

  $

  $

  $

  $

In  the  second  quarter  of  2023,  the  Company  identified  a  change  in  future  projected  cash  flows  related  to  its  Birmingham  asset  group.  The  Company
prepared an undiscounted cash flow for its Birmingham asset group as of June 30, 2023, as required under ASC 360 and determined the carrying amount of
the  asset  group  exceeded  its  estimated  undiscounted  future  cash  flows.  The  Company  determined  the  fair  value  of  the  Birmingham  asset  group  using
replacement cost and market approaches based on the in-exchange value. The Company recognized an impairment loss of $162,905 of its property and
equipment in the Birmingham operating segment during the second quarter of 2023.

In  the  fourth  quarter  of  2022,  the  Company  identified  a  change  in  its  future  projected  cash  flows  related  to  certain  of  its  asset  groups.  The  Company
prepared  an  undiscounted  cash  flow  for  the  asset  groups  as  of  December  31,  2022,  as  required  under  ASC  360  and  determined  the  carrying  amounts
exceeded the estimated undiscounted future cash flows for those asset groups. The Company determined the fair value of the asset groups and recognized
an  impairment  loss  of  $185,469  of  its  property  and  equipment  in  the  Birmingham  and  Corporate  asset  groups  during  the  fourth  quarter  of  2022.  The
Company  also  concluded  that  the  finite-lived  intangible  assets  of  its  former  zPREDICTA  asset  group,  which  is  now  reported  within  the  Pittsburgh
operating  segment,  were  fully  impaired  as  of  December  31,  2022,  and  recognized  an  impairment  loss  on  those  finite-lived  intangible  assets  during  the
fourth quarter of 2022. See Note 5 –Intangible Assets.

F-19

 
 
 
 
 
 
   
   
   
 
     
       
       
       
 
 
 
   
   
   
 
     
       
       
       
 
 
 
 
 
 
 
   
 
   
   
 
 
 
 
 
 
   
 
   
   
   
   
   
   
 
 
 
Depreciation expense was $711,890 and $898,369 in 2023 and 2022, respectively.

NOTE 5 – INTANGIBLE ASSETS

Finite-lived Intangible Assets

Finite-lived intangible assets consist of patents and trademarks, developed technology, customer relationships, and tradenames, and are amortized over their
estimated  useful  life.  Amortization  expense  was  $27,426  and  $414,706  in  2023  and  2022,  respectively.  Accumulated  amortization  is  included  in
intangibles, net in the accompanying consolidated balance sheets. The Company reviews finite-lived intangible assets for impairment in accordance with
ASC  360,  whenever  events  or  changes  in  circumstances  indicate  the  carrying  amount  may  not  be  recoverable.  Events  or  changes  in  circumstances  that
indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant
adverse change in the business climate in which the Company operates.

As of December 31, 2023, there were $252,457 in net intangibles as compared to $253,865 in net intangibles as of December 31, 2022. 

The components of intangible assets were as follows:

As of December 31, 2023

As of December 31, 2022

Patents & Trademarks
Developed Technology
Customer Relationships
Tradename
Total

  $

  $

Gross
Carrying
Costs
535,096    $
-     
-     
-     
535,096    $

Accumulated
Amortization   

(286,639)   $
-     
-     
-     
(286,639)   $

Net
Carrying
Amount

252,457    $

Gross
Carrying
Costs
509,141    $
-      3,500,000     
200,000     
-     
80,000     
-     
252,457    $ 4,289,141    $

Accumulated
Amortization    Impairment    

Net
Carrying
Amount

(255,276)   $
-    $
(386,459)     (3,113,541)    
(177,917)    
(57,917)    
(685,901)   $ (3,349,375)   $

(22,083)    
(22,083)    

253,865 
- 
- 
- 
253,865 

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2023:

Year ending December 31,
2024
2025
2026
2027
2028
Thereafter
Total

Expense

27,451 
27,451 
27,451 
27,451 
27,451 
115,202 
252,457 

  $

  $

No impairment charges related to finite-lived intangible assets were incurred during the year ended December 31, 2023.

In  the  fourth  quarter  of  2022,  the  Company  identified  a  change  in  its  future  projected  cash  flows  related  to  certain  of  its  asset  groups.  The  Company
prepared  an  undiscounted  cash  flow  for  these  asset  groups  as  of  December  31,  2022  as  required  under  ASC  360  and  determined  the  carrying  amounts
exceeded the estimated undiscounted future cash flows for those asset groups. The Company determined the fair value of the asset groups and concluded
that the finite-lived intangible assets of its former zPREDICTA asset group, which is now reported within the Pittsburgh operating segment, were fully
impaired as of December 31, 2022, and recognized an impairment loss of $3,349,375 on those finite-lived intangible assets during the fourth quarter of
2022. The Company also recognized an impairment loss on its property and equipment in the Soluble and Corporate asset groups during the fourth quarter
of 2022. See Note 4 – Property and Equipment.

F-20

 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
   
   
   
 
   
   
   
 
 
 
 
   
   
   
   
   
 
 
 
Goodwill

Goodwill of $7,231,093 was recognized in the zPREDICTA acquisition in 2021 and represented the excess of the consideration transferred over the fair
values of assets acquired and liabilities assumed. During the second quarter of 2022, the Company concluded that potential impairment indicators were
present and that an impairment assessment was warranted for goodwill. In testing goodwill for impairment as of June 30, 2022, the Company performed a
quantitative impairment test, including computing the fair value of the former zPREDICTA reporting unit and comparing that value to its carrying value.
Based upon the Company’s quantitative goodwill impairment test, the Company concluded that goodwill was fully impaired as of June 30, 2022. When
evaluating  the  fair  value  of  the  former  zPREDICTA  reporting  unit,  the  Company  used  a  discounted  cash  flow  model  and  market  comparisons.  Key
assumptions used to determine the estimated fair value included: (a) expected cash flow for the 10-year period following the testing date (including net
revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures) and (b) an estimated terminal
value using a terminal year growth rate of 4.0% determined based on the growth prospects of the reporting unit. The Company further used a probability
weighting of various forecasts to address forecast risk. The Company used an estimated discount rate of 65% based on management’s best estimate and
considering the Company’s current market capitalization. The majority of the inputs used in the discounted cash flow model were unobservable and thus
are considered to be Level 3 inputs. The inputs for the market capitalization calculation were considered Level 1 inputs. zPREDICTA Inc. was merged with
Predictive Oncology Inc. at the end of 2022 and is now reported as part of the Pittsburgh operating segment.

The following tables present changes in the carrying value of goodwill on our consolidated balance sheet:

Goodwill balance at December 31, 2021
Adjustment to fair value
Impairment
Goodwill balance at December 31, 2022

NOTE 6 – LEASES

  $

  $

6,857,790 
373,303 
(7,231,093)
- 

The  Company’s  corporate  offices  and  other  offices  are  in  Pittsburgh,  Pennsylvania.  Upon  expiration  of  previous  leases  for  office  space  and  laboratory
operations, the Company entered two new leases for office space and laboratory operations on January 4, 2023. The leases each have an approximate five-
year term ending February 29, 2028, and the Company recorded corresponding right of use (“ROU”) assets and liabilities of $2,922,365.

The Company has an additional office in Birmingham, Alabama, which is used for office space and laboratory operations. The lease is effective through
August 31, 2025.

The Company has an office in Eagan, Minnesota, which is used for office space and manufacturing. Since July 31, 2022, the lease was month-to-month
tenancy. On June 1, 2023, the lease was amended for two additional years until May 31, 2025 and the Company recorded a corresponding ROU asset and
liability of $74,816.

Lease expense under operating lease arrangements was $892,993 and $746,590 for 2023 and 2022, respectively.

The following table summarizes other information related to the Company’s operating leases:

Weighted average remaining lease term – operating leases in years
Weighted average discount rate – operating leases

F-21

December 31,
2023

December 31,
2022

3.99 

12%   

1.72 

8%

 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
 
The Company’s operating lease obligation as of December 31, 2023, which includes expected lease extensions that are reasonably certain of renewal, are as
follows:

2024
2025
2026
2027
2028
Total lease payments
Less interest
Present value of lease liabilities

NOTE 7 – NOTE PAYABLE

  $

  $

818,463 
857,622 
803,724 
827,909 
139,022 
3,446,740 
(740,334)
2,706,406 

In  June  2023,  the  Company  purchased  Directors  and  Officers  insurance  policies  with  a  policy  period  ending  June  2024.  In  July  2023,  the  Company
financed $364,721 of its total premium by entering into a note payable with a finance provider that requires ten monthly installment payments through
April 2024. The note is secured by a first priority lien on the financed policies. The short-term note bears interest at an annual percentage rate of 9.25%
over the life of the note. As of December 31, 2023, the outstanding balance of the note was $150,408 including interest.

NOTE 8 – DERIVATIVES

Certain  warrants  issued  to  placement  agents  were  determined  to  be  a  derivative  liability  due  to  certain  features  of  the  warrants  which  could,  in  certain
circumstances,  result  in  the  holder  receiving  the  Black  Scholes  value  of  the  outstanding  warrants  in  the  same  type  of  consideration  as  the  common
stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the
warrants were classified as a liability.

The fair value of the placement agent warrants issued in connection with the March 2020 private placement was determined to be $135 and $3,355 as of
December 31, 2023, and December 31, 2022, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of
$3,220 and $37,981 during the year ended December 31, 2023, and December 31, 2022, respectively. The placement agent warrants expire in March 2025.

The fair value of the placement agent warrants issued in connection with the May 2020 offering of securities was determined to be $333 and $4,479 as of
December 31, 2023, and December 31, 2022, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of
$4,146 and $38,167 during the year ended December 31, 2023, and December 31, 2022, respectively. The placement agent warrants expire in May 2025.

The placement agent warrants issued in connection with the June 2020 warrant exercise and issuance had a fair value of $908 and $5,999 as of December
31, 2023, and December 31, 2022, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $5,091 and
$39,499 during the year ended December 31, 2023, and December 31, 2022, respectively. The placement agent warrants expire in June 2025.

The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above.

Derivative liability balance at December 31, 2021
Gain recognized to revalue derivative instrument at fair value
Derivative liability balance at December 31, 2022
Gain recognized to revalue derivative instrument at fair value
Derivative liability balance at December 31, 2023

F-22

  $

  $

  $

129,480 
(115,647)
13,833 
(12,457)
1,376 

 
 
 
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
 
NOTE 9 – STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

Series F Preferred Stock Dividend and Reverse Stock Split

On March 16, 2023, the Board of Directors of the Company authorized the issuance of 80,000 shares of Series F Preferred Stock, par value $0.01 per share.

On March 16, 2023, the Board of Directors of the Company declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value
$0.01 per share, for each outstanding share of the Company’s common stock held on record as of March 27, 2023. 79,404 shares of Series F Preferred
Stock were issued pursuant to the stock dividend. Each share of Series F Preferred Stock entitled the holder thereof to 1,000,000 votes per share to vote
together  with  the  outstanding  shares  of  common  stock  of  the  Company  as  a  single  class  to  adopt  an  amendment  to  the  Company’s  Certificate  of
Incorporation to affect a reverse stock split.

On April 19, 2023, the Company completed a one-for-twenty reverse stock split that was effective for trading purposes on April 24, 2023. No fractional
shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded
up to the next whole number. The number of authorized shares of common stock under the Company’s certificate of incorporation, as amended, remained
unchanged at 200,000,000 shares. All numbers of shares and per-share amounts in this report have been adjusted to reflect the reverse split. Proportionate
reductions  were  made  to  the  number  of  shares  of  common  stock  reserved  for  future  issuance  under  our  2012  Equity  Incentive  Plan  and  the  number  of
shares of common stock that may be issued upon exercise or vesting of outstanding equity incentive awards and warrants, and proportionate increases were
made to the exercise price or share-based performance criteria, if any, applicable to such awards and warrants.

Redemption of Series F Preferred Stock

On April 17, 2023, the Company convened a special meeting of stockholders, which was adjourned due to the lack of a quorum and reconvened on April
19, 2023 (the “Special Meeting”), at which the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect
a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-25, with such ratio to be determined by the Company’s
Board of Directors (the “Reverse Split Proposal”). All shares of Series F Preferred Stock that were not present in person or by proxy at the Special Meeting
as  of  immediately  prior  to  the  opening  of  the  polls  (the  “Initial  Redemption  Time”)  were  automatically  redeemed  (the  “Initial  Redemption”).  All
outstanding shares of Series F Preferred Stock that were not redeemed pursuant to the Initial Redemption were redeemed automatically upon the approval
by the Company’s stockholders of the Reverse Split Proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”).
Both  the  Initial  Redemption  and  the  Subsequent  Redemption  occurred  on  April  19,  2023.  As  a  result,  no  shares  of  Series  F  Preferred  Stock  remain
outstanding.

May 2022 Offerings

On May 16, 2022, the Company issued and sold an aggregate of 191,864 shares of its common stock, at a purchase price of $12.00 per share to several
institutional and accredited investors in a registered direct offering (the “First Offering”). Pursuant to the securities purchase agreement, the Company also
agreed  to  issue  to  these  purchasers  unregistered  warrants  to  purchase  up  to  an  aggregate  of  191,864  shares  of  common  stock  (the  “Warrants”)  in  a
concurrent private placement. The Warrants have an exercise price equal to $14.00 per share, will become exercisable six months from the date of issuance,
and will expire five and one-half years from the date of issuance.

In addition, in a concurrent registered direct offering (the “Second Offering”), on May 16, 2022, the Company issued and sold to several institutional and
accredited investors an aggregate of 408,136 shares of its common stock, at a purchase price of $12.00 per share. The Company also entered into a warrant
amendment  agreement  (the  “Warrant  Amendment”)  with  each  of  the  purchasers  in  the  Second  Offering.  Under  the  Warrant  Amendment,  the  Company
agreed  to  amend  certain  existing  warrants  to  purchase  up  to  816,272  shares  of  common  stock  that  were  previously  issued  in  2020  and  2021  to  those
purchasers, with exercise prices ranging from $20.00 to $40.00 per share (the “Existing Warrants”), were amended to: (i) lower the exercise price of the
Existing Warrants to $14.00 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until six months following the closing
date  of  the  Second  Offering,  and  (iii)  extend  the  original  expiration  date  of  the  Existing  Warrants  by  five and one-half years following the close of the
Second Offering.

F-23

 
 
 
 
 
 
 
 
 
 
 
 
 
In each case, the Company paid to the placement agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the
offering and a management fee equal to 1% of the aggregate gross proceeds received by the Company in the offering and provided the placement agent
expense  allowance  of  $65,000  for  non-accountable  and  other  out-of-pocket  expenses.  In  addition,  the  Company  granted  to  the  placement  agent  or  its
assigns  warrants  to  purchase  7.5%  of  the  shares  sold  to  investors  in  the  offering  at  an  exercise  price  equal  to  125%  of  the  price  of  the  shares  in  the
transaction, or $15.00 per share, with a term of five years (the “Agent Warrants”). The Agent Warrants become exercisable six months after issuance.

Equity Line

On October 24, 2019, the Company entered into an equity purchase agreement with an investor, providing for an equity financing facility. According to the
terms  and  subject  to  the  conditions  in  the  purchase  agreement,  the  investor  was  committed  to  purchase  shares  having  an  aggregate  value  of  up  to
$15,000,000 of the Company’s common stock for a period of up to three years. The Company issued to the investor 5,233 commitment shares at a fair
market value of $450,000 for entering into the agreement. From time to time during the three-year commitment period, provided that the closing conditions
were  satisfied,  the  Company  could  provide  the  investor  with  put  notices  to  purchase  a  specified  number  of  shares  subject  to  certain  limitations  and
conditions and at specified prices, which generally represent discounts to the market price of the common stock. During the year ended December 31, 2022,
the Company issued 15,750 shares of its common stock valued at $236,009 pursuant to the equity line. In connection with the May 2022 offerings, the
Company agreed not to access the remaining balance for a period of one year after the closing date, or May 18, 2022. The equity line expired on October
23, 2022.

Series B Convertible Preferred Stock

As of December 31, 2023, and December 31, 2022, there were 79,246 shares of Series B Convertible Preferred Stock outstanding. The conversion rate of
Series B Convertible Preferred Stock to Common Stock is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations, or
similar events. The 79,246 shares of Series B Convertible Preferred Stock outstanding at December 31, 2023 were convertible to 16 shares of common
stock. In addition, the Series B Convertible Preferred Stock will automatically convert into shares of common stock upon the occurrence of a fundamental
transaction, as described in the certificate of designations for the Series B Convertible Preferred Stock including mergers, sales of the company’s assets,
changes in control and similar transactions. The Series B Convertible Preferred Stock is not convertible by the holder of such preferred stock to the extent
(and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company. The Series
B Convertible Preferred Stock has no voting rights, except for the right to approve certain amendments to the certificate of designations or similar actions.
With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Company, the Series B Convertible
Preferred Stock shall rank equal to the common stock of the Company. No sinking fund has been established for the retirement or redemption of the Series
B Convertible Preferred Stock.

Equity Incentive Plan

The Company’s Amended and Restated 2012 Stock Incentive Plan (the “2012 Plan”) allows for the issuance of incentive and non-qualified stock options,
stock appreciation rights, stock awards, restricted stock, restricted stock units (“RSUs”) and performance awards to employees, directors, and consultants of
the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting
requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options outstanding under this
plan have a contractual life of ten years.

On  December  1,  2022,  during  the  2022  annual  meeting  of  stockholders  (the  “Annual  Meeting”),  the  stockholders  approved  a  proposal  to  increase  the
reserve shares of common stock authorized for issuance under the Amended and Restated 2012 Stock Incentive Plan by 162,500 to 287,500 reserve shares.

F-24

 
 
 
 
 
 
 
 
 
 
ASC 718, Compensation – Stock Compensation (“ASC 718”), requires that a company that issues equity as compensation needs to record compensation
expense on its statements of net loss that corresponds to the estimated cost of those equity grants. ASC 718 requires companies to estimate the fair value of
stock-based payment awards on the date of grant using an option-pricing model or other acceptable means.

During  the  year  ended  December  31,  2021,  the  Company  issued  22,500  RSUs  under  the  plan  which  had  market,  performance,  and  service  vesting
conditions  through  January  1,  2024.  16,667  RSUs  became  vested  during  the  year  ended  December  31,  2022.  At  December  31,  2022,  there  were  4,167
RSUs outstanding under the plan. At December 31, 2023, there were no RSUs outstanding under the plan.

Valuation and Accounting for Stock Options and Warrants

The  Company  determines  the  grant  date  fair  value  of  options  and  warrants  using  a  Black-Scholes  option  valuation  model  based  upon  assumptions
regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. See Note 1 – Summary of Significant Accounting Policies.

The  fair  value  of  each  option  and  warrant  grant  is  estimated  on  the  grant  date  using  the  Black-Scholes  option  valuation  model  with  the  following
assumptions:

Expected dividend yield
Expected stock price volatility
Risk-free interest rate
Expected life (years)

Expected dividend yield
Expected stock price volatility
Risk-free interest rate
Expected life (years)

Stock Options and Warrants Granted by the Company

The following summarizes transactions for stock options and warrants for the periods indicated: 

Year Ended December 31,
2022
2023

Stock Options

0.0%

0.0%

90.8% –98.2%      
3.38% –3.95%      

86.5% –92.2%  
1.83% –4.26%  

10

0.0%
0%
0%
0

Warrants

10

0.0%
92.2%

2.96% –2.97%  

5 – 5.5

Outstanding at December 31, 2021

Issued
Forfeited
Expired
Cancelled
Outstanding at December 31, 2022

Issued
Forfeited
Expired
Outstanding at December 31, 2023

Stock Options

Warrants

Number of
Shares

Average
Exercise
Price

Number of
Shares

Average
Exercise
Price

53,144    $

96.60     

1,584,995    $

33.20 

1,599     
(2,013)    
(3,677)    
-     
49,053    $

1,075     
(49)    
(2,415)    
47,664    $

8.40     
17.60     
208.40     
-     
91.60     

5.45     
6.18     
139.30     
82.23     

1,053,136     
-     
(5,422)    
(816,272)    
1,816,437    $

-     
-     
(9,848)    
1,806,589    $

14.00 
- 
329.60 
30.20 
22.60 

- 
- 
219.60 
21.52 

At December 31, 2023, 46,814 stock options were fully vested and currently exercisable with a weighted average exercise price of $83.61 and a weighted
average remaining term of 5.56 years. At December 31, 2023, there were 1,806,589 warrants that were fully vested and currently exercisable.

F-25

 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
     
 
   
   
 
   
 
 
 
 
   
     
 
   
     
 
   
     
 
   
 
 
 
 
 
 
   
 
 
 
   
   
   
 
   
 
     
       
       
       
 
   
   
   
   
   
 
     
       
       
       
 
   
   
   
   
 
 
At December 31, 2022, 47,682 stock options were fully vested and exercisable with a weighted average exercise price of $93.80 and a weighted average
remaining term of 6.54 years. At December 31, 2022, there were 1,816,437 warrants that were fully vested and currently exercisable.

Stock-based compensation recognized in 2023 and 2022 was $2,038 and $108,596, respectively. The Company has $1,644 of unrecognized compensation
expense related to non-vested stock options that are expected to be recognized over the next 16 months.

The following summarizes the status of options and warrants outstanding at December 31, 2023:

Range of Exercise Prices

Shares

Weighted Average
Remaining Life  

Options
$ 3.44 –14.65
$ 16.28 –29.40
$ 30.80 –52.20
$ 101.00 –69,375.00
Total

Warrants:
$ 14.00 –20.00
$ 21.05 –30.00
$ 34.38 –40.00
$ 43.75 –200.00
Total

12,029     
4,935     
16,049     
14,651     
47,664     

1,168,465     
368,246     
180,314     
89,564     
1,806,589     

Stock options and warrants expire on various dates from February 2024 to July 2033.

The following table is the listing of outstanding stock options and warrants as of December 31, 2023 by year of grant:

Stock Options:

Year
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Total

Warrants:

Year
2019
2020
2021
2022
Total

Shares

3    $
12     
296     
10,478     
2,893     
14,970     
14,883     
2,248     
846     
1,035     
47,664    $

Shares

84,514    $
65,586     
603,353     
1,053,136     
1,806,589    $

F-26

Range of Exercise Prices
–
–
–
–
–
–
–
–
–
–
–

32,500.00     
30.80     
30.80     
30.80     
30.80     
30.80     
14.65     
14.40     
7.70     
3.44     
3.44     

    $

Range of Exercise Prices
–
–
–
–
–

16.90     
36.00     
16.00     
14.00     
14.00     

    $

6.67 
7.57 
4.13 
3.52 

3.62 
2.06 
5.87 
1.83 

69,375.00 
17,250.00 
850.00 
420.00 
226.00 
158.00 
32.80 
29.40 
14.65 
7.68 
69,375.00 

200.00 
59.84 
48.75 
15.00 
200.00 

 
 
 
 
 
   
   
       
       
 
     
     
     
     
     
  
   
       
       
 
       
       
 
     
     
     
     
     
  
 
 
 
 
 
   
 
   
     
   
     
   
     
   
     
   
     
   
     
   
     
   
     
   
     
   
     
   
 
 
 
   
 
   
     
   
     
   
     
   
     
   
 
NOTE 10 – INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred
income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled.

The Company incurred zero income tax expense during the years ended December 31, 2023, and December 31, 2022, due to losses in both years.

Actual income tax benefit differs from statutory federal income tax benefit as follows:

Statutory federal income tax benefit
State tax benefit, net of federal taxes
Foreign tax benefit
Foreign operations tax rate differential
State rate adjustment
Nondeductible/nontaxable items
Goodwill impairment
NOL and deferred only adjustments
Other
Valuation allowance decrease
Total income tax benefit

Year Ended December 31,
2022
2023

  $

  $

2,936,633    $
599,958     
-     
-     
(125,150)    
121,708     
-     
(59,913,532)    
(5,182)    
56,385,565     
-    $

5,404,903 
856,735 
- 
- 
(7,795,184 
(7,709)
(1,654,212)
(1,149,895)
89,162 
4,256,200 
- 

F-27

 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
   
   
   
   
   
   
   
   
 
Deferred taxes consist of the following:

Deferred tax assets:
Noncurrent:
Inventory
Compensation accruals
Accruals and reserves
Deferred revenue
Charitable contribution carryover
Derivatives
Intangibles
Capitalized R&D
Depreciation
Lease liabilities
NQSO compensation
NOL and credits
Total deferred tax assets

Deferred tax liabilities:
Noncurrent:

Depreciation
Lease right-of-use assets
Total deferred tax liabilities

Net deferred tax assets
Less: valuation allowance
Total

  December 31, 2023   

December 31,
2022

  $

-    $
87,131     
204,083     
36,169     
1,724     
349     
852,414     
919,789     
59,511     
703,026     
627,997     
21,737,285     
25,229,478     

- 
150,168 
254,213 
51,198 
1,766 
3,192 
1,191,874 
635,862 
- 
6,925 
1,625,108 
77,042,831 
80,963,137 

-     
(691,119)    
(691,119)    

(39,213)
- 
(39,213)

24,538,359     
(24,538,359)    
-    $

80,923,924 
(80,923,924)
- 

  $

The Company has determined, based upon its history, that it is probable that future taxable income may be insufficient to fully realize the benefits of the
NOL carryforwards and other deferred tax assets. As such, the Company has determined that it is more likely than not that it will not realize its deferred tax
assets.

Pursuant  to  the  Internal  Revenue  Code  of  1986,  as  amended  (the  “Code”)  Sections  382  and  383,  annual  use  of  a  company’s  NOL  and  research  and
development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount
of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may
further affect the limitation in future years.

During the year-ended December 31, 2023, the Company completed an assessment of the available NOL and tax credit carryforwards under Section 382
and 383 and determined that the Company underwent several ownership changes during the period from 2008 to 2022. The Company has adjusted its NOL
and tax credit carryforwards to reflect the limitations resulting from the identified ownership changes. The Company reduced its available gross federal and
state NOL carryforwards by $237,816,096 and $178,311,455, respectively, and recorded a reduction of $49,941,380 and $7,344,800, respectively, to the
federal and state deferred tax asset, each of which related to losses generated for the years ended December 31, 2022, and prior. Accordingly, the NOL and
tax  credit  carryforwards  presented  above  for  the  year  ended  December  31,  2023,  were  reduced  by  $57,446,259,  with  a  corresponding  reduction  to  the
valuation allowance.  The Company has recorded the adjustments noted above in 2023 as an out-of-period adjustment and concluded that the adjustments
were not material to the 2022 consolidated financial statements and evaluated the recording of this prior year item in the current period and concluded that
the net accounting impact is not material to the 2023 consolidated financial statements.

As  of  December  31,  2023,  the  Company  had  $86,840,808  of  NOLs  to  reduce  future  federal  taxable  income,  the  majority  of  which  are  expected  to  be
available for use in 2024, subject to the Section 382 limitation described above. The federal NOLs of $43,354,286 begin to expire in 2024 if unused and
$43,486,522 will carry forward indefinitely. The Company also had $59,425,348 of NOLs to reduce future state taxable income as of December 31, 2023.
The state NOLs will begin to expire in 2024 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation
allowance. As of December 31, 2023, the federal and state valuation allowances were $20,558,729 and $3,979,630, respectively.

F-28

 
 
 
 
 
     
       
 
     
       
 
   
   
   
   
   
   
   
   
   
   
   
   
 
     
       
 
     
       
 
     
       
 
   
   
   
 
     
       
 
   
   
 
 
 
 
 
As of December 31, 2022, prior to the Section 382 analysis, the Company had $316,548,085 of NOLs to reduce future federal taxable income, the majority
of which were expected to be available for use in 2023. The federal NOLs of $254,897,407 were to begin to expire in 2023 if unused and $60,829,929 were
to carry forward indefinitely. Prior to the Section 382 state analysis, the Company also had $232,097,127 of NOLs to reduce future state taxable income at
December 31, 2022. As of December 31, 2022, the federal and state valuation allowances were $66,733,005 and $14,190,055, respectively.

Tax years after 2003 remain open to examination by federal and state tax authorities due to unexpired NOL carryforwards.

The  Company  reviews  income  tax  positions  expected  to  be  taken  in  income  tax  returns  to  determine  if  there  are  any  income  tax  uncertainties.  The
Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by
taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Due to the existence of the valuation
allowance, changes in the Company’s unrecognized tax benefits are not expected to impact the Company’s effective tax rate.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax
expense. As of December 31, 2023, and 2022, the Company recorded no accrued interest or penalties related to uncertain tax positions.

NOTE 11 – COLLABORATIVE AGREEMENT

Collaborative Agreement with Cancer Research Horizons

On March 16, 2023, the Company entered into a Collaboration Agreement (the “CRH Agreement”) with Cancer Research Horizons (“CRH”), pursuant to
which  the  Company  will  use  its  PEDAL  technology  to  evaluate  CRH  pre-clinical  drug  inhibitors  of  Glutaminase  to  determine  which  cancer  types  and
patient populations are most likely to respond to treatment with these compounds (the “Project”). Under the CRH Agreement, both parties will retain rights
to  their  respective  background  intellectual  property.  Rights  to  reports,  findings,  supporting  data,  and  materials  (“Project  Intellectual  Property”)  that  are
generated by the Company pursuant to its performance under the CRH Agreement vest exclusively in CRH. Each party funds its own participation in the
Project. Costs incurred to participate in the CRH Agreement are recorded in Cost of Sales in the Company’s consolidated Statements of Net Loss.

Pursuant  to  the  CRH  Agreement,  the  Company  shall  receive  a  percentage  of  net  revenue,  as  defined  in  the  agreement,  received  by  CRH  for  the
commercialization of the CRH Candidates and any CRH Derivatives. The percentage of net revenue varies depending on the stage of development. The
revenue sharing fees represent variable consideration, which is measured using the expected value method under ASC 606 based on the actual net revenues
earned  by  CRH  under  Relevant  Transfer  Agreements  relating  to  the  CRH  Candidates  and  CRH  Derivatives.  Due  to  the  uncertainty  associated  with  the
timing and amount of revenue sharing fees, the Company concluded that the revenue sharing fees should be fully constrained until such time that Relevant
Transfer Agreements have been entered and net revenues have been earned. These estimates will be reassessed at each reporting period. During the year
ended December 31, 2023, the Company recognized no revenue under the CRH Agreement.

NOTE 12 – RETIREMENT SAVINGS PLANS

The  Company  has  a  pre-tax  salary  reduction/profit-sharing  plan  under  the  provisions  of  Section  401(k)  of  the  Internal  Revenue  Code,  which  covers
employees meeting certain eligibility requirements. During 2023 and 2022, the Company matched 100% of the employee’s contribution up to 4.0% of their
earnings. Employer contributions were $192,499 and $99,924 in 2023 and 2022, respectively. There were no discretionary contributions to the plan in 2023
and 2022.

F-29

 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE 13 – LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

Year Ended December 31,
2022
2023

Numerator:
Net loss attributable to common stockholders per common share: basic and diluted calculation

  $

(13,983,967)   $

(25,737,634)

Denominator:
Weighted average common shares outstanding-basic
Effect of diluted stock options, warrants and preferred stock (1)
Weighted average common shares outstanding-diluted

4,014,848     
-     
4,014,848     

3,685,954 
- 
3,685,954 

Loss per common share-basic and diluted

  $

(3.48)   $

(6.98)

(1)  The  following  is  a  summary  of  the  number  of  underlying  shares  outstanding  at  the  end  of  the  respective  periods  that  have  been  excluded  from  the
diluted calculations because the effect on loss per common share would have been anti-dilutive:

Options
RSUs
Warrants
Preferred stock: Series B

NOTE 14 – SEGMENTS

Year Ended December 31,
2022
2023

47,664     
-     
1,806,589     
16     

49,053 
4,167 
1,816,437 
16 

The  Company  has  determined  its  operating  segments  in  accordance  with  ASC  280  –  Segment  Reporting.  Factors  used  to  determine  the  Company’s
reportable  segments  include  the  availability  of  separate  financial  statements,  the  existence  of  locally  based  leadership  across  geographic  regions,  the
economic factors affecting each segment, and the evaluation of operating results at the segment level. The Chief Operating Decision Maker (“CODM”)
allocates the Company’s resources for each of the operating segments and evaluates their relative performance. Each operating segment listed below has
separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the
operating  segments  below  have  different  products  and  services.  The  financial  information  is  consolidated  and  evaluated  regularly  by  the  CODM  in
assessing performance and allocating resources. As of January 1, 2023, the Company changed its reportable segments to align with its business areas. The
Company has retrospectively revised the reported segment information for all periods presented for consistency.

The Company has three reportable segments, which have been delineated by location and business area:

● Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also

creates proprietary 3D culture models used in drug development.

● Birmingham segment: provides contract services and research focused on solubility improvements, stability studies, and protein production.

● Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and

patient-to-drain medical fluid disposal.

See discussion of revenue recognition in Note 1 – Summary of Significant Accounting Policies for a description of the products and services recognized in
each segment. The segment revenues and segment net losses for the year ended December 31, 2023, and 2022 are included in the table below. All revenues
are earned from external customers.

F-30

 
 
 
 
 
 
 
 
 
 
   
 
     
       
 
 
     
       
 
     
       
 
   
   
   
 
     
       
 
 
 
 
 
 
 
 
   
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
The tables below summarize the Company’s segment reporting as of and for years ended December 31, 2023, and 2022.

Revenue
Depreciation and amortization
Impairment expense – long-lived tangible assets
Net loss

Assets
Expenditures for additions to long-lived assets

  $

  $

  $

Pittsburgh     Birmingham    

    Corporate    

492,596    $
(207,658)    
-     
(4,503,906)   $

Year Ended December 31, 2023
Eagan
1,135,101    $
(29,750)    
-     
(969,281)   $

152,396    $
(494,527)    
(162,905)    
(1,966,406)   $

Total
1,780,093 
(739,316)
(162,905)
(6,544,374)   $ (13,983,967)

-    $
(7,381)    
-     

Pittsburgh     Birmingham    

    Corporate    

December 31, 2023
Eagan
1,390,031    $
24,691     

981,914    $
254,819     

8,782,034    $
15,437     

Total
14,417,249 
302,371 

3,263,270    $
7,424     

Revenue
Depreciation and amortization
Impairment expense – goodwill
Impairment expense – intangibles
Impairment expense – long-lived tangible assets
Net loss

  $

358,776    $
(836,671)    
(7,231,093)    
(3,349,375)    
-     
  $ (15,741,206)   $

Pittsburgh     Birmingham    

    Corporate    

Year Ended December 31, 2022
Eagan
1,063,493    $
(28,481)    
-     
-     
-     
(417,774)   $

82,301    $
(378,708)    
-     
-     
(115,775)    
(1,817,283)   $

Total
1,505,459 
(1,313,075)
(7,231,093)
(3,349,375)
(185,469)
(7,761,371)   $ (25,737,634)

889    $
(69,215)    
-     
-     
(69,694)    

Assets
Expenditures for additions to long-lived assets

  $

1,055,228    $
76,636     

1,353,434    $
157,334     

946,394    $
29,362     

22,379,588    $
212,365     

Pittsburgh     Birmingham    

    Corporate    

December 31, 2022
Eagan

Total
25,734,644 
475,697 

In each of the years ended December 31, 2023, and 2022, substantially all the Company revenues were located or derived from operations in the United
States. As of December 31, 2023, all the Company’s long-lived assets were located within the United States. During the year ended December 31, 2023,
revenues of $489,921 reported in the Company’s Pittsburgh segment were attributable to a single customer. As of December 31, 2023, accounts receivable
due from this customer was $52,072.

NOTE 15 – SUBSEQUENT EVENTS

Departure of Chief Business Officer

On February 2, 2024, the Company and Pamela Bush, Ph.D., MBA, the Company’s Chief Business Officer, agreed that Dr. Bush would leave the Company
effective February 15, 2024. In accordance with her Employment Agreement, the Company and Ms. Bush entered into a Separation Agreement and Mutual
Release whereby the Company agreed to pay a separation benefit of $410,000 over the subsequent twelve months.

F-30

 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
SEPARATION AGREEMENT AND MUTUAL RELEASE

This  Separation  Agreement  and  Mutual  Release  ("Agreement")  is  made  by  and  between  Robert  Myers  ("Employee")  and  Predictive

Oncology Inc. (the "Company"), each of whom enter into this Agreement intending to be legally bound.

Exhibit 10.9

1. Terms of Employment; Separation Date.

a. The terms of Employee's employment with the Company are set forth in that certain Employment Agreement, dated August 11, 2012,

and Amendment to Employment Agreement, dated August 20, 2018 (together, the "Employment Agreement").

b. Employee's employment will terminate effective as of September 30, 2023 (the "Separation Date"). Regardless of whether Employee

signs this Agreement, Employee will receive timely payment of his final paycheck.

2. Separation Benefits. In  accordance  with  the  Employment  Agreement,  and  in  exchange  for  Employee's  waiver  and  release  of  claims  set
forth in Section 3 and other promises set forth in this Agreement, and provided that Employee (i) signs, dates, and returns this Agreement
within the time period described in Section 4, (ii) does not rescind this Agreement within the time period described in Section 4; and (iii)
successfully completes the transition obligations set forth in Section 7(g) of this Agreement, the Company agrees to pay to Employee the
following amounts (collectively, the "Separation Benefits"):

a.

b.

c.

an  amount  equal  to  twelve  (12)  months  of  Employee's  current  base  salary  ($430,000),  less  applicable  taxes  and  withholdings,
payable as salary continuation in accordance with the Company's ordinary payroll procedures;

if any bonus shall be paid to the Company's Chief Executive Officer for 2023, payment of Employee's pro-rata bonus earned for
2023, less applicable taxes and withholdings; and

a  lump  sum  in  the  amount  of  $36,797.94  in  payment  of  Employee's  unused  vacation  time  for  2023,  less  applicable  taxes  and
withholdings.

The  first  installment  of  the  Separation  Benefits  shall  be  paid  with  the  Company's  first  administratively  feasible  payroll  date  following  the
Effective Date (defined below).

3. Waiver and Release of Claims.

a. Employee's General Release and Waiver of Claims.

In exchange for the Separation Benefits set forth in Section 2, Employee agrees to unconditionally waive and release any and all claims,

complaints, causes of action, and

1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
demands of whatever kind which Employee has or may have against the Released Parties (as defined below) to the maximum extent permitted
by applicable law up to the moment Employee signed this Agreement, including any claims, complaints, causes of action, or demands relating in
any  way  to  Employee's  employment  with  the  Company  and  Employee's  separation  from  employment  with  the  Company  including,  but  not
limited to, the following:

i. All claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act
(regarding existing but not prospective claims), the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income
Security  Act  (regarding  unvested  benefits),  the  Civil  Rights  Act  of  1991,  Section  1981  of  U.S.C.  Title  42,  the  Fair  Credit
Reporting Act, the Worker Adjustment and Retraining Notification Act, the National Labor Relations Act, the Uniform Services
Employment  and  Reemployment  Rights  Act,  the  Genetic  Information  Nondiscrimination  Act,  the  Immigration  Reform  and
Control Act, the Minnesota Human Rights Act, the Minnesota Whistleblower Act, the Minnesota Equal Pay for Equal Work law,
all  claims  allowed  under  Minnesota  Statute  Chapter  181,  and  retaliation  claims  under  Minn.  Stat.  §176.82,  including  without
limitation any and all amendments to each of the foregoing and their respective implementing regulations, and any other federal,
state, local, or foreign law (statutory, regulatory, common law, or otherwise) that may be legally waived and released; however, the
identification of specific statutes is for purposes of example only, and the omission of any specific statute or law shall not limit the
scope of this general release in any manner;

ii. All  claims  arising  under  tort,  contract,  and  quasi-contract  law,  including  but  not  limited  to  claims  of  breach  of  an  express  or
implied  contract,  wrongful  or  retaliatory  discharge,  fraud,  defamation,  negligent  or  intentional  infliction  of  emotional  distress,
tortious  interference  with  a  contract  or  prospective  business  advantage,  breach  of  the  implied  covenant  of  good  faith  and  fair
dealing, promissory estoppel, detrimental reliance, invasion of privacy, false imprisonment, nonphysical injury, personal injury or
sickness, or any other harm;

iii. All  claims  for  any  other  form  of  pay,  compensation,  or  employee  benefits  of  any  kind  that  is  not  provided  in  this  Agreement
including, without limitation, bonuses, commissions, deferred compensation, stock-based incentive compensation, stock options,
phantom stock, equity of any kind, vacation pay, expense reimbursement, and any other claims under any applicable federal, state,
and local law, statute, ordinance, or regulation to the fullest extent permitted by law;

iv. All claims for monetary or equitable relief, including but not limited to attorneys' fees, back pay, front pay, reinstatement, experts'

fees, medicalfees or expenses, costs and disbursements, punitive damages, liquidated damages, and penalties.

2

 
 
 
 
 
 
 
 
 
 
 
Employee  understands  and  agrees  that  the  above  list  contains  examples  only  and  does  not  contain  all  claims  that  Employee  is  releasing.  By
signing this Agreement, Employee is fully and finally waiving and releasing, to the fullest extent permitted by law, all claims against the Released Parties.
Employee agrees that the Company's payment of the Separation Benefits is full and fair payment for the waiver and release of Employee's claims and has
a  value  greater  than  anything  Employee  is  entitled  to  if  Employee  does  not  sign  this  Agreement.  However,  this  general  release  and  waiver  of  claims
excludes, and the Employee does not waive, release, or discharge: (A) any claims that by law cannot be released in a private agreement; (B) any claims
that arise after the date Employee signed this Agreement; (C) any claims that relate to the obligations of Employee or the Company under this Agreement;
(D)  any  right  to  file  an  unfair  labor  practice  charge  under  the  National  Labor  Relations  Act  or  otherwise  access  the  National  Labor  Relations  Board's
processes; and (E) any rights to vested benefits, such as pension or retirement benefits, the rights to which are governed by the terms of the applicable
plan documents and award agreements.

For purposes of this Agreement, the term "Released Parties" means the Company and all of the Company's past and present parents, subsidiaries,
and  affiliated  companies,  and  all  and  each  of  the  past  and  present  employees,  officers,  officials,  managers,  members,  directors,  agents,  insurers,
representatives,  counsel,  shareholders,  owners,  partners,  predecessors,  successors,  and  assigns  of  any  and  all  of  the  foregoing  entities  and  persons.  In
addition, for purposes of Section 3, the term "Employee" means Robert Myers and any person who has or obtains any legal rights or claims against the
Company or the Released Parties through Robert Myers, including without limitation any and all heirs, executors, agents and assignees.

b. Company's General Release and Waiver of Claims. Company fully and completely releases Employee and Employee's representatives, attorneys,
predecessors, heirs, successors, and permitted assigns ("Employee Parties") from any and all claims or causes of action that Company may have
against the Employee Parties, known or unknown, including claims or causes of action that relate in any way to Employee's employment with
any Company party or the termination thereof, from the beginning of time through the date Company signs this Agreement.

c. Company's Partial Waiver and Non-Enforcement of Non-Compete. Company agrees to partially waive and to not enforce the non-competition
provision in Section 6(a) of the Employment Agreement to the extent Employee is not engaged, directly or indirectly, as an employee, owner,
consultant or in any other capacity whatsoever, for Employee's own behalf or on behalf of any other person or entity, anywhere in the United
States  of  America  in  the  discovery,  characterization  or  evaluation  of  chemical  or  biological  compositions  for  the  diagnosis  or  treatment  of
disease.  For  the  avoidance  of  doubt,  all  other  provisions  in  Section  6  of  the  Employment  Agreement  survive,  remain  valid  and  are  fully
enforceable.

3

 
 
 
 
 
 
 
 
4. Employee's Legal Rights.

a. Advice to Consult With an Attorney. This Agreement is a legal document. Employee has been advised in writing to consult with an

attorney prior to executing the Agreement.

b. Period to Consider this Agreement. Employee was given this Agreement on September 15, 2023. Employee has twenty-one (21) days
following  receipt  of  the  Agreement  to  consider  the  offer  as  expressed.  Signing  this  Agreement  before  the  21-day  period  expires
constitutes a waiver by Employee of any remaining time period for review and consideration to which Employee may be entitled. If
Employee does not sign this Agreement within the 21-day consideration period, the offer contained within this Agreement will expire.
Employee  agrees  and  understands  that  if  Employee  does  not  sign  this  Agreement  within  the  21-day  consideration  period,  this
Agreement will be null and void and Employee will not receive the Separation Benefits in Section 2.

c. Period to Revoke this Agreement. Employee understands that Employee has the right to revoke this Agreement within fifteen (15)
calendar days after the date on which Employee signs this Agreement. This Agreement shall not become effective or enforceable until
the 15-day revocation period has expired without Employee's revoking this Agreement. Provided that Employee does not revoke this
Agreement,  it  shall  become  effective  on  the  day  immediately  following  the  foregoing  revocation  period  (such  date,  the  "Effective
Date").

d. Revocation Procedure. To revoke, Employee must put the revocation in writing and deliver it to the Company by overnight delivery or
e-mail  to  Raymond  Vennare  (Predictive  Oncology  Inc.  c/o  Raymond  Vennare,  91  43rd  Street,  Ste.  210,  Pittsburgh,  PA  15201;
rvennare@predictive-oncology.com) within the 15-day period.

If Employee rescinds this Agreement as described in this Section 4, Employee understands that (i) this Agreement is null and void, (ii)
the Company shall have no further obligation under this Agreement, (iii) Employee will not receive the Separation Benefits in Section 2
of this Agreement or any other benefits listed within this document, and (iv) Employee's employment will still end on the Separation
Date.

5. Filings. Employee understands that, without being penalized or having an obligation to notify the Company, this Agreement does not prohibit
Employee from filing an administrative charge of discrimination or complaint with the Equal Employment Opportunity Commission, National
Labor  Relations  Board,  Occupational  Safety  and  Health  Administration,  the  Equal  Employment  Opportunity  Commission,  Securities  and
Exchange  Commission,  Civil  Rights  Division,  Minnesota  Department  of  Human  Rights,  or  any  other  federal,  state,  or  local  governmental
agency or commission or law enforcement agency ("Government Agencies"). Employee understands that this

4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agreement does not limit Employee's ability to communicate with any Government Agencies or otherwise participate in any investigation or
proceeding  that  may  be  conducted  by  any  Government  Agencies,  including  providing  documents  or  other  information,  without  notice  to  the
Company.  If  Employee  had  filed  or  files  a  charge  or  complaint,  Employee  agrees  that  the  Company's  payment  of  the  Separation  Benefits
completely  satisfies  any  and  all  claims  for  monetary  relief  in  connection  with  such  charge  or  complaint,  and  this  Agreement  does  not  limit
Employee's  right  to  receive  an  award  for  information  (a)  provided  pursuant  to  the  Securities  and  Exchange  Commission's  whistleblower
protections and incentives; or (b) provided to any other Government Agencies. Employee is not entitled to any other monetary relief of any kind
with respect to the claims that Employee has released in this Agreement unless Employee's waiver and release of claims is deemed unlawful or
otherwise invalid.

6. Governing Law/Venue. The laws of the State of Minnesota will govern the validity, construction, and performance of this Agreement, without
regard  to  the  conflict  of  law  provisions  of  any  other  jurisdictions.  Employee  irrevocably  consents  to  the  exclusive  jurisdiction  of  courts  in
Minnesota  for  the  purposes  of  any  action  arising  out  of  or  related  to  this  Agreement  or  any  dispute  between  the  Company  and  Employee,
including any actions for temporary, preliminary, and permanent equitable relief.

7. Additional Agreements and Understandings.

a. Company  Property.  By  the  Separation  Date,  Employee  must  return  to  the  Company  all  the  Company  property  in  Employee's
possession  or  under  Employee's  control  including,  but  not  limited  to,  all  corporate  credit  cards,  identification  badges,  computer
hardware  and  software,  cell  phones,  tablets,  PDAs,  books,  records,  documents,  data,  access  cards,  financial  data,  confidential
information, trade secrets, files, notebooks, passwords, plans, sales reports, records, and all other property, equipment, or information
owned  by  the  Company  or  to  which  Employee  was  provided  access  by  the  Company  during  Employee's  employment  (collectively,
"Company  Property").  Employee  further  agrees  that  by  no  later  than  the  Separation  Date,  to  the  fullest  extent  permitted  by  law,
Employee  will  conduct  a  thorough  search  for  and  return  to  the  Company  and  subsequently  irrevocably  delete  any  and  all  intangible
Company  Property  which  exists  or  is  stored  (i)  in  any  personal  e-mail  account  (ii)  in  any  personal  "cloud"  account;  or  (iii)  on  any
personal computer, tablet, cellular phone, smartphone, flash drive, laptop or other electronic storage device, the foregoing of which are
accessible,  controlled  or  owned  by  Employee  (and  not  by  the  Company).  By  signing  this  Agreement,  Employee  represents  that
Employee has complied with the terms of this paragraph.

b. Post-Employment Obligations. Employee acknowledges that any and all post-employment obligations to which Employee is or may
be subject, whether set forth in the Employment Agreement or otherwise, including without limitation regarding confidentiality, non-
disclosure of confidential information, non-competition and non-solicitation, shall remain in full force and effect and are incorporated
by reference into this Agreement as if fully restated herein.

5

 
 
 
 
 
 
 
 
 
 
 
The Company advises Employee as follows under the federal Defend Trade Secrets Act: An individual shall not be held criminally or
civilly  liable  under  any  Federal  or  State  trade  secret  law  for  the  disclosure  of  a  trade  secret  that  (A)  is  made  (i)  in  confidence  to  a
Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or
investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such
filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation
of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the
individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to
court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets
that are expressly allowed by 18 U.S.C. § 1833(b).

c. Consideration. Employee agrees that (i) the Separation Benefits in Section 2 are above and beyond that to which Employee would be
entitled  if  Employee  did  not  sign  this  Agreement,  (ii)  the  Separation  Benefits  in  Section  2  constitute  independent  and  sufficient
consideration for all aspects of this Agreement, and (iii) Employee is not eligible for any other payments or benefits except for those
expressly described in this Agreement, provided that Employee signs and returns this Agreement within the specified time period and
does not revoke this Agreement.

d. References. Should anyone contact the Company for a reference, the Company will only verify Employee's employment dates, job title,

and compensation.

e. Non-Disparagement. Employee agrees not to make disparaging or defamatory remarks about the Company or the Company's services,
products, or other matters pertaining to its business. This non-disparagement provision does not apply to Employee's legally protected
communications and does not prohibit Employee from (i) filing an administrative charge or complaint with, or cooperating, assisting,
testifying, or participating in an investigation or legal proceeding conducted or initiated by, any Government Agencies, or (ii) inquiring
about, discussing, or disclosing Employee's and other employees' pay, hours, and other terms and conditions of employment. Company's
Board of Directors serving as of the Separation Date each agree that they will not knowingly or intentionally make, or cause to be made,
any statement (oral or written) that disparages Employee.

6

 
 
 
 
 
 
 
 
 
f. Confidentiality. Employee agrees that Employee is to keep the terms and conditions of this Agreement strictly confidential. Employee
agrees that Employee will not disclose, discuss, or reveal the existence or the terms of this Agreement except as follows: (i) as required
by  court  order  or  as  required  by  law;  (ii)  to  Employee's  immediate  family;  or  (iii)  to  Employee's  attorneys,  financial  planners,  and
accountants. Employee must ensure that any person or entity described in subsections (ii) and (iii) to whom such disclosures are made
will, as a condition of such disclosure, agrees to keep the terms of this Agreement strictly confidential. Employee understands that the
foregoing  does  not  prohibit  him  from  filing  an  administrative  charge  or  complaint  with,  or  cooperating,  assisting,  testifying,  or
participating  in  an  investigation  or  legal  proceeding  conducted  or  initiated  by,  any  Government  Agencies;  or  inquiring  about,
discussing, or disclosing his and other employees' pay, hours, and other terms and conditions of employment.

g. Transition and Cooperation. Employee agrees to successfully transition his work responsibilities prior to the Separation Date as and to
the extent requested by the Company. Employee represents that he has delivered or will deliver all passwords for any Company devices
and/or  accounts  in  use  at  the  time  of  the  Separation  Date.  Employee  will  cooperate  with  the  Company  and  use  his  best  efforts  to
transition  his  work  during  the  remaining  period  of  employment  and  shall  agree  to  be  available,  on  a  reasonable  basis,  to  answer
questions that may arise after the Separation Date, as necessary to achieve a smooth transition. Employee also agrees to be available to
and cooperate with the Company and its counsel in connection with any investigation, administrative proceeding or litigation relating to
any  matter,  occurring  during  his  employment,  in  which  he  was  involved  or  of  which  he  has  knowledge,  and  that  Employee  will  be
compensated  for  such  cooperation  activities  at  an  hourly  rate  equivalent  to  his  base  salary  divided  by  2,080  hours.  Employee
understands and agrees that such cooperation includes, but is not limited to, making himself available to the Company and/or its counsel
upon reasonable notice for: interviews and factual investigations; preparing for and appearing to give testimony in a deposition or at
trial without requiring service of a subpoena or other legal process; volunteering to the Company or its counsel pertinent information;
and turning over all relevant documents which are or may come into his possession.

h. Non-Admission. It is expressly understood that this Agreement does not constitute, nor shall it be construed as, an admission by the
Company of any liability or unlawful conduct whatsoever. The Company specifically denies any liability or unlawful conduct on the
Company's pai1.

i.

Successors  and  Assigns.  This  Agreement  is  personal  to  Employee  and  may  not  be  assigned  by  Employee  without  the  written
agreement of the Company. The rights and obligations of this Agreement shall inure to the successors and assigns of the Company.

7

 
 
 
 
 
 
 
 
 
 
j. Severability. If a court finds any term of this Agreement to be invalid, unenforceable, or void, Employee and the Company agree that the court
shall modify such term to make it enforceable to the maximum extent possible. If the term cannot be modified, Employee and the Company
agree  that  the  term  shall  be  severed  and  all  other  terms  of  this  Agreement  shall  remain  in  effect.  Employee  and  the  Company  agree  that
Employee's waiver and release of claims should be interpreted as broadly as possible to achieve Employee's intention of releasing all claims
against the Released Parties.

k. Entire Agreement. This Agreement constitutes the sole understanding of Employee and the Company with respect to the matters provided for
herein. Employee and the Company agree that this Agreement supersedes and terminates any and all other written and oral agreements and
understandings between Employee and the Company concerning separation benefits Employee may have been eligible for or entitled to from
the  Company.  Notwithstanding  anything  in  this  Agreement  to  the  contrary,  Employee  agrees  and  acknowledges  that  the  postemployment
obligations  set  forth  in  the  Employment  Agreement  remain  in  full  force  and  effect  after  the  Separation  Date.  This  Agreement  may  not  be
modified, altered, or changed in any way except by written agreement signed by Employee and the Company's Chief Executive Officer.

l. No Waiver. No claim or right arising out of a breach or default under this Agreement may be discharged by a waiver of that claim or right
unless the waiver is made in writing and signed by the Company's Chief Executive Officer. A waiver by any party of a breach or default of the
other  party  of  any  provision  contained  in  this  Agreement  shall  not  be  deemed  a  waiver  of  future  compliance  of  such  provisions,  and  such
provisions shall remain in full force and effect.

m. Remuneration. Employee acknowledges and agrees that the Company will pay Employee any and all monies, wages, salary, accrued unused
paid time off, expenses, bonuses, and commissions (if applicable) due to Employee through the Separation Date on the first regular payday
following the Separation Date, or as otherwise required by law. Employee is not entitled to any additional remuneration from the Company
other  than  the  consideration  outlined  within  this  Agreement.  In  addition,  Employee  acknowledges  that  Employee  is  not  aware  of  any  time
worked during Employee's employment for which Employee has not already been fully compensated.

n. Acknowledgements. Employee acknowledges and agrees that: (i) Employee has not suffered any work-related injury for which Employee has
not  already  filed  a  claim;  and  (ii)  Employee  has  been  properly  provided  any  leave  of  absence  including  for  Employee's  own  or  a  family
member's health condition.

o. Taxes. Employee acknowledges that Employee has not relied on any tax advice provided by the Company and that, if necessary, Employee is
solely  responsible  for  properly  reporting  the  payment  received  pursuant  to  this  Agreement  and  paying  any  applicable  taxes,  penalties,  and
interest. Employee acknowledges and agrees that Employee has been provided with the opportunity to consult legal and financial counsel with
respect to the tax treatment of the payment Employee will receive pursuant to this Agreement and on account of Employee's separation from
employment. Employee has been advised by the Company to consult with such counsel.

8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Execution/Counterparts. Employee agrees not to sign this Agreement prior to the end of Employee's workday on the Separation Date. To
accept  this  Agreement,  Employee  must  deliver  this  signed  and  dated  Agreement  to  Raymond  Vennare,  by  email  (rvennare@predictive-
oncology.com), hand or by mail (Predictive Oncology Inc. c/o Raymond Vennare, 91 43rd Street, Ste. 210, Pittsburgh, PA 15201) within the
time period set forth in Section 4. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. This Agreement may be executed either by original or facsimile, either of which
will be equally binding.

Dated:

9/29/2023

Dated:

9/30/2023

/s/ Robert Myers
Robert Myers

PREDICTIVE ONCOLOGY INC.
By:
Its:

/s/ Raymond F. Vennare
Chief Executive Officer

9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREDICTIVE ONCOLOGY INC.
SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1

Subsidiary

Helomics Corporation
Skyline Medical, Inc.

Jurisdiction of Incorporation

Delaware
Delaware

 
 
 
 
 
 
 
 
Consent of Independent Registered Public Accounting Firm

Exhibit 23.1

We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-239207, 333-252584, 333-252585 and 333-
267689); Form S-3 (File No. 333-221966, 333-228908, 333-235441, 333-237581, 333-239851, 333-254309 and 333-255582); Form S-4 (File No. 333-
228031); and Form S-8 (File No. 333-186464, 333-188510, 333-198378, 333-213742, 333-216711, 333-230704, 333-250149, and 333-259264) of
Predictive Oncology, Inc. (the Company) of our report dated March 28, 2024, relating to the consolidated financial statements which appears in this Annual
Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, P.C.
Minneapolis, Minnesota

March 28, 2024

 
 
 
 
 
 
 
 
 
 
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-239207, 333-252584, 333-252585, and 333-
267689); Form S-3 (File No. 333-221966, 333-228908, 333-235441, 333-237581, 333-239851, 333-254309 and 333-255582); Form S-4 (File No. 333-
228031); and Form S-8 (File No. 333-186464, 333-188510, 333-198378, 333-213742, 333-216711, 333-230704, 333-250149, and 333-259264) of
Predictive Oncology Inc. (the “Company”) of our report dated March 21, 2023, relating to the consolidated financial statements, which report expresses an
unqualified opinion on the consolidated financial statements for the year ended December 31, 2022.

Exhibit 23.2

/s/ Baker Tilly US, LLP

Minneapolis, Minnesota
March 28, 2024

 
 
 
 
 
 
 
 
Exhibit 31.1

CERTIFICATION
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Raymond F. Vennare, certify that:

1.

I have reviewed this annual report on Form 10-K of Predictive Oncology Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our

supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent

fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control

over financial reporting.

Date: March 28, 2024

/s/ Raymond F. Vennare
Raymond F. Vennare
Chief Executive Officer

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 31.2

CERTIFICATION
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Josh Blacher, certify that:

1.

I have reviewed this annual report on Form 10-K of Predictive Oncology Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements in light of the circumstances under which some statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our

supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent

fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report (that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control

over financial reporting.

Date: March 28, 2024

/s/ Josh Blacher
Josh Blacher
Interim Chief Financial Officer

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

In connection with the Annual Report on Form 10-K of Predictive Oncology Inc. (the “Company”) for the year ended December 31, 2023 as
filed with the Securities and Exchange Commission (the “Report”), I, Raymond F. Vennare, Chief Executive Officer (Principal Executive Officer) and, I,
Josh Blacher, Interim Chief Financial Officer (Principal Financial Officer) of the Company, hereby certify as of the date hereof, solely for purposes of §
906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. § 1350, that to the best of my knowledge:

(1)      The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the

Company at the dates and for the periods indicated.

Date: March 28, 2024

Date: March 28, 2024

/s/ Raymond F. Vennare
Raymond F. Vennare
Chief Executive Officer
(Principal Executive Officer)

/s/ Josh Blacher
Josh Blacher
Interim Chief Financial Officer
(Principal Financial Officer)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREDICTIVE ONCOLOGY INC.
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION

Exhibit 97

Purpose

The purpose of this policy is to set forth the procedures established by the Predictive Oncology (the “Company”) Board of Directors (the “Board”) for the
recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with the financial reporting
requirements under the U.S. federal securities laws in accordance with the terms and conditions set forth herein. 

Definitions

For purposes of this policy, the terms set forth below shall have the following meanings:

Code: the U.S. Internal Revenue Code of 1986, as amended, and the regulations and guidance thereunder.

Committee: the Compensation Committee of the Board.

Covered Compensation: any Incentive-Based Compensation granted, vested, or paid to a person who served as an Executive Officer at any time during the
performance period for the Incentive-Based Compensation and that was received (i) on or after October 2, 2023, (ii) after the person became an Executive
Officer, and (iii) at a time that the Company had a class of securities listed on a U.S. national securities exchange.

For purposes of this policy, Incentive-Based Compensation is deemed “received” in the Company’s fiscal period during which the Financial Reporting
Measure specified in or otherwise relating to the Incentive-Based Compensation award is attained, even if the grant, vesting, or payment of the Incentive-
Based Compensation occurs after the end of that period. 

Erroneously Awarded Compensation: the amount of Covered Compensation granted, vested, or paid to a person during the fiscal period when the
applicable Financial Reporting Measure relating to such Covered Compensation was attained that exceeds the amount of Covered Compensation that
otherwise would have been granted, vested, or paid to the person had such amount been determined based on the applicable Restatement, computed without
regard to any taxes paid (i.e., on a pre-tax basis). For Covered Compensation based on stock price or total stockholder return, where the amount of
Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Restatement, the Committee will
determine the amount of such Covered Compensation that constitutes Erroneously Awarded Compensation, if any, based on a reasonable estimate of the
effect of the Restatement on the stock price or total stockholder return upon which the Covered Compensation was granted, vested, or paid and the
Committee shall maintain documentation of such determination and provide such documentation to the NASDAQ.

Exchange Act: the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder.

Executive Officer: those persons who are designated by the Board as an “officer” of the Corporation as such term is defined in Rule 16a-1(f) under the
Exchange Act. Both current and former Executive Officers are subject to this policy in accordance with its terms.

Financial Reporting Measure: (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the
Company’s financial statements, and any measures derived wholly or in part from such measures, (ii) stock price, or (iii) total stockholder return. For the
avoidance of doubt, any such measure does not need to be presented within the Company’s financial statements or included in a filing with the SEC to
constitute a Financial Reporting Measure.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incentive-Based Compensation: any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting
Measure. For purposes of this policy, “Incentive-Based Compensation” shall also be deemed to include any amounts which were determined based on (or
were otherwise calculated by reference to) Incentive-Based Compensation (including, without limitation, any amounts under any long-term disability, life
insurance, or supplemental retirement or severance plan or agreement or any notional account that is based on Incentive-Based Compensation, as well as
any earnings accrued thereon).

Lookback Period: the three completed fiscal years (plus any transition period of less than nine months that is within or immediately following the three
completed fiscal years and that results from a change in the Company’s fiscal year) immediately preceding the date on which the Company is required to
prepare a Restatement for a given reporting period, with such date being the earlier of: (i) the date the Board, a committee of the Board, or the officer or
officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company
is required to prepare a Restatement, or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.
Recovery of any Erroneously Awarded Compensation under this policy is not dependent on if or when the Restatement is actually filed.

NASDAQ: the National Association of Securities Dealers Automated Quotations.

Restatement: a required accounting restatement of any Predictive Oncology financial statement due to the material noncompliance of the Company with
any financial reporting requirement under U.S. federal securities laws, including (i) to correct an error in previously issued financial statements that is
material to the previously issued financial statements or (ii) to correct an error in previously issued financial statements that is not material to the previously
issued financial statements but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current
period. Recovery of any Erroneously Awarded Compensation under this policy is not dependent on fault, fraud, or misconduct by any person in connection
with the Restatement.
For purposes of this policy, a Restatement shall not be deemed to occur in the event of a revision of the Company’s financial statements due to an out-of-
period adjustment (i.e., when the error is immaterial to the previously issued financial statements and the correction of the error is also immaterial to the
current period) or a retrospective (1) application of a change in accounting principles; (2) revision to reportable segment information due to a change in the
structure of the Company’s internal organization; (3) reclassification due to a discontinued operation; (4) application of a change in reporting entity, such as
from a reorganization of entities under common control; or (5) revision for stock splits, reverse stock splits, stock dividends, or other changes in capital
structure.

SEC: the U.S. Securities and Exchange Commission.

Recoupment of Erroneously Awarded Compensation

In the event of a Restatement, any Erroneously Awarded Compensation received during the Lookback Period prior to the Restatement (a) that is then-
outstanding but has not yet been paid shall be automatically and immediately forfeited and (b) that has been paid to any person shall be subject to
reasonably prompt repayment to the Company. The Committee must pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of
such Erroneously Awarded Compensation, except as provided below.

Notwithstanding the foregoing, the Committee may determine not to pursue the forfeiture and/or recovery of Erroneously Awarded Compensation from any
person if the Committee determines that such forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the direct
expense paid to a third party to assist in enforcing this policy would exceed the amount to be recovered (following reasonable attempts by the Company to
recover such Erroneously Awarded Compensation, the documentation of such attempts, and the provision of such documentation to the NASDAQ); or (ii)
recovery would likely cause any otherwise tax-qualified retirement plan, under which benefits are broadly available to employees, to fail to meet the
requirements of Sections 401(a)(13) or 411(a) of the Code.

 
 
 
 
 
 
 
 
 
 
 
Notwithstanding anything to the contrary herein, the Company has no obligation to seek recoupment of amounts that are granted, vested, or earned based
solely upon the occurrence or non-occurrence of non-financial events. Such exempt compensation includes, without limitation, base salary; time-vesting
awards; compensation awarded on the basis of the achievement of metrics that are not Financial Reporting Measures; and compensation awarded solely at
the discretion of the Committee, the Board, or a group composed entirely of independent members of the Board; provided that such amounts are in no way
contingent on, and were not in any way granted on the basis of, the achievement of any Financial Reporting Measure.

Means of Repayment

In the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation, the Committee shall provide written
notice to such person by email or certified mail to the physical address on file with the Company for such person, and the person shall satisfy such
repayment in a manner and on such terms as required by the Committee, and the Company shall be entitled to set off the repayment amount against any
amount owed to the person by the Company, to require the forfeiture of any award granted by the Company to the person, or to take any and all necessary
actions to reasonably promptly recoup the repayment amount from the person, in each case, to the fullest extent permitted under applicable law, including,
without limitation, Section 409A of the Code. If the Committee does not specify a repayment timing in the written notice described above, the applicable
person shall be required to repay the Erroneously Awarded Compensation to the Company by wire, cash, or cashier’s check no later than thirty (30) days
after receipt of such notice.

No Indemnification

The Company shall not indemnify any person, directly or indirectly, for any losses that such person may incur in connection with the recovery of
Erroneously Awarded Compensation pursuant to this policy, including through the payment of insurance premiums or gross-up payments. 

Administration

This policy shall be administered and interpreted by the Committee. The Committee shall make all determinations regarding the application and operation
of this policy in its sole discretion (including the manner and timing for promptly recouping Erroneously Awarded Compensation), and all such
determinations shall be final and binding. In the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation,
the person shall satisfy such repayment in a manner and on such terms as required by the Committee to the fullest extent permitted under applicable law
including, without limitation, Section 409A of the Code. 

Other

This policy is intended to comply with the requirements of Section 10D of the Exchange Act and Section 5608 of the NASDAQ Stock Market LLC Rules.
The provisions of this policy shall be interpreted in a manner that satisfies such requirements and this policy shall be operated accordingly. If any provision
of this policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict.

Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this policy shall be deemed to
include the restrictions imposed herein and incorporate this policy by reference and, in the event of any inconsistency, the terms of this policy will govern.

The provisions in this policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this policy is found to be
unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted and shall automatically be deemed
amended in a manner consistent with its objectives to the extent necessary to conform to applicable law. The invalidity or unenforceability of any provision
of this policy shall not affect the validity or enforceability of any other provision of this policy.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rights of the Company under this policy to seek forfeiture or reimbursement are in addition to, and not in lieu of, any rights of recoupment, or remedies
or rights other than recoupment, that may be available to the Company pursuant to the terms of any law, government regulation, or stock exchange listing
requirement or any other policy, plan, or agreement of the Company; provided, however, that any amounts recouped under any other policy that would be
recoupable under this policy shall count toward any required recoupment under this policy and vice versa.